

Patient Centricity Global Benchmarks

	Table of Contents
	Table Description
Patient (Centricity Global Benchmarks
<u>1</u>	Q1. Importance on pharma delivering on patient-focused missions/visions
<u>2</u>	Q2. Confidence on pharma delivering on patient-focused missions/visions
<u>3</u>	Q11. How would you finish this sentence? - My department is mostly concerned about our results
	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company helps make sure that the people who need
<u>4</u>	medicines have access to them
	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company communicates with care and compassion,
<u>5</u>	transparent and unbiased information on diseases, treatment options, and available resources
	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company provides easy-to-understand and convenient
<u>6</u>	information in plain language because they understand that "words matter"
	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company helps patients gain affordable access to their
<u>7</u>	medications
	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company equips patients to make informed choices
<u>8</u>	about healthcare and treatment options
	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company listens and responds to patient feedback with
<u>9</u>	respect and humility
	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company partners with patients to innovate and
<u>10</u>	measure impact and outcomes that are important to them
	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company provides access to support programmes and
<u>11</u>	resources to help patients improve quality of life
	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - Everything my company does begins with an understanding
<u>12</u>	of patient needs and experiences
	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company helps empower patients to help other patients
<u>13</u>	and their families
<u>14</u>	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - GRID SUMMARY
<u>15</u>	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - Top 2 Box Summary
<u>16</u>	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - Bottom 2 Box Summary
<u>17</u>	Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - Mean Summary

18	Q18. Patient centricity status statements agreement 1-5 scale - long term success - When we focus on delivering the best patient outcomes, we will create the best results for patients, healthcare professionals and our companies
	Q18. Patient centricity status statements agreement 1-5 scale - long term success - Finding the intersection where optimal outcomes for patients, healthcar
<u>19</u>	professionals and pharma companies all coincide is the crucial skill in the pharma, biotech and medical device industry
<u>20</u>	Q18. Patient centricity status statements agreement 1-5 scale - long term success - Focusing on patients" needs leads to better business outcomes
<u>21</u>	Q18. Patient centricity status statements agreement 1-5 scale - long term success - A long-term focus is key to success with patient-centric efforts
	Q18. Patient centricity status statements agreement 1-5 scale - long term success - Companies can act in the best interest of patients but I don''t believe we
<u>22</u>	can achieve long-term business success by doing so
<u>23</u>	Q18. Patient centricity status statements agreement 1-5 scale - long term success - Companies must serve shareholders first
2.4	O19 Detient contricity status statements agreement 1.5 scale, long term success. Dharmalls goals are micaligned with conting nationts entimally
24	Q18. Patient centricity status statements agreement 1-5 scale - long term success - Pharma''s goals are misaligned with serving patients optimally Q18. Patient centricity status statements agreement 1-5 scale - long term success - GRID SUMMARY
<u>25</u> 26	Q18. Patient centricity status statements agreement 1-5 scale - long term success - Grib Solviniant
27	Q18. Patient centricity status statements agreement 1-5 scale - long term success - Top 2 Box Summary Q18. Patient centricity status statements agreement 1-5 scale - long term success - Bottom 2 Box Summary
28	Q18. Patient centricity status statements agreement 1-5 scale - long term success - Mean Summary
<u>29</u>	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I believe in my company''s future
30	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I care about the company's vision and goals
<u>50</u>	Q151 Company related statements agreement 1 5 scale from product the company 5 vision and goals
<u>31</u>	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I am confident my company is making the world a better place
	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I am proud to tell people outside our industry that I work in a pharma, biotech/
<u>32</u>	medical device company
	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I know how to communicate my role such that people outside our industry
<u>33</u>	understand and admire our work
	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I have posted on Facebook articles or pictures that demonstrate my pride in the
<u>34</u>	good that our industry does
	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I have posted on Linkedin articles or pictures that demonstrate my pride in the
<u>35</u>	good that our industry does
	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - When asked about my profession at a personal social event, I am concerned
<u>36</u>	about how people will react
	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - Helping patients is my primary motivation for working in the
37	pharma/biotech/med device industry

	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I communicate why I work in the pharma/ biotech/ med device industry to my
<u>38</u>	customers
<u>39</u>	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I feel trusted and admired by my customers / stakeholders
<u>40</u>	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - My customers would say that I help improve patient care
<u>41</u>	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - GRID SUMMARY
<u>42</u>	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - Top 2 Box Summary
<u>43</u>	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - Bottom 2 Box Summary
44	Q19. Company related statements agreement 1-5 scale - I am proud/Pride - Mean Summary
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Patients" trust affected if they were to secretly
<u>45</u>	observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Clinical - Patients' trust affected if they were to
<u>46</u>	secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Corporate Affairs - Patients' trust affected if they
<u>47</u>	were to secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Government Affairs or Public Affairs - Patients'
<u>48</u>	trust affected if they were to secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Health Economics and Outcomes Research -
<u>49</u>	Patients" trust affected if they were to secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - HR - Patients" trust affected if they were to secretly
<u>50</u>	observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - IT - Patients" trust affected if they were to secretly
<u>51</u>	observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Manufacturing - Patients' trust affected if they
<u>52</u>	were to secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Market Access - Patients'' trust affected if they
<u>53</u>	were to secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Market Research - Patients" trust affected if they
<u>54</u>	were to secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Marketing - Patients'' trust affected if they were to
<u>55</u>	secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Medical Affairs - Patients'' trust affected if they
<u>56</u>	were to secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Operations and Finance - Patients'' trust affected if
57	they were to secretly observe a typical day in that department

	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Patient Affairs or Patient Advocacy - Patients" trust
<u>58</u>	affected if they were to secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - R&D pre-clinical - Patients" trust affected if they
<u>59</u>	were to secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - R&D clinical - Patients' trust affected if they were
<u>60</u>	to secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Regulatory Affairs - Patients' trust affected if they
<u>61</u>	were to secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Sales - Patients" trust affected if they were to
<u>62</u>	secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Training - Patients' trust affected if they were to
<u>63</u>	secretly observe a typical day in that department
	Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Other (please specify) - Patients" trust affected if
<u>64</u>	they were to secretly observe a typical day in that department
<u>65</u>	Q26. Training people to behave in patient-focused ways in your department
<u>66</u>	Q35. Change as a result from organization's patient-focused efforts (trust) - Employee engagement
<u>67</u>	Q35. Change as a result from organization's patient-focused efforts (trust) - Employee attraction/retention
<u>68</u>	Q35. Change as a result from organization's patient-focused efforts (trust) - Patient outcomes
<u>69</u>	Q35. Change as a result from organization's patient-focused efforts (trust) - Health care professionals trust in us
<u>70</u>	Q35. Change as a result from organization's patient-focused efforts (trust) - Patients and patient advocacy groups trust in us
71	Q35. Change as a result from organization's patient-focused efforts (trust) - Payors, health system bureaucrats and government bodies trust in us
72	Q35. Change as a result from organization's patient-focused efforts (trust) - Willingness of stakeholders to engage with us
<u>73</u>	Q35. Change as a result from organization's patient-focused efforts (trust) - Company revenues
<u>74</u>	Q35. Change as a result from organization's patient-focused efforts (trust) - GRID SUMMARY
<u>75</u>	Q35. Change as a result from organization's patient-focused efforts (trust) - Top 2 Box Summary
<u>76</u>	Q35. Change as a result from organization's patient-focused efforts (trust) - Bottom 2 Box Summary
<u>77</u>	Q35. Change as a result from organization's patient-focused efforts (trust) - Mean Summary
<u>78</u>	Q64. Overall trust in pharmaceutical industry
<u>79</u>	Q67. Trust in relevant pharmaceutical industry
<u>79</u>	
<u>79</u> <u>80</u>	
	Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company helps make sure that the people

	Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company provides easy-to-understand and
<u>82</u>	convenient information in plain language because they understand that "words matter"
	Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company helps you gain affordable access
<u>83</u>	to their medications
	Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company equips you to make informed
<u>84</u>	choices about healthcare and treatment options
	Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company listens and responds to your
<u>85</u>	feedback with respect and humility
	Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company partners with you to innovate and
<u>86</u>	measure impact and outcomes that are important to you
	Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company provides access to support
<u>87</u>	programmes and resources to help you improve quality of life
	Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - Everything the company does begin with an
<u>88</u>	understanding of your needs and experiences
	Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company helps empower you to help other
<u>89</u>	patients and their families
<u>90</u>	Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - GRID SUMMARY
<u>91</u>	Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - Top 2 Box Summary
<u>92</u>	Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - Bottom 2 Box Summary
<u>93</u>	Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - Mean Summary
	Q80. Delivering patient centricity status statements agreement 1-5 scale - When companies focus on delivering the best patient outcomes, we will create
<u>94</u>	the best results for patients, healthcare professionals and our companies
	Q80. Delivering patient centricity status statements agreement 1-5 scale - Finding the intersection where optimal outcomes for patients, healthcare
<u>95</u>	professionals and pharma companies all coincide is the crucial skill in the pharma, biotech and medical device industry
<u>96</u>	Q80. Delivering patient centricity status statements agreement 1-5 scale - Focusing on patients" needs leads to better business outcomes
<u>97</u>	Q80. Delivering patient centricity status statements agreement 1-5 scale - A long-term focus is key to success with patient-centric efforts
	Q80. Delivering patient centricity status statements agreement 1-5 scale - Pharma companies can act in the best interest of patients but I don't believe we
<u>98</u>	can achieve long-term business success by doing so
<u>99</u>	Q80. Delivering patient centricity status statements agreement 1-5 scale - Pharma companies must serve shareholders first
<u>100</u>	Q80. Delivering patient centricity status statements agreement 1-5 scale - Pharma''s goals are misaligned with serving patients optimally
<u>101</u>	Q80. Delivering patient centricity status statements agreement 1-5 scale - GRID SUMMARY
<u>102</u>	Q80. Delivering patient centricity status statements agreement 1-5 scale - Top 2 Box Summary
<u>103</u>	Q80. Delivering patient centricity status statements agreement 1-5 scale - Bottom 2 Box Summary
<u>104</u>	Q80. Delivering patient centricity status statements agreement 1-5 scale - Mean Summary



Q1. Importance on pharma delivering on patient-focused missions/visions

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job titl	le/level
	Total	Patient or	Suppliers	Pharma	HCP	Pure patient	Patients only	Patient	Very	Less	Small	Medium	Large	Global	Europe	North and	Asia	Africa	South	Australasia	Department	Senior
		Health				(not part of		Health	confident	confident						Central			America		Head or	managers o
		Charity				any other		Charity and								America					higher	lower
						group)		Patients														
			_		_	_	_									_		_	_	_	_	
		A	В	С	D	E	F	G	Н	1	J	K	L	M	N	0	P	Q	R	S	T	U
Danie Alliana and ante	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
Base: All respondents Extremely important 10	823	57	217	419	73	57	101	143	268	555	108	43	268	137	90	114	95 54	22	32	22	201	218
extremely important to	64.0%	78.0%	61.0%	62.0%	69.0%	81.0%	82.0%	80.0%	69.0%	62.0%	60.0%	54.0%	64.0%	64.0%	56.0%	72.0%	57.0%	58.0%	59.0%	69.0%	63.0%	61.0%
	04.078	78.0% BC	01.076	02.076	05.076	BC	BCD	BC	05.076	02.076	00.076	34.076	04.076	04.076	30.076	72.0% NP	37.0%	38.0%	35.0%	05.076	03.076	01.076
9	203	5	56	123	15	4	7	9	62	141	31	17	75	36	31	31	13	5	11	6	61	62
	16.0%	7.0%	16.0%	18.0%	14.0%	6.0%	6.0%	6.0%	16.0%	16.0%	17.0%	22.0%	18.0%	17.0%	19.0%	19.0%	14.0%	13.0%	20.0%	19.0%	19.0%	17.0%
	10.070	7.070	EFG	AEFG	FG	0.070	0.070	0.070	10.070	10.070	17.070	22.070	10.070	17.070	15.070	15.070	11.070	15.070	20.070	15.070	15.070	17.070
8	138	4	50	69	12	3	6	7	39	99	18	8	43	28	18	4	14	5	5	2	30	39
	11.0%	5.0%	14.0%	10.0%	11.0%	4.0%	5.0%	5.0%	10.0%	11.0%	10.0%	10.0%	10.0%	13.0%	11.0%	3.0%	15.0%	13.0%	9.0%	6.0%	9.0%	11.0%
			AEFG	G										0	0		0	0	0			
7	70	2	20	42	2	4	4	6	17	53	16	8	18	8	13	7	9	3	4	1	16	26
	5.0%	3.0%	6.0%	6.0%	2.0%	6.0%	3.0%	4.0%	4.0%	6.0%	9.0%	10.0%	4.0%	4.0%	8.0%	4.0%	9.0%	8.0%	7.0%	3.0%	5.0%	7.0%
											L	L					М					
6	16	1	6	7	2	0	1	1	0	16	1	1	5	2	2	1	1	1	0	0	4	3
	1.0%	1.0%	2.0%	1.0%	2.0%	-	1.0%	1.0%	-	2.0%	1.0%	1.0%	1.0%	1.0%	1.0%	1.0%	1.0%	3.0%	-	-	1.0%	1.0%
										Н												
5	16	1	5	8	1	1	1	2	0	16	3	1	4	3	2	0	3	0	0	0	1	7
	1.0%	1.0%	1.0%	1.0%	1.0%	1.0%	1.0%	1.0%	-	2.0%	2.0%	1.0%	1.0%	1.0%	1.0%	-	3.0%	-	-	=	*	2.0%
										Н							0					T
4	7	0	1	5	0	1	1	1	0	7	3	0	2	0	3	1	1	2	1	1	5	0
	1.0%	-	*	1.0%	-	1.0%	1.0%	1.0%	1	1.0%	2.0%	-	*	-	2.0%	1.0%	1.0%	5.0%	2.0%	3.0%	2.0%	-
															M			MO	M	M	U	
3	5	1	2	2	0	0	1	1	0	5	0	1	1	0	1	1	0	0	1	0	1	1
	*	1.0%	1.0%	*	-	-	1.0%	1.0%	-	1.0%	-	1.0%	*	-	1.0%	1.0%	-	-	2.0%	-	*	*
2	2		1	0	0	0				2	0	0	0	0	0		0		M			0
2	2	1.0%	*	0	0	0	1	1 00/	0	2	0	0	0	0	0	0	0	0	0	0	0	0
	*	1.0%	-	-	-	-	1.0% C	1.0%	-	•	-	-	-	-	-	-	-	-	-	-	-	-
Not at all important 1	2	1	0	0	1	0	0	C	1	1	0	0	0	0	0	0	0	0	0	0	0	0
Not at all important 1	*	1.0%	-	-	1.0%	-	-	1.0%	*	*	-	-	-	-	-	-	-	-	-	-	-	-
		BC	_		C 1.0%	-	-	C C			-	_	-	_	_	-		_	_	_	-	-
Sigma	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
Signia	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	200.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070
Summary																						
TOP 3 BOX	1164	66	323	611	100	64	114	130	369	795	157	68	386	201	139	149	81	32	48	30	292	319
	91.0%	90.0%	90.0%	91.0%	94.0%	91.0%	93.0%	91.0%	95.0%	89.0%	87.0%	86.0%	93.0%	94.0%	87.0%	94.0%	85.0%	84.0%	89.0%	94.0%	92.0%	90.0%
	52.570								1				JK	NPQ		NPQ						
BOTTOM 3 BOX	9	3	3	2	1	0	2	3	1	8	0	1	1	0	1	1	0	0	1	0	1	1
	1.0%	4.0%	1.0%		1.0%	-	2.0%	2.0%	*	1.0%	-	1.0%	*	-	1.0%	1.0%	-	-	2.0%	-	*	*
		BC						С											M			
Mean	9.3	9.3	9.2	9.3	9.4	9.5	9.5	9.4	9.5	9.2	9.2	9.1	9.3	9.4	9.1	9.5	9	8.9	9.1	9.4	9.3	9.2
						В	BCG		I					NPQ		NPQR	-					
Std. Dev.	1.3	1.8	1.3	1.2	1.3	1.2	1.4	1.5	1	1.4	1.3	1.4	1.1	1.1	1.4	1	1.4	1.6	1.5	1.2	1.2	1.2
Std. Err.	*	0.2	0.1		0.1	0.1	0.1	0.1	*	*	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.3	0.2	0.2	0.1	0.1
Sta. Err.																						

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

wining Base: 3 (), Jinan Base: 12 ()
Column Froportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)
Table of Contents



Q2. Confidence on pharma delivering on patient-focused missions/visions


					Туре				Confi	dence	Pha	arma: Company	size			Geo	graphical loca	tion			Job tit	le/level
	Total	Patient or	Suppliers	Pharma	НСР	Pure patient	Patients only	Patient	Very	Less	Small	Medium	Large	Global	Europe	North and	Asia	Africa	South	Australasia	Department	Senior
		Health				(not part of		Health	confident	confident						Central			America		Head or	managers o
		Charity				any other		Charity and								America					higher	lower
						group)		Patients														
		A	В	С	D	E	F	G	Н	- 1	J	K	L	M	N	0	P	Q	R	S	T	U
	4000	70	252	675	400	=0	400	440	207	005	400	70	***	24.4	450	450	0.5	20			240	255
Base: All respondents	1282 102	73	358 21	675 65	106 8	70 5	123 8	143	387 102	895 0	180 19	79	416 39	214 12	160 14	159 16	95 17	38	54 11	32 0	319 22	356 43
Extremely confident 10	8.0%	4.0%	6.0%	10.0%	8.0%	7.0%	7.0%	6.0%	26.0%	-	11.0%	9.0%	9.0%	6.0%	9.0%	10.0%	18.0%	11.0%	20.0%	-	7.0%	12.0%
	8.0%	4.0%	0.0%	10.0% R	8.0%	7.0%	7.0%	0.0%	26.0%	-	11.0%	9.0%	9.0%	6.0%	9.0%	10.0%	MNS	11.0%	MNOS	-	7.0%	12.0% T
q	90	3	17	59	7	4	6	7	90	0	15	8	36	17	11	14	8	3	9	2	24	35
	7.0%	4.0%	5.0%	9.0%	7.0%	6.0%	5.0%	5.0%	23.0%	-	8.0%	10.0%	9.0%	8.0%	7.0%	9.0%	8.0%	8.0%	17.0%	6.0%	8.0%	10.0%
			0.070	В		0.07.	0.071	0.07.0	1		0.0,1		0.070	0.0,1	110,0	0.0.1	0.0,0	0.070	N	0.07.0	0.070	2010,0
8	195	5	33	137	14	6	9	11	195	0	35	19	83	42	28	38	18	9	9	6	64	73
	15.0%	7.0%	9.0%	20.0%	13.0%	9.0%	7.0%	8.0%	50.0%	-	19.0%	24.0%	20.0%	20.0%	18.0%	24.0%	19.0%	24.0%	17.0%	19.0%	20.0%	21.0%
				ABEFG					I													
7	275	9	74	159	21	12	16	21	0	275	40	20	99	55	43	36	15	6	10	9	72	87
	21.0%	12.0%	21.0%	24.0%	20.0%	17.0%	13.0%	15.0%	-	31.0%	22.0%	25.0%	24.0%	26.0%	27.0%	23.0%	16.0%	16.0%	19.0%	28.0%	23.0%	24.0%
				AFG						Н					P							
6	249	9	95	118	18	9	17	18	0	249	35	8	75	42	33	17	20	12	6	8	68	50
	19.0%	12.0%	27.0%	17.0%	17.0%	13.0%	14.0%	13.0%	-	28.0%	19.0%	10.0%	18.0%	20.0%	21.0%	11.0%	21.0%	32.0%	11.0%	25.0%	21.0%	14.0%
			ACDEFG							Н				0	0		0	OR		0	U	
5	163	17	57	69	11	9	25	26	0	163	19	7	43	23	11	23	7	0	5	5	35	34
	13.0%	23.0%	16.0%	10.0%	10.0%	13.0%	20.0%	18.0%	-	18.0%	11.0%	9.0%	10.0%	11.0%	7.0%	14.0%	7.0%	-	9.0%	16.0%	11.0%	10.0%
4	98	CD 11	30	43	8	6	CDE 13	C 17	0	H 98	12	5	26	Q 17	10	NQ 10	8	3	3	Q 2	22	21
4	8.0%	15.0%	8.0%	6.0%	8.0%	9.0%	11.0%	12.0%	-	11.0%	7.0%	6.0%	6.0%	8.0%	6.0%	6.0%	8.0%	8.0%	6.0%	6.0%	7.0%	6.0%
	8.076	C	8.076	0.076	8.076	5.0%	11.076	C	-	H	7.0%	0.076	0.076	8.076	0.076	0.076	8.076	8.076	0.076	0.076	7.076	0.076
3	53	6	16	16	7	8	11	14	0	53	3	4	9	4	8	2	1	1	0	0	8	8
	4.0%	8.0%	4.0%	2.0%	7.0%	11.0%	9.0%	10.0%	-	6.0%	2.0%	5.0%	2.0%	2.0%	5.0%	1.0%	1.0%	3.0%	-	-	3.0%	2.0%
		C			C	BC	C	BC		Н		0.0.1		,	0			0.070			0.070	
2	31	4	10	6	5	6	8	10	0	31	0	1	5	1	1	3	1	0	0	0	3	3
	2.0%	5.0%	3.0%	1.0%	5.0%	9.0%	7.0%	7.0%	-	3.0%	-	1.0%	1.0%	*	1.0%	2.0%	1.0%	-	-	-	1.0%	1.0%
		С	С		С	BC	С	BC		Н												
Not at all confident 1	26	6	5	3	7	5	10	11	0	26	2	0	1	1	1	0	0	0	1	0	1	2
	2.0%	8.0%	1.0%	*	7.0%	7.0%	8.0%	8.0%	-	3.0%	1.0%	-	*	*	1.0%	-	-	-	2.0%	-	*	1.0%
		BC			BC	BC	BC	BC		Н												ļ
Sigma	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Commence																						
Summary	387	11	74	261	29	4.5	23	26	387	0	60	34	158	74	53	co	43	16	29	8	110	454
TOP 3 BOX	30.0%	15.0%	71 20.0%	39.0%	27.0%	15 21.0%	19.0%	18.0%	100.0%	0	69 38.0%	43.0%	38.0%	71 33.0%	33.0%	68 43.0%	45.0%	42.0%	54.0%	25.0%	34.0%	151 42.0%
	30.0%	15.0%	20.0%	ABDEFG	27.0%	21.0%	19.0%	16.0%	100.0%	-	36.0%	45.0%	38.0%	33.0%	33.0%	45.0%	45.0% MNS	42.0%	MNS	25.0%	34.0%	42.0% T
BOTTOM 3 BOX	110	16	31	25	19	19	29	35	0	110	5	5	15	6	10	5	2	1	1	0	12	13
BOTTOW 3 BOX	9.0%	22.0%	9.0%	4.0%	18.0%	27.0%	24.0%	24.0%	-	12.0%	3.0%	6.0%	4.0%	3.0%	6.0%	3.0%	2.0%	3.0%	2.0%	-	4.0%	4.0%
	3.070	BC	C C	1.070	BC BC	BC BC	BC BC	BC BC		H	3.070	0.070	1.070	3.070	0.070	5.070	2.070	3.070	2.070		1.070	11070
Mean	6.4	5.1	6.1	6.9	6	5.5	5.3	5.3	8.8	5.4	6.9	7	6.9	6.7	6.8	7	7.2	7.1	7.5	6.6	6.8	7.1
			AEFG	ABDEFG	AFG				I								M		MNOS			Т
Std. Dev.	2.1	2.3	1.9	1.8	2.4	2.6	2.5	2.4	0.8	1.6	1.8	1.9	1.8	1.7	1.9	1.9	2	1.7	2	1.3	1.8	1.9
Std. Err.	0.1	0.3	0.1	0.1	0.2	0.3	0.2	0.2	*	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.3	0.3	0.2	0.1	0.1
1												1		1	1			1			1	

Statistics:

Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)

wininum base: 3 (), Jinan base: 12 ()
Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)
Table of Contents



Q11. How would you finish this sentence? - My department is mostly concerned about our results....

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ition			Job tit	itle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	t Senior managers o lower
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
This quarter	59	0	0	59	0	0	0	0	19	40	18	7	34	10	15	22	8	7	2	5	21	38
	9.0%	-	-	9.0%	-	-	-	-	7.0%	10.0%	10.0%	9.0%	8.0%	5.0%	9.0%	14.0%	8.0%	18.0%	4.0%	16.0%	7.0%	11.0%
																MR		MR		M		
This year	296	0	0	296	0	0	0	0	108	188	73	30	193	90	67	70	40	18	27	13	121	175
	44.0%	-	-	44.0%	-	-	-	-	41.0%	45.0%	41.0%	38.0%	46.0%	42.0%	42.0%	44.0%	42.0%	47.0%	50.0%	41.0%	38.0%	49.0%
Next year	75	0	0	75	0	0	0	0	29	46	26	9	40	26	24	17	4	1	2	3	46	29
	11.0%	-	-	11.0%	-	-	-	-	11.0%	11.0%	14.0%	11.0%	10.0%	12.0%	15.0%	11.0%	4.0%	3.0%	4.0%	9.0%	14.0%	8.0%
														Р	PQR						U	
3-5 years from now	198	0	0	198	0	0	0	0	89	109	45	30	123	69	42	41	33	12	21	11	105	93
	29.0%	-	-	29.0%	-	-	-	-	34.0%	26.0%	25.0%	38.0%	30.0%	32.0%	26.0%	26.0%	35.0%	32.0%	39.0%	34.0%	33.0%	26.0%
									1			J							0			
Other (please specify)	47	0	0	47	0	0	0	0	16	31	18	3	26	19	12	9	10	0	2	0	26	21
	7.0%	-	-	7.0%	-	-	-	-	6.0%	7.0%	10.0%	4.0%	6.0%	9.0%	8.0%	6.0%	11.0%	-	4.0%	-	8.0%	6.0%
																	Q					
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Statistics: Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)
Table of Contents



Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company helps make sure that the people who need medicines have access to them

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ntion			Job tit	tle/level
	Total	Patient or	Suppliers	Pharma	HCP	Pure patient	Patients only	Patient	Very	Less	Small	Medium	Large	Global	Europe	North and	Asia	Africa	South	Australasia	Department	
	10.00	Health Charity	Sapplicis			(not part of any other group)		Health Charity and Patients	confident	confident			zu ge	5.52.0.	Zarope	Central America			America	, , , , , , , , , , , , , , , , , , , ,	Head or higher	managers o
		А	В	С	D	Е	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	228	0	0	228	0	0	0	0	106	122	64	26	138	65	60	59	30	11	13	13	99	129
Strongly agree 3	34.0%	-	-	34.0%	-	-	-	-	41.0%	29.0%	36.0%	33.0%	33.0%	30.0%	38.0%	37.0%	32.0%	29.0%	24.0%	41.0%	31.0%	36.0%
4	210	0	0	210	0	0	0	0	87	123	50	20	140	74	47	46	25	13	17	7	99	111
	31.0%	-	-	31.0%	-	-	-	-	33.0%	30.0%	28.0%	25.0%	34.0%	35.0%	29.0%	29.0%	26.0%	34.0%	31.0%	22.0%	31.0%	31.0%
3	123	0	0	123	0	0	0	0	39	84	20	17	86	36	30	24	21	6	9	9	61	62
	18.0%	-	-	18.0%	-	-	-	-	15.0%	20.0%	11.0%	22.0%	21.0%	17.0%	19.0%	15.0%	22.0%	16.0%	17.0%	28.0%	19.0%	17.0%
2	52	0	0	52	0	0	0	0	12	40	15	J 11	J 26	13	13	11	10	4	10	2	26	26
ĺ	8.0%	-	-	8.0%	-	-	-	-	5.0%	10.0%	8.0%	14.0%	6.0%	6.0%	8.0%	7.0%	11.0%	11.0%	19.0%	6.0%	8.0%	7.0%
										Н		L							MNO			
Strongly disagree 1	16	0	0	16	0	0	0	0	2	14	7	2	7	6	2	4	3	1	2	0	7	9
	2.0%	-	-	2.0%	-	-	-	-	1.0%	3.0% H	4.0%	3.0%	2.0%	3.0%	1.0%	3.0%	3.0%	3.0%	4.0%	-	2.0%	3.0%
Don't know or NA	46	0	0	46	0	0	0	0	15	31	24	3	19	20	8	15	6	3	3	1	27	19
	7.0%	-	-	7.0%	-	-	-	-	6.0%	7.0%	13.0% KL	4.0%	5.0%	9.0%	5.0%	9.0%	6.0%	8.0%	6.0%	3.0%	8.0%	5.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	438	0	0	438	0	0	0	0	193	245	114	46	278	139	107	105	55	24	30	20	198	240
	65.0%	-	-	65.0%	-	-	-	-	74.0%	59.0%	63.0%	58.0%	67.0%	65.0%	67.0%	66.0%	58.0%	63.0%	56.0%	62.0%	62.0%	67.0%
BOTTOM 2 BOX	68	0	0	68	0	0	0	0	14	54	22	13	33	19	15	15	13	5	12	2	33	35
	10.0%	-	-	10.0%	-	-	-	-	5.0%	13.0% H	12.0%	16.0%	8.0%	9.0%	9.0%	9.0%	14.0%	13.0%	22.0% MNO	6.0%	10.0%	10.0%
Mean	3.9	-	-	3.9	-	-	-	-	4.2	3.8	4	3.8	3.9	3.9	4	4	3.8	3.8	3.6	4	3.9	4
Std. Dev.	1.1	-	-	1.1	-	-	÷	-	0.9	1.1	1.2	1.2	1	R 1	R 1	R 1.1	1.1	1.1	1.2	1	1.1	1.1
Std. Err.	*	-	-	*	-	-	-	-	0.1	0.1	0.1	0.1	*	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1

Statistics:

Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company communicates with care and compassion, transparent and unbiased information on diseases, treatment options, and available resources

					Туре				Confi	dence	Pha	ırma: Company	size			Geo	ographical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	E	F	G	Н	- 1	J	К	L	М	N	0	Р	Q	R	S	T	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	258	0	0	258	0	0	0	0	131	127	76	22	160	72	63	69	35	11	21	11	121	137
	38.0%	-	-	38.0%	-	-	-	-	50.0%	31.0%	42.0%	28.0%	38.0%	34.0%	39.0%	43.0%	37.0%	29.0%	39.0%	34.0%	38.0%	38.0%
					_		_	_	1		K											
4	231	0	0	231	0	0	0	0	80	151	47	35	149	85	60	46	30	16	13	14	104	127
	34.0%	-	-	34.0%	-	-	-	-	31.0%	36.0%	26.0%	44.0%	36.0%	40.0%	38.0%	29.0%	32.0%	42.0%	24.0%	44.0%	33.0%	36.0%
								_				J	J	OR						_		
3	107	0	0	107	0	0	0	0	30	77	30	11	66	29	20	26	21	5	13	5	51	56
	16.0%	-	-	16.0%	-	-	-	-	11.0%	19.0%	17.0%	14.0%	16.0%	14.0%	12.0%	16.0%	22.0%	13.0%	24.0%	16.0%	16.0%	16.0%
_								_	_	Н	_	_					N		N			
1 ²	38	0	0	38	0	0	0	0	8	30	8	7	23	14	8	10	3	2	4	2	19	19
	6.0%	-	-	6.0%	-	-	-	-	3.0%	7.0%	4.0%	9.0%	6.0%	7.0%	5.0%	6.0%	3.0%	5.0%	7.0%	6.0%	6.0%	5.0%
o. 1 !! .	7	0	0	7		0	0	0	3	H 4	0	2	5	1		2	1	0		0	4	-
Strongly disagree 1	1.0%		-	1.0%	0	_	-	-	1.0%		-	3.0%	1.0%	1	1.0%	1.0%	1.0%	-	2.0%	-	1.0%	3
	1.0%	-	-	1.0%	-	-	-	-	1.0%	1.0%	-	3.0%	1.0%		1.0%	1.0%	1.0%	-	2.0%	-	1.0%	1.0%
Don't know or NA	34	0	0	34	0	0	0	0	9	25	19	2	13	13	7	6	5	4	2	0	20	14
	5.0%	-	-	5.0%	-	-	-	-	3.0%	6.0%	11.0%	3.0%	3.0%	6.0%	4.0%	4.0%	5.0%	11.0%	4.0%	-	6.0%	4.0%
											KL											1
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	489	0	0	489	0	0	0	0	211	278	123	57	309	157	123	115	65	27	34	25	225	264
	72.0%	-	-	72.0%	-	-	-	-	81.0%	67.0%	68.0%	72.0%	74.0%	73.0%	77.0%	72.0%	68.0%	71.0%	63.0%	78.0%	71.0%	74.0%
									ı						R							
BOTTOM 2 BOX	45	0	0	45	0	0	0	0	11	34	8	9	28	15	10	12	4	2	5	2	23	22
	7.0%	-	-	7.0%	-	-	-	-	4.0%	8.0%	4.0%	11.0%	7.0%	7.0%	6.0%	8.0%	4.0%	5.0%	9.0%	6.0%	7.0%	6.0%
										Н		J										
Mean	4.1	-	-	4.1	-	-	-	-	4.3	3.9	4.2	3.9	4.1	4.1	4.1	4.1	4.1	4.1	3.9	4.1	4.1	4.1
0.1.0		+	+		-	1					K											1
Std. Dev.	0.9	-	-	0.9	-	-	-	-	0.9	1	0.9	1	0.9	0.9	0.9	1	0.9	0.9	1.1	0.9	1	0.9
Cad For	*		-						0.4	*	0.1	0.4	*	0.1	0.1	0.4	0.4	0.4	0.1	0.2	0.1	0.4
Std. Err.	-	-	-	-	-	-	-	-	0.1	-	0.1	0.1	-	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1
Ctatistics		1	1																			

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company provides easy-to-understand and convenient information in plain language because they understand that "words matter"

					Туре				Confi	dence	.Ph:	arma: Company	size			.Geo	ographical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	Е	F	G	Н	- 1	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	212	0	0	212	0	0	0	0	110	102	77	23	112	67	44	55	33	11	21	10	98	114
	31.0%	-	-	31.0%	-	-	-	-	42.0%	25.0%	43.0%	29.0%	27.0%	31.0%	28.0%	35.0%	35.0%	29.0%	39.0%	31.0%	31.0%	32.0%
									1		KL											
4	216	0	0	216	0	0	0	0	81	135	46	23	147	70	53	46	27	10	20	8	94	122
	32.0%	-	-	32.0%	-	-	-	-	31.0%	33.0%	26.0%	29.0%	35.0%	33.0%	33.0%	29.0%	28.0%	26.0%	37.0%	25.0%	29.0%	34.0%
		_			_	_	_	_					J									4
3	151	0	0	151	0	0	0	0	55	96	31	24	96	45	42	36	22	9	11	8	80	71
	22.0%	-	-	22.0%	-	-	-	-	21.0%	23.0%	17.0%	30.0%	23.0%	21.0%	26.0%	23.0%	23.0%	24.0%	20.0%	25.0%	25.0%	20.0%
									_			J		24		40	4.0				20	
2	57	0	0	57	0	0	0	0	5	52	11	5	41	21	9	13	10	3	1	4	30	27
	8.0%	-	-	8.0%	-	-	-	-	2.0%	13.0% H	6.0%	6.0%	10.0%	10.0%	6.0%	8.0%	11.0%	8.0%	2.0%	12.0% R	9.0%	8.0%
Character discourse 4	12	0	0	12	0	0	0	0	3	9	4	1	7	2	4	5	1	1	1	0	3	9
Strongly disagree 1	2.0%	-	-	2.0%	-	-	-	-	1.0%	2.0%	2.0%	1.0%	2.0%	1.0%	2.0%	3.0%	1.0%	3.0%	2.0%	-	1.0%	3.0%
	2.0%	-	-	2.0%	-	-	-	-	1.0%	2.0%	2.0%	1.0%	2.0%	1.0%	2.0%	3.0%	1.0%	3.0%	2.0%	-	1.0%	3.0%
Don't know or NA	27	0	0	27	0	0	0	0	7	20	11	3	13	9	8	4	2	4	0	2	14	13
	4.0%	-	-	4.0%	-	-	-	-	3.0%	5.0%	6.0%	4.0%	3.0%	4.0%	5.0%	3.0%	2.0%	11.0%	-	6.0%	4.0%	4.0%
																		OPR				1
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
_	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	428	0	0	428	0	0	0	0	191	237	123	46	259	137	97	101	60	21	41	18	192	236
	63.0%	-	-	63.0%	-	-	-	-	73.0%	57.0%	68.0%	58.0%	62.0%	64.0%	61.0%	64.0%	63.0%	55.0%	76.0%	56.0%	60.0%	66.0%
									- 1										NQ			
BOTTOM 2 BOX	69	0	0	69	0	0	0	0	8	61	15	6	48	23	13	18	11	4	2	4	33	36
	10.0%	-	-	10.0%	-	-	-	-	3.0%	15.0%	8.0%	8.0%	12.0%	11.0%	8.0%	11.0%	12.0%	11.0%	4.0%	12.0%	10.0%	10.0%
										Н												
Mean	3.9	-	-	3.9	-	-	-	-	4.1	3.7	4.1	3.8	3.8	3.9	3.8	3.9	3.9	3.8	4.1	3.8	3.8	3.9
C. I. D.			1						1		L	-									_	+
Std. Dev.	1	-	-	1	-	-	-	-	0.9	1.1	1.1	1	1	1	1	1.1	1.1	1.1	0.9	1.1	1	1
Chil For	*		-		-				0.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.4	0.2	0.4	0.3	0.1	0.1
Std. Err.	-	-	-	-	-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1
Statistics:		1	1	1	I	1	l			1	L	1	1	1	1	1	l	1	1	1	l	

Statistics:

Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company helps patients gain affordable access to their medications

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job tit	tle/level
	Total	Patient or	Suppliers	Pharma	НСР	Pure patient	Patients only	Patient	Very	Less	Small	Medium	Large	Global	Europe	North and	Asia	Africa	South	Australasia	Department	
		Health Charity				(not part of any other group)		Health Charity and Patients	confident	confident			8-			Central America			America		Head or higher	managers o
		А	В	С	D	Е	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	202	0	0	202	0	0	0	0	108	94	57	25	120	55	48	60	29	14	12	9	96	106
Strongly agree 5	30.0%	-	-	30.0%	-	-	-	-	41.0%	23.0%	32.0%	32.0%	29.0%	26.0%	30.0%	38.0%	31.0%	37.0%	22.0%	28.0%	30.0%	30.0%
	407			407						400			405			MR	20	40	40			440
4	197 29.0%	-	-	197 29.0%	-	-	-	0 -	74 28.0%	123 30.0%	48 27.0%	24 30.0%	125 30.0%	62 29.0%	43 27.0%	48 30.0%	26 27.0%	13 34.0%	19 35.0%	11 34.0%	87 27.0%	110 31.0%
2	127	0	0	127	0	0	0	0	41	86	21	15	91	39	32	20	25	5	6	7	59	68
3	19.0%	-	-	19.0%	-	-	-	-	16.0%	21.0%	12.0%	19.0%	22.0%	18.0%	20.0%	13.0%	26.0%	13.0%	11.0%	22.0%	18.0%	19.0%
													J				OR					
2	63 9.0%	0	0	63 9.0%	0	0	0	0	15 6.0%	48 12.0%	18 10.0%	7 9.0%	38 9.0%	21 10.0%	17 11.0%	11 7.0%	8 8.0%	2 5.0%	11 20.0%	6.0%	35 11.0%	28 8.0%
	3.0%			3.070					0.070	H	10.070	3.070	5.070	10.070	11.070	7.076	0.070	3.070	MOPQ	0.070	11.070	0.070
Strongly disagree 1	21	0	0	21	0	0	0	0	5	16	5	3	13	6	7	5	2	1	2	0	7	14
	3.0%	-	-	3.0%	-	-	-	-	2.0%	4.0%	3.0%	4.0%	3.0%	3.0%	4.0%	3.0%	2.0%	3.0%	4.0%	-	2.0%	4.0%
Don't know or NA	65	0	0	65	0	0	0	0	18	47	31	5	29	31	13	15	5	3	4	3	35	30
	10.0%	-	-	10.0%	-	-	-	-	7.0%	11.0%	17.0% KL	6.0%	7.0%	14.0% P	8.0%	9.0%	5.0%	8.0%	7.0%	9.0%	11.0%	8.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	399	0	0	399	0	0	0	0	182	217	105	49	245	117	91	108	55	27	31	20	183	216
	59.0%	-	-	59.0%	=	=	9	-	70.0%	52.0%	58.0%	62.0%	59.0%	55.0%	57.0%	68.0% MN	58.0%	71.0%	57.0%	62.0%	57.0%	61.0%
BOTTOM 2 BOX	84	0	0	84	0	0	0	0	20	64	23	10	51	27	24	16	10	3	13	2	42	42
	12.0%	-	-	12.0%	-	-	-	-	8.0%	15.0% H	13.0%	13.0%	12.0%	13.0%	15.0%	10.0%	11.0%	8.0%	24.0%	6.0%	13.0%	12.0%
Mean	3.8	-	_	3.8	-	-		-	4.1	3.6	3.9	3.8	3.8	3.8	3.7	4	3.8	4.1	MOPQS 3.6	3.9	3.8	3.8
																MNR		R				
Std. Dev.	1.1	-	-	1.1	-	-	-	-	1	1.1	1.1	1.1	1.1	1.1	1.2	1.1	1.1	1	1.2	0.9	1.1	1.1
Std. Err.	*	-	-		-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company equips patients to make informed choices about healthcare and treatment options

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job titl	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower
		Α	В	С	D	E	F	G	Н		J	K	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	135	0	0	135	0	0	0	0	81	54	49	10	76	38	29	36	18	10	13	6	54	81
Strongly agree 3	20.0%	-	-	20.0%	-	-	-	-	31.0%	13.0%	27.0%	13.0%	18.0%	18.0%	18.0%	23.0%	19.0%	26.0%	24.0%	19.0%	17.0%	23.0%
	20.070			20.070					1	15.070	KL	15.070	10.070	10.070	10.070	25.070	15.070	20.070	21.070	13.070	17.070	25.070
4	200	0	0	200	0	0	0	0	83	117	35	26	139	71	49	43	22	9	10	6	98	102
	30.0%	-	-	30.0%	-	-	-	-	32.0%	28.0%	19.0%	33.0%	33.0%	33.0%	31.0%	27.0%	23.0%	24.0%	19.0%	19.0%	31.0%	29.0%
												J	J	R								
3	165	0	0	165	0	0	0	0	53	112	41	18	106	55	42	34	26	8	10	11	81	84
	24.0%	-	-	24.0%	-	-	-	-	20.0%	27.0%	23.0%	23.0%	25.0%	26.0%	26.0%	21.0%	27.0%	21.0%	19.0%	34.0%	25.0%	24.0%
										Н												
2	87	0	0	87	0	0	0	0	18	69	18	13	56	23	19	25	14	3	13	5	41	46
	13.0%	-	-	13.0%	-	-	-	-	7.0%	17.0%	10.0%	16.0%	13.0%	11.0%	12.0%	16.0%	15.0%	8.0%	24.0%	16.0%	13.0%	13.0%
										Н									MNQ			
Strongly disagree 1	25	0	0	25	0	0	0	0	7	18	7	4	14	2	6	8	3	2	4	1	12	13
	4.0%	-	-	4.0%	-	-	-	-	3.0%	4.0%	4.0%	5.0%	3.0%	1.0%	4.0%	5.0%	3.0%	5.0%	7.0%	3.0%	4.0%	4.0%
																M			M			
Don't know or NA	63	0	0	63	0	0	0	0	19	44	30	8	25	25	15	13	12	6	4	3	33	30
	9.0%	-	-	9.0%	-	-	-	-	7.0%	11.0%	17.0%	10.0%	6.0%	12.0%	9.0%	8.0%	13.0%	16.0%	7.0%	9.0%	10.0%	8.0%
											L											
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
C																						
TOP 2 BOX	335	0	0	335	0	0	0	0	164	171	84	36	215	109	78	79	40	19	23	12	152	183
TOP 2 BOX	50.0%	-	-	50.0%	-	-	-	-	63.0%	41.0%	47.0%	46.0%	52.0%	51.0%	49.0%	50.0%	42.0%	50.0%	43.0%	38.0%	48.0%	51.0%
	30.0%	-	-	30.076	-	<u> </u>	-	-	03.076	41.070	47.076	40.076	32.076	31.0%	45.070	30.0%	42.076	30.076	43.070	36.076	46.076	31.076
BOTTOM 2 BOX	112	0	0	112	0	0	0	0	25	87	25	17	70	25	25	33	17	5	17	6	53	59
BOTTOWIZ BOX	17.0%	-	-	17.0%	-	-	-	-	10.0%	21.0%	14.0%	22.0%	17.0%	12.0%	16.0%	21.0%	18.0%	13.0%	31.0%	19.0%	17.0%	17.0%
	17.070			17.070					10.070	H	14.070	22.070	17.070	12.070	10.070	M	10.070	15.070	MNO	13.070	17.070	17.070
Mean	3.5	-	_	3.5	-	-	-	-	3.9	3.3	3.7	3.4	3.5	3.6	3.5	3.5	3.5	3.7	3.3	3.4	3.5	3.6
	5.5			2.5					I	2.0		2.11	2.0	R	2.0	5.5	2.3		2.3		2.5	5.0
Std. Dev.	1.1	-	-	1.1	-	-	-	-	1	1.1	1.2	1.1	1.1	1	1.1	1.2	1.1	1.2	1.3	1.1	1.1	1.1
																			-			
Std. Err.	*	-	-		-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company listens and responds to patient feedback with respect and humility

					Туре				Confi	dence	Pha	rma: Company	, size			Geo	ographical loca	ation			Job tit	tle/level
	Total	Patient or	Suppliers	Pharma	HCP	Pure patient	Patients only	Patient	Very	Less	Small	Medium	Large	Global	Europe	North and	Asia	Africa	South	Australasia	Department	
		Health Charity				(not part of any other group)		Health Charity and Patients	confident	confident						Central America			America		Head or higher	managers o lower
		А	В	С	D	E	F	G	Н	ı	J	К	L	M	N	0	P	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	235	0	0	235	0	0	0	0	123	112	69	23	143	86	52	50	28	10	18	12	111	124
	35.0%	-	-	35.0%	-	-	-	-	47.0%	27.0%	38.0%	29.0%	34.0%	40.0%	32.0%	31.0%	29.0%	26.0%	33.0%	38.0%	35.0%	35.0%
4	200	0	0	200	0	0	0	0	76	124	55	26	119	63	42	52	29	14	19	6	91	109
	30.0%	-	-	30.0%	-	-	1	-	29.0%	30.0%	31.0%	33.0%	29.0%	29.0%	26.0%	33.0%	31.0%	37.0%	35.0%	19.0%	29.0%	31.0%
2	116	0	0	116	0	0	0	0	38	78	18	15	83	33	26	28	22	4	9	6	61	55
3	17.0%	-	-	17.0%	-	-	-	-	15.0%	19.0%	10.0%	19.0%	20.0%	15.0%	16.0%	18.0%	23.0%	11.0%	17.0%	19.0%	19.0%	15.0%
	17.0%	-	-	17.076	_		-	_	13.076	15.076	10.076	J J	J	13.076	10.076	18.0%	23.070	11.076	17.070	15.076	13.076	13.076
2	55	0	0	55	0	0	0	0	8	47	13	7	35	15	18	12	8	3	4	4	25	30
	8.0%	-	-	8.0%	-	-	1	-	3.0%	11.0%	7.0%	9.0%	8.0%	7.0%	11.0%	8.0%	8.0%	8.0%	7.0%	12.0%	8.0%	8.0%
			_		_	_				Н		_		_	_			_	_		_	
Strongly disagree 1	18	0	0	18	0	0	0	0	3	15	7	2	9	2	3	7	4	3	2	1	9	9
	3.0%	-	-	3.0%	-	-	-	-	1.0%	4.0%	4.0%	3.0%	2.0%	1.0%	2.0%	4.0% M	4.0%	8.0% MN	4.0%	3.0%	3.0%	3.0%
Don't know or NA	51	0	0	51	0	0	0	0	13	38	18	6	27	15	19	10	4	4	2	3	22	29
	8.0%	-	-	8.0%	-	-	-	-	5.0%	9.0%	10.0%	8.0%	6.0%	7.0%	12.0%	6.0%	4.0%	11.0%	4.0%	9.0%	7.0%	8.0%
										Н					P							
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	435	0	0	435	0	0	0	0	199	236	124	49	262	149	94	102	57	24	37	18	202	233
	64.0%	-	-	64.0%	-	-	-	-	76.0%	57.0%	69.0%	62.0%	63.0%	70.0%	59.0%	64.0%	60.0%	63.0%	69.0%	56.0%	63.0%	65.0%
BOTTOM 2 BOX	73	0	0	73	0	0	0	0	11	62	20	9	44	N 17	21	19	12	6	6	5	34	39
BOTTOM 2 BOX	11.0%	-	0	11.0%	-	-	-	-	4.0%	15.0%	11.0%	11.0%	11.0%	8.0%	13.0%	12.0%	13.0%	16.0%	11.0%	16.0%	11.0%	11.0%
	11.0%	-	-	11.0%	-	-	-	-	4.076	15.0% H	11.0%	11.0%	11.070	6.0%	13.0%	12.0%	13.0%	10.0%	11.0%	10.076	11.0%	11.0%
Mean	3.9	-	-	3.9	-	-	-	-	4.2	3.7	4	3.8	3.9	4.1	3.9	3.8	3.8	3.7	3.9	3.8	3.9	3.9
Std. Dev.	1.1	_	_	1.1	_	-		_	0.9	1.1	1.1	1.1	1.1	OP 1	1.1	1.1	1.1	1.2	1.1	1.2	1.1	1.1
3.0.00	1.1			1.1					0.5	1.1	1.1	1.1	1.1		1.1	1.1	1.1	1.2	1.1	1.2	1.1	1.1
Std. Err.	*	-	-	*	-	-	1	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1
Statistics:																						

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company partners with patients to innovate and measure impact and outcomes that are important to them

					Туре				Confi	dence	Pha	ırma: Company	size			Geo	ographical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	T	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	130	0	0	130	0	0	0	0	72	58	45	10	75	50	25	34	19	4	7	5	55	75
	19.0%	-	-	19.0%	-	-	-	-	28.0%	14.0%	25.0%	13.0%	18.0%	23.0%	16.0%	21.0%	20.0%	11.0%	13.0%	16.0%	17.0%	21.0%
	400			400					70	407	K	24	440	70			- 10			_		
4	186	0	0	186	0	0	0	0	79	107	46	21	119	70	44	33	19	14	12	7	89	97
	28.0%	-	-	28.0%	-	-	-	-	30.0%	26.0%	26.0%	27.0%	29.0%	33.0%	28.0%	21.0%	20.0%	37.0%	22.0%	22.0%	28.0%	27.0%
2	159	0	0	450	0	0	0		63	07	20	20	100	OP	22	40	47	OP 5	1.0	9	0.2	76
3	24.0%	-	-	159 24.0%		0	0	0	62 24.0%	97	30 17.0%	20	109 26.0%	50	33		17 18.0%	_	16	28.0%	83	76
	24.0%	-	-	24.0%	-	-	-	-	24.0%	23.0%	17.0%	25.0%	26.0%	23.0%	21.0%	25.0%	18.0%	13.0%	30.0%	28.0%	26.0%	21.0%
2	108	0	0	108	0	0	0	0	21	87	27	15	66	22	32	27	21	4	10	6	52	56
2	16.0%	-	-	16.0%	-	-	-	-	8.0%	21.0%	15.0%	19.0%	16.0%	10.0%	20.0%	17.0%	22.0%	11.0%	19.0%	19.0%	16.0%	16.0%
	10.0%	-	-	10.0%	-	-	-	-	8.0%	21.0% H	15.0%	19.0%	10.0%	10.0%	20.0% M	17.0%	22.0% M	11.0%	19.0%	19.0%	10.0%	10.0%
Strongly disagree 1	49	0	0	49	0	0	0	0	14	35	15	8	26	10	15	18	9	4	7	4	21	28
Strongly disagree 1	7.0%	-	-	7.0%	-	-	-	-	5.0%	8.0%	8.0%	10.0%	6.0%	5.0%	9.0%	11.0%	9.0%	11.0%	13.0%	12.0%	7.0%	8.0%
	7.076	-	_	7.076	_	-	-		3.076	8.076	8.076	10.076	0.076	3.0%	5.076	M	3.076	11.076	M	12.076	7.076	8.076
Don't know or NA	43	0	0	43	0	0	0	0	13	30	17	5	21	12	11	7	10	7	2	1	19	24
Don't know or tur	6.0%	-	-	6.0%	-	-	-	-	5.0%	7.0%	9.0%	6.0%	5.0%	6.0%	7.0%	4.0%	11.0%	18.0%	4.0%	3.0%	6.0%	7.0%
	0.0								0.07.		L	0.0.1	0.0,1	0.07.		,.		MNOR		0.0,1	0.0,1	110,1
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	316	0	0	316	0	0	0	0	151	165	91	31	194	120	69	67	38	18	19	12	144	172
	47.0%	-	-	47.0%	-	-	-	-	58.0%	40.0%	51.0%	39.0%	47.0%	56.0%	43.0%	42.0%	40.0%	47.0%	35.0%	38.0%	45.0%	48.0%
									I					NOPR								
BOTTOM 2 BOX	157	0	0	157	0	0	0	0	35	122	42	23	92	32	47	45	30	8	17	10	73	84
	23.0%	-	-	23.0%	-	-	-	-	13.0%	29.0%	23.0%	29.0%	22.0%	15.0%	29.0%	28.0%	32.0%	21.0%	31.0%	31.0%	23.0%	24.0%
										Н					M	M	М		M	M		
Mean	3.4	-	-	3.4	-	-	-	-	3.7	3.2	3.5	3.1	3.4	3.6	3.2	3.2	3.2	3.3	3	3.1	3.4	3.4
									1					NOPRS								1
Std. Dev.	1.2	-	-	1.2	-	-	-	-	1.1	1.2	1.3	1.2	1.2	1.1	1.2	1.3	1.3	1.2	1.2	1.3	1.2	1.2
																				1		1
Std. Err.	*	-	-	*	-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1
Ctatistics																						

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company provides access to support programmes and resources to help patients improve quality of life

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		Α	В	С	D	E	F	G	Н	- 1	J	K	L	М	N	0	P	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	221	0	0	221	0	0	0	0	113	108	50	18	153	71	51	55	29	13	14	11	102	119
Strongly agree 3	33.0%	-	-	33.0%	-	-	-	-	43.0%	26.0%	28.0%	23.0%	37.0% JK	33.0%	32.0%	35.0%	31.0%	34.0%	26.0%	34.0%	32.0%	33.0%
4	198	0	0	198	0	0	0	0	73	125	42	23	133	66	48	45	18	8	13	9	86	112
	29.0%	-	-	29.0%	-	-	-	-	28.0%	30.0%	23.0%	29.0%	32.0%	31.0%	30.0%	28.0%	19.0%	21.0%	24.0%	28.0%	27.0%	31.0%
													J	P	P							
3	111	0	0	111	0	0	0	0	38	73	29	17	65	27	24	31	31	6	11	7	64	47
	16.0%	-	-	16.0%	-	-	-	-	15.0%	18.0%	16.0%	22.0%	16.0%	13.0%	15.0%	19.0%	33.0% MNOQ	16.0%	20.0%	22.0%	20.0% U	13.0%
2	69	0	0	69	0	0	0	0	15	54	22	10	37	21	22	12	9	4	9	2	30	39
	10.0%	-	-	10.0%	-	-	-	-	6.0%	13.0% H	12.0%	13.0%	9.0%	10.0%	14.0%	8.0%	9.0%	11.0%	17.0% O	6.0%	9.0%	11.0%
Strongly disagree 1	23	0	0	23	0	0	0	0	7	16	11	4	8	7	4	4	3	2	5	1	12	11
	3.0%	-	-	3.0%	-	-	-	-	3.0%	4.0%	6.0%	5.0%	2.0%	3.0%	2.0%	3.0%	3.0%	5.0%	9.0% NO	3.0%	4.0%	3.0%
Don't know or NA	53	0	0	53	0	0	0	0	15	38	26	7	20	22	11	12	5	5	2	2	25	28
	8.0%	-	-	8.0%	-	-	-	-	6.0%	9.0%	14.0% L	9.0%	5.0%	10.0%	7.0%	8.0%	5.0%	13.0%	4.0%	6.0%	8.0%	8.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	419	0	0	419	0	0	0	0	186	233	92	41	286	137	99	100	47	21	27	20	188	231
	62.0%	-	-	62.0%	-	-	-	-	71.0%	56.0%	51.0%	52.0%	69.0% JK	64.0% P	62.0% P	63.0% P	49.0%	55.0%	50.0%	62.0%	59.0%	65.0%
BOTTOM 2 BOX	92	0	0	92	0	0	0	0	22	70	33	14	45	28	26	16	12	6	14	3	42	50
	14.0%	-	-	14.0%	-	-	-	-	8.0%	17.0% H	18.0%	18.0%	11.0%	13.0%	16.0%	10.0%	13.0%	16.0%	26.0% MOP	9.0%	13.0%	14.0%
Mean	3.8	-	-	3.8	-	-	-	-	4.1	3.7	3.6	3.6	4	3.9	3.8	3.9	3.7	3.8	3.4	3.9	3.8	3.9
Std. Dev.	1.1	=	_	1.1	-	-	-	-	1.1	1.2	1.3	1.2	JK 1.1	R 1.1	R 1.1	R 1.1	1.1	1.3	1.3	1.1	1.1	1.1
Std. Err.	*	-	-	*	-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - Everything my company does begins with an understanding of patient needs and experiences

					Туре				Confi	dence	Pha	rma: Company	size			Geo	ographical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	E	F	G	Н	1	J	К	L	M	N	0	Р	Q	R	S	T	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	157	0	0	157	0	0	0	0	88	69	55	13	89	45	39	35	29	10	12	8	72	85
	23.0%	-	-	23.0%	-	-	-	-	34.0%	17.0%	31.0%	16.0%	21.0%	21.0%	24.0%	22.0%	31.0%	26.0%	22.0%	25.0%	23.0%	24.0%
	105	0	0	185	0	0		0	0.0	00	KL 47	20	400		44	44	25	9	42	6	00	0.0
4	185 27.0%	- 0	-	27.0%		0	0	-	86 33.0%	99 24.0%	26.0%	30 38.0%	108 26.0%	66 31.0%	41 26.0%	41 26.0%	25 26.0%	24.0%	13 24.0%	19.0%	89 28.0%	96 27.0%
	27.0%	-	-	27.0%	-	-	-	-	33.0%	24.0%	26.0%	38.0%	26.0%	31.0%	26.0%	26.0%	26.0%	24.0%	24.0%	19.0%	28.0%	27.0%
2	181	0	0	181	0	0	0	0	53	128	39	14	128	60	34	51	21	9	16	10	89	92
3	27.0%	-	-	27.0%	-	-	-	-	20.0%	31.0%	22.0%	18.0%	31.0%	28.0%	21.0%	32.0%	22.0%	24.0%	30.0%	31.0%	28.0%	26.0%
	27.070			27.070					20.070	H	22.070	10.070	JK	20.070	21.070	N N	22.070	24.070	30.070	31.070	20.070	20.070
2	99	0	0	99	0	0	0	0	22	77	20	15	64	28	31	20	16	6	10	6	44	55
	15.0%	-	-	15.0%	-	-	-	-	8.0%	19.0%	11.0%	19.0%	15.0%	13.0%	19.0%	13.0%	17.0%	16.0%	19.0%	19.0%	14.0%	15.0%
	20.070								0.0,1	Н		-0.0,0	20.07.0		-0.07.	-0.0,1	211070					
Strongly disagree 1	32	0	0	32	0	0	0	0	4	28	11	4	17	11	9	8	2	1	3	0	16	16
	5.0%	-	-	5.0%	-	-	-	-	2.0%	7.0%	6.0%	5.0%	4.0%	5.0%	6.0%	5.0%	2.0%	3.0%	6.0%	-	5.0%	4.0%
										Н												
Don't know or NA	21	0	0	21	0	0	0	0	8	13	8	3	10	4	6	4	2	3	0	2	9	12
	3.0%	-	-	3.0%	-	-	-	-	3.0%	3.0%	4.0%	4.0%	2.0%	2.0%	4.0%	3.0%	2.0%	8.0%	-	6.0%	3.0%	3.0%
																		MR				
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary					-		_	_														
TOP 2 BOX	342	0	0	342	0	0	0	0	174	168	102	43	197	111	80	76	54	19	25	14	161	181
	51.0%	-	-	51.0%	-	-	-	-	67.0%	41.0%	57.0%	54.0%	47.0%	52.0%	50.0%	48.0%	57.0%	50.0%	46.0%	44.0%	50.0%	51.0%
DOTTOM 2 DOV	131	0	0	131	0	0	0	0	26	105	31	19	81	39	40	28	18	7	13	6	60	71
BOTTOM 2 BOX	19.0%	-	-	19.0%	-	-	-	-	10.0%	25.0%	17.0%	24.0%	19.0%	18.0%	25.0%	18.0%	19.0%	18.0%	24.0%	19.0%	19.0%	20.0%
	19.0%	-	-	19.0%	-	-	-	-	10.0%	25.0% H	17.0%	24.0%	19.0%	16.0%	25.0%	16.0%	19.0%	16.0%	24.0%	19.0%	19.0%	20.0%
Mean	3.5	_	_	3.5	-	_	-	_	3.9	3.3	3.7	3.4	3.5	3.5	3.5	3.5	3.7	3.6	3.4	3.5	3.5	3.5
ivican	3.3	-	-	ر.د			-	_	3.3 I	3.3	3.7	3.4	3.3	ر.ر	3.3	3.3	3.1	3.0	3.4	3.3	3.3	2.2
Std. Dev.	1.2	-	-	1.2	-	-	-	-	1	1.2	1.2	1.1	1.1	1.1	1.2	1.1	1.2	1.2	1.2	1.1	1.1	1.2
									_													
Std. Err.	*	-	-	*	-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1
			1	1		1	l			-		1				1			l	1		

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - My company helps empower patients to help other patients and their families

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
			R				F					.,					p				т	<u> </u>
		A	В	С	D	E	F	G	Н	ı	J	K	L	M	N	0	Р	Q	R	S	- 1	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	116	0	0	116	0	0	0	0	67	49	38	10	68	38	25	30	18	6	7	2	49	67
	17.0%	-	-	17.0%	-	-	-	-	26.0%	12.0%	21.0%	13.0%	16.0%	18.0%	16.0%	19.0%	19.0%	16.0%	13.0%	6.0%	15.0%	19.0%
									- 1													
4	164	0	0	164	0	0	0	0	76	88	42	22	100	56	34	38	18	10	17	9	83	81
	24.0%	-	-	24.0%	-	-	-	-	29.0%	21.0%	23.0%	28.0%	24.0%	26.0%	21.0%	24.0%	19.0%	26.0%	31.0%	28.0%	26.0%	23.0%
3	177	0	0	177	0	0	0	0	68	109	31	22	124	55	39	40	25	10	12	11	89	88
3	26.0%	-	-	26.0%	-	-	-	-	26.0%	26.0%	17.0%	28.0%	30.0%	26.0%	24.0%	25.0%	26.0%	26.0%	22.0%	34.0%	28.0%	25.0%
											21.075		J							0		
2	113	0	0	113	0	0	0	0	21	92	29	12	72	28	36	25	19	6	11	6	57	56
	17.0%	-	-	17.0%	-	-	-		8.0%	22.0%	16.0%	15.0%	17.0%	13.0%	22.0%	16.0%	20.0%	16.0%	20.0%	19.0%	18.0%	16.0%
										Н					M							<u> </u>
Strongly disagree 1	32	0	0	32	0	0	0	0	7	25	12	4	16	7	7	13	2	1	4	3	15	17
	5.0%	-	-	5.0%	-	-	-	-	3.0%	6.0% H	7.0%	5.0%	4.0%	3.0%	4.0%	8.0% MP	2.0%	3.0%	7.0%	9.0%	5.0%	5.0%
Don't know or NA	73	0	0	73	0	0	0	0	22	н 51	28	9	36	30	19	13	13	5	3	1	26	47
DOI! CKNOW OF IVA	11.0%	-	-	11.0%	-	-	-	-	8.0%	12.0%	16.0%	11.0%	9.0%	14.0%	12.0%	8.0%	14.0%	13.0%	6.0%	3.0%	8.0%	13.0%
									0.0,1		L		0.070			0.070				0.0,0	0.0,1	Т
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary TOP 2 BOX	280	0	0	280	0	0	0	0	143	137	80	32	168	94	59	68	36	16	24	11	132	148
TOF 2 BOX	41.0%	-	-	41.0%	-	-	-	-	55.0%	33.0%	44.0%	41.0%	40.0%	44.0%	37.0%	43.0%	38.0%	42.0%	44.0%	34.0%	41.0%	42.0%
	12.070			12.070					1	33.070	441.070	12.070	10.070	11.070	37.070	15.670	30.070	42.070	111070	51.070	12.070	12.070
BOTTOM 2 BOX	145	0	0	145	0	0	0	0	28	117	41	16	88	35	43	38	21	7	15	9	72	73
	21.0%	-	-	21.0%	-	-	-	-	11.0%	28.0%	23.0%	20.0%	21.0%	16.0%	27.0%	24.0%	22.0%	18.0%	28.0%	28.0%	23.0%	21.0%
										Н					M							
Mean	3.4	-	-	3.4	-	-	-	-	3.7	3.1	3.4	3.3	3.3	3.5	3.2	3.3	3.4	3.4	3.2	3	3.3	3.4
Std. Dev.	1.1	-	-	1.1	_	-	-	-	1.1	1.1	1.3	1.1	1.1	NS 1.1	1.2	1.2	1.1	1.1	1.2	1.1	1.1	1.2
Stu. Dev.	1.1	-	-	1.1	-	-	-	-	1.1	1.1	1.3	1.1	1.1	1.1	1.2	1.2	1.1	1.1	1.2	1.1	1.1	1.2
Std. Err.	*	-	-		-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

tient Centricity Global Benchmarks

Table: 14

Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - GRID SUMMARY

	My company helps make sure that the people who need medicines have access to them	My company communicat es with care and compassion, transparent and unbiased information on diseases, treatment options, and available resources	provides easy-to- understand and convenient information in plain language because they understand	helps patients gain affordable access to their medications	My company equips patients to make informed choices about healthcare and treatment options	My company listens and responds to patient feedback with respect and humility	My company partners with patients to innovate and measure impact and outcomes that are important to them	My company provides access to support programmes and resources to help patients improve quality of life	Everything my company does begins with an understandin g of patient needs and experiences	My company helps empower patients to help other patients and their families
	A	В	С	D	Е	F	G	Н	ı	J
Base: Pharma Companies	675	675	675	675	675	675	675	675	675	675
Strongly agree 5	228	258	212	202	135	235	130	221	157	116
Strongly agree 3	34.0%	38.0%	31.0%	30.0%	20.0%	35.0%	19.0%	33.0%	23.0%	17.0%
	DEGIJ	ACDEGHIJ	EGIJ	EGIJ	20.070	DEGIJ	13.070	EGIJ	GJ	17.070
4	210	231	216	197	200	200	186	198	185	164
	31.0%	34.0%	32.0%	29.0%	30.0%	30.0%	28.0%	29.0%	27.0%	24.0%
	1	DEGHIJ	IJ	J	J	J	20.070	J	27.070	21.070
3	123	107	151	127	165	116	159	111	181	177
	18.0%	16.0%	22.0%	19.0%	24.0%	17.0%	24.0%	16.0%	27.0%	26.0%
			ABFH		ABDFH		ABDFH		ABCDFH	ABDFH
2	52	38	57	63	87	55	108	69	99	113
	8.0%	6.0%	8.0%	9.0%	13.0%	8.0%	16.0%	10.0%	15.0%	17.0%
			В	В	ABCDF	В	ABCDFH	В	ABCDFH	ABCDEFH
Strongly disagree 1	16	7	12	21	25	18	49	23	32	32
-	2.0%	1.0%	2.0%	3.0%	4.0%	3.0%	7.0%	3.0%	5.0%	5.0%
	В			В	BC	В	ABCDEFHIJ	В	ABCF	ABCF
Don't know or NA	46	34	27	65	63	51	43	53	21	73
	7.0%	5.0%	4.0%	10.0%	9.0%	8.0%	6.0%	8.0%	3.0%	11.0%
	CI	1		ABCGI	ABCGI	BCI	CI	BCI		ABCFGHI
Sigma	675	675	675	675	675	675	675	675	675	675

	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary										
TOP 2 BOX	438	489	428	399	335	435	316	419	342	280
	65.0%	72.0%	63.0%	59.0%	50.0%	64.0%	47.0%	62.0%	51.0%	41.0%
	DEGIJ	ACDEFGHIJ	EGIJ	EGIJ	J	DEGIJ	J	EGIJ	J	
BOTTOM 2 BOX	68	45	69	84	112	73	157	92	131	145
	10.0%	7.0%	10.0%	12.0%	17.0%	11.0%	23.0%	14.0%	19.0%	21.0%
	В		В	В	ABCDF	В	ABCDEFHI	ABC	ABCDFH	ABCDEFH
Mean	3.9	4.1	3.9	3.8	3.5	3.9	3.4	3.8	3.5	3.4
	DEGIJ	ACDEFGHIJ	EGIJ	EGIJ	GJ	DEGIJ		EGIJ	GJ	
Std. Dev.	1.1	0.9	1	1.1	1.1	1.1	1.2	1.1	1.2	1.1
Std. Err.	*	*	*	*	*	*	*	*	*	*
	·		·		·			·		

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G/H/I/J Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G/H/I/J Minimum Base: 5 (**), Small Base: 15 (*)



Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - Top 2 Box Summary

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job tit	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	E	F	G	Н	- I	J	K	L	M	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
My company helps make sure that the people	438	0	0	438	0	0	0	0	193	245	114	46	278	139	107	105	55	24	30	20	198	240
who need medicines have access to them	65.0%	-	-	65.0%	-	-	-	-	74.0%	59.0%	63.0%	58.0%	67.0%	65.0%	67.0%	66.0%	58.0%	63.0%	56.0%	62.0%	62.0%	67.0%
									- 1													
My company communicates with care and	489	0	0	489	0	0	0	0	211	278	123	57	309	157	123	115	65	27	34	25	225	264
compassion, transparent and unbiased	72.0%	-	-	72.0%	-	-	-	-	81.0%	67.0%	68.0%	72.0%	74.0%	73.0%	77.0%	72.0%	68.0%	71.0%	63.0%	78.0%	71.0%	74.0%
information on diseases, treatment options.									1						R							
My company provides easy-to-understand and	428	0	0	428	0	0	0	0	191	237	123	46	259	137	97	101	60	21	41	18	192	236
convenient information in plain language	63.0%	-	-	63.0%	-	-	-	-	73.0%	57.0%	68.0%	58.0%	62.0%	64.0%	61.0%	64.0%	63.0%	55.0%	76.0%	56.0%	60.0%	66.0%
because they understand that 'words matter'									1										NQ			
My company helps patients gain affordable	399	0	0	399	0	0	0	0	182	217	105	49	245	117	91	108	55	27	31	20	183	216
access to their medications	59.0%	-	-	59.0%	-	-	-	-	70.0%	52.0%	58.0%	62.0%	59.0%	55.0%	57.0%	68.0%	58.0%	71.0%	57.0%	62.0%	57.0%	61.0%
									1							MN						
My company equips patients to make informed	335	0	0	335	0	0	0	0	164	171	84	36	215	109	78	79	40	19	23	12	152	183
choices about healthcare and treatment	50.0%	-	-	50.0%	-	-	-	-	63.0%	41.0%	47.0%	46.0%	52.0%	51.0%	49.0%	50.0%	42.0%	50.0%	43.0%	38.0%	48.0%	51.0%
options									1													
My company listens and responds to patient	435	0	0	435	0	0	0	0	199	236	124	49	262	149	94	102	57	24	37	18	202	233
feedback with respect and humility	64.0%	-	-	64.0%	-	-	-	-	76.0%	57.0%	69.0%	62.0%	63.0%	70.0%	59.0%	64.0%	60.0%	63.0%	69.0%	56.0%	63.0%	65.0%
									1					N								
My company partners with patients to innovate	316	0	0	316	0	0	0	0	151	165	91	31	194	120	69	67	38	18	19	12	144	172
and measure impact and outcomes that are	47.0%	-	-	47.0%	-	-	-	-	58.0%	40.0%	51.0%	39.0%	47.0%	56.0%	43.0%	42.0%	40.0%	47.0%	35.0%	38.0%	45.0%	48.0%
important to them									1					NOPR								
My company provides access to support	419	0	0	419	0	0	0	0	186	233	92	41	286	137	99	100	47	21	27	20	188	231
programmes and resources to help patients	62.0%	-	-	62.0%	-	-	-	-	71.0%	56.0%	51.0%	52.0%	69.0%	64.0%	62.0%	63.0%	49.0%	55.0%	50.0%	62.0%	59.0%	65.0%
improve quality of life									1				JK	P	Р	P						
Everything my company does begins with an	342	0	0	342	0	0	0	0	174	168	102	43	197	111	80	76	54	19	25	14	161	181
understanding of patient needs and	51.0%	-	-	51.0%	-	-	-	-	67.0%	41.0%	57.0%	54.0%	47.0%	52.0%	50.0%	48.0%	57.0%	50.0%	46.0%	44.0%	50.0%	51.0%
experiences											L											
My company helps empower patients to help	280	0	0	280	0	0	0	0	143	137	80	32	168	94	59	68	36	16	24	11	132	148
other patients and their families	41.0%	-		41.0%		-	-	-	55.0%	33.0%	44.0%	41.0%	40.0%	44.0%	37.0%	43.0%	38.0%	42.0%	44.0%	34.0%	41.0%	42.0%
									l l												·	

Statistics:

Overlap formulae used

- Column Means: - column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: S (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)

Table of Contents



Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - Bottom 2 Box Summary

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower
		Α	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	T	U
Base: Pharma Companies	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
My company helps make sure that the people	68	0	0	68	0	0	0	0	14	54	22	13	33	19	15	15	13	5	12	2	33	35
who need medicines have access to them	10.0%	-	-	10.0%	-	-	-	-	5.0%	13.0%	12.0%	16.0%	8.0%	9.0%	9.0%	9.0%	14.0%	13.0%	22.0%	6.0%	10.0%	10.0%
who need medicines have access to them	10.070			20.070					3.070	Н	12.070	10.070	0.070	3.070	3.070	3.070	11.070	15.070	MNO	0.070	10.070	10.070
My company communicates with care and	45	0	0	45	0	0	0	0	11	34	8	9	28	15	10	12	4	2	5	2	23	22
compassion, transparent and unbiased	7.0%	-	-	7.0%	-	-	-	-	4.0%	8.0%	4.0%	11.0%	7.0%	7.0%	6.0%	8.0%	4.0%	5.0%	9.0%	6.0%	7.0%	6.0%
information on diseases, treatment options.	7.070			7.070					1.070	Н	1.070	11.070	7.070	7.070	0.070	0.070	1.070	5.070	3.070	0.070	7.070	0.070
My company provides easy-to-understand and	69	0	0	69	0	0	0	0	8	61	15	6	48	23	13	18	11	4	2	4	33	36
convenient information in plain language	10.0%	-	-	10.0%	-	-	-	-	3.0%	15.0%	8.0%	8.0%	12.0%	11.0%	8.0%	11.0%	12.0%	11.0%	4.0%	12.0%	10.0%	10.0%
because they understand that 'words matter'	10.070			20.070					3.070	Н	0.070	0.070	12.070	11.070	0.070	11.070	12.070	11.070	1.070	12.070	10.070	10.070
My company helps patients gain affordable	84	0	0	84	0	0	0	0	20	64	23	10	51	27	24	16	10	3	13	2	42	42
access to their medications	12.0%	-	-	12.0%	-	-	-	-	8.0%	15.0%	13.0%	13.0%	12.0%	13.0%	15.0%	10.0%	11.0%	8.0%	24.0%	6.0%	13.0%	12.0%
decess to their medications									0.070	Н	2010/1							0.072	MOPQS	0.071		
My company equips patients to make informed	112	0	0	112	0	0	0	0	25	87	25	17	70	25	25	33	17	5	17	6	53	59
choices about healthcare and treatment	17.0%	-	-	17.0%	-	-	-	-	10.0%	21.0%	14.0%	22.0%	17.0%	12.0%	16.0%	21.0%	18.0%	13.0%	31.0%	19.0%	17.0%	17.0%
ontions										Н						M			MNQ			
My company listens and responds to patient	73	0	0	73	0	0	0	0	11	62	20	9	44	17	21	19	12	6	6	5	34	39
feedback with respect and humility	11.0%	-	-	11.0%	-	-	-	-	4.0%	15.0%	11.0%	11.0%	11.0%	8.0%	13.0%	12.0%	13.0%	16.0%	11.0%	16.0%	11.0%	11.0%
recuback with respect and naminty										Н				0.0,1								
My company partners with patients to innovate	157	0	0	157	0	0	0	0	35	122	42	23	92	32	47	45	30	8	17	10	73	84
and measure impact and outcomes that are	23.0%	-	-	23.0%	-	-	-	-	13.0%	29.0%	23.0%	29.0%	22.0%	15.0%	29.0%	28.0%	32.0%	21.0%	31.0%	31.0%	23.0%	24.0%
important to them										Н					М	M	М		М	M		
My company provides access to support	92	0	0	92	0	0	0	0	22	70	33	14	45	28	26	16	12	6	14	3	42	50
programmes and resources to help patients	14.0%	-	-	14.0%	-	-	-	-	8.0%	17.0%	18.0%	18.0%	11.0%	13.0%	16.0%	10.0%	13.0%	16.0%	26.0%	9.0%	13.0%	14.0%
improve quality of life										Н	L								MOP			
Everything my company does begins with an	131	0	0	131	0	0	0	0	26	105	31	19	81	39	40	28	18	7	13	6	60	71
understanding of patient needs and	19.0%	-	-	19.0%	-	-	-	-	10.0%	25.0%	17.0%	24.0%	19.0%	18.0%	25.0%	18.0%	19.0%	18.0%	24.0%	19.0%	19.0%	20.0%
experiences										Н												
My company helps empower patients to help	145	0	0	145	0	0	0	0	28	117	41	16	88	35	43	38	21	7	15	9	72	73
other patients and their families	21.0%	-	-	21.0%		-	-	-	11.0%	28.0%	23.0%	20.0%	21.0%	16.0%	27.0%	24.0%	22.0%	18.0%	28.0%	28.0%	23.0%	21.0%
										Н					М							

Statistics:

Overlap formulae used - Column Means:


- column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: S (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)

Table of Contents



Q13. Company related statements agreement 1-5 scale - Patient centricity within my company - Mean Summary

					Туре				Confi	idence	Pha	rma: Company	/ size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower
		Α	В	С	D	Е	F	G	Н	1	J	К	L	М	N	0	P	Q	R	S	Т	U
Base: Pharma Companies	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
My company helps make sure that the people	3.9	-	-	3.9	-	-	-	-	4.2	3.8	4	3.8	3.9	3.9	4	4	3.8	3.8	3.6	4	3.9	4
who need medicines have access to them									1					R	R	R						
My company communicates with care and	4.1	-	-	4.1	-	-	-	-	4.3	3.9	4.2	3.9	4.1	4.1	4.1	4.1	4.1	4.1	3.9	4.1	4.1	4.1
compassion, transparent and unbiased									1		K											
My company provides easy-to-understand and	3.9	-	-	3.9	-	-	-	-	4.1	3.7	4.1	3.8	3.8	3.9	3.8	3.9	3.9	3.8	4.1	3.8	3.8	3.9
convenient information in plain language									1		L											
My company helps patients gain affordable	3.8	-	-	3.8	-	-	-	-	4.1	3.6	3.9	3.8	3.8	3.8	3.7	4	3.8	4.1	3.6	3.9	3.8	3.8
access to their medications									1							MNR		R				
My company equips patients to make informed	3.5	-	-	3.5	-	-	-	-	3.9	3.3	3.7	3.4	3.5	3.6	3.5	3.5	3.5	3.7	3.3	3.4	3.5	3.6
choices about healthcare and treatment									1					R								
My company listens and responds to patient	3.9	-	-	3.9	-	-	-	-	4.2	3.7	4	3.8	3.9	4.1	3.9	3.8	3.8	3.7	3.9	3.8	3.9	3.9
feedback with respect and humility									1					OP								
My company partners with patients to innovate	3.4	-	-	3.4	-	-	-	-	3.7	3.2	3.5	3.1	3.4	3.6	3.2	3.2	3.2	3.3	3	3.1	3.4	3.4
and measure impact and outcomes that are									1					NOPRS								
My company provides access to support	3.8	-	-	3.8	-	-	-	-	4.1	3.7	3.6	3.6	4	3.9	3.8	3.9	3.7	3.8	3.4	3.9	3.8	3.9
programmes and resources to help patients									1				JK	R	R	R						
Everything my company does begins with an	3.5	-	-	3.5	-	-	-	-	3.9	3.3	3.7	3.4	3.5	3.5	3.5	3.5	3.7	3.6	3.4	3.5	3.5	3.5
understanding of patient needs and									1													
My company helps empower patients to help	3.4	-	-	3.4	-	-	-	-	3.7	3.1	3.4	3.3	3.3	3.5	3.2	3.3	3.4	3.4	3.2	3	3.3	3.4
other patients and their families									1					NS								

Statistics: Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/k/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)
Table of Contents



Q18. Patient centricity status statements agreement 1-5 scale - long term success - When we focus on delivering the best patient outcomes, we will create the best results for patients, healthcare professionals and our companies

					Туре				Conf	dence	Pha	arma: Company	, size			Ger	ographical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	Е	F	G	н	- 1	J	К	L	М	N	0	Р	Q	R	S	Т	U
																					i	
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	425	0	0	425	0	0	0	0	182	243	107	46	272	135	94	109	54	22	40	20	205	220
	63.0%	-	-	63.0%	-	-	-	-	70.0%	59.0%	59.0%	58.0%	65.0%	63.0%	59.0%	69.0%	57.0%	58.0%	74.0%	62.0%	64.0%	62.0%
	179	0	0	179	0	0	0	0	I 56	123	52	25	102	58	44	39	28	14	NP 8	9	82	97
4	27.0%	-	-	27.0%	-	-	-	-	21.0%	30.0%	29.0%	32.0%	25.0%	27.0%	28.0%	25.0%	29.0%	37.0%	15.0%	28.0%	26.0%	27.0%
	27.076	_		27.076	-	-	-	-	21.076	30.0% H	25.076	32.076	23.076	27.076	28.076	23.076	23.076 R	37.0% R	13.0%	28.076	20.076	27.076
3	48	0	0	48	0	0	0	0	14	34	14	7	27	15	16	10	7	1	4	1	21	27
	7.0%	-	-	7.0%	-	-		-	5.0%	8.0%	8.0%	9.0%	6.0%	7.0%	10.0%	6.0%	7.0%	3.0%	7.0%	3.0%	7.0%	8.0%
																					i	
2	9	0	0	9	0	0	0	0	2	7	3	1	5	2	2	1	2	0	2	1	5	4
	1.0%	-	-	1.0%	-	-	-	-	1.0%	2.0%	2.0%	1.0%	1.0%	1.0%	1.0%	1.0%	2.0%	-	4.0%	3.0%	2.0%	1.0%
																						
Strongly disagree 1	2	0	0	2	0	0	0	0	0	2	2	0	0	1	0	0	0	1	0	0	1	1
	*	-	-	*	-	-	9	-	-	*	1.0%	-	-	•	-	-	-	3.0% NO	-	-	*	*
Don't know or NA	12	0	0	12	0	0	0	0	7	5	2	0	10	3	4	0	4	0	0	1	5	7
DOIL CKNOW OF IVA	2.0%	-	-	2.0%	-	-	-	-	3.0%	1.0%	1.0%	-	2.0%	1.0%	2.0%	-	4.0%	-	-	3.0%	2.0%	2.0%
	2.070			2.070					3.070	2.070	1.070		2.070	1.070	0		0			0	1	2.070
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	604	0	0	604	0	0	0	0	238	366	159	71	374	193	138	148	82	36	48	29	287	317
	89.0%	-	-	89.0%	-	-	-	-	91.0%	88.0%	88.0%	90.0%	90.0%	90.0%	86.0%	93.0% N	86.0%	95.0%	89.0%	91.0%	90.0%	89.0%
BOTTOM 2 BOX	11	0	0	11	0	0	0	0	2	9	5	1	5	3	2	1	2	1	2	1	6	5
BOTTOW 2 BOX	2.0%	-	-	2.0%	-	-	-	-	1.0%	2.0%	3.0%	1.0%	1.0%	1.0%	1.0%	1.0%	2.0%	3.0%	4.0%	3.0%	2.0%	1.0%
	2.070			2.070					1.070	2.070	3.070	1.070	1.070	1.070	1.070	1.070	2.070	3.070	4.070	3.076	2.070	1.070
Mean	4.5	-	-	4.5	-	-	-	-	4.6	4.5	4.5	4.5	4.6	4.5	4.5	4.6	4.5	4.5	4.6	4.5	4.5	4.5
									<u> </u>													
Std. Dev.	0.7	-	-	0.7	-	-	-	-	0.6	0.8	0.8	0.7	0.7	0.7	0.7	0.6	0.7	0.8	0.8	0.7	0.7	0.7
Std. Err.	*	-	-	*	-	-	-	-	*	*	0.1	0.1	*	*	0.1	0.1	0.1	0.1	0.1	0.1	*	*
Statistics:		1	1									1				1						

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q18. Patient centricity status statements agreement 1-5 scale - long term success - Finding the intersection where optimal outcomes for patients, healthcare professionals and pharma companies all coincide is the crucial skill in the pharma, biotech and medical device industry

					Туре				Confi	dence	Pha	ırma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		Α	В	С	D	E	F	G	Н		J	K	L	М	N	0	P	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	422	0	0	422	0	0	0	0	168	254	106	49	267	142	95	114	44	21	33	17	205	217
Strongly agree 5	63.0%	-	-	63.0%	-	-	-	-	64.0%	61.0%	59.0%	62.0%	64.0%	66.0% P	59.0% P	72.0% NPQS	46.0%	55.0%	61.0%	53.0%	64.0%	61.0%
4	165	0	0	165	0	0	0	0	57	108	52	20	93	52	38	28	29	7	16	8	75	90
	24.0%	-	-	24.0%	-	=	-	-	22.0%	26.0%	29.0%	25.0%	22.0%	24.0%	24.0%	18.0%	31.0%	18.0%	30.0%	25.0%	24.0%	25.0%
		_										_					0	_	0			
3	51 8.0%	0	0	51 8.0%	0	0	0	0	21 8.0%	30 7.0%	16 9.0%	5 6.0%	30 7.0%	12 6.0%	7.0%	9.0%	14 15.0%	5 13.0%	7.0%	5 16.0%	7.0%	28 8.0%
	8.0%	-	-	8.0%	-	-	-	-	8.0%	7.0%	9.0%	6.0%	7.0%	6.0%	7.0%	9.0%	15.0% MN	13.0%	7.0%	16.0% M	7.0%	8.0%
2	14	0	0	14	0	0	0	0	6	8	3	2	9	4	7	2	2	2	1	0	7	7
	2.0%	-	-	2.0%	-	-	-	-	2.0%	2.0%	2.0%	3.0%	2.0%	2.0%	4.0%	1.0%	2.0%	5.0%	2.0%	Ē	2.0%	2.0%
Strongly disagree 1	1	0	0	1	0	0	0	0	0	1	0	0	1	0	1	0	0	0	0	0	0	1
	*	-	-	*	-	-	-	-		*		-	*	-	1.0%	-	-	-	-	-	-	*
Don't know or NA	22	0	0	22	0	0	0	0	9	13	3	3	16	4	8	1	6	3	0	2	9	13
	3.0%	-	-	3.0%	-	-	-	-	3.0%	3.0%	2.0%	4.0%	4.0%	2.0%	5.0%	1.0%	6.0% MO	8.0% MOR	-	6.0%	3.0%	4.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	587	0	0	587	0	0	0	0	225	362	158	69	360	194	133	142	73	28	49	25	280	307
	87.0%	-	-	87.0%	-	-	-	-	86.0%	87.0%	88.0%	87.0%	87.0%	91.0%	83.0%	89.0%	77.0%	74.0%	91.0%	78.0%	88.0%	86.0%
DOTTOLLO DOV	45								_		3		4.0	NPQS		PQ	_		PQ		_	
BOTTOM 2 BOX	15 2.0%	0	0	15 2.0%	0	0	0	0	6 2.0%	9 2.0%	2.0%	3.0%	10 2.0%	2.0%	5.0%	1.0%	2.0%	5.0%	2.0%	0	7 2.0%	2.0%
	2.0%	-	-	2.070	-	1	-	-	2.076	2.0%	2.0%	3.0%	2.0%	2.0%	0	1.076	2.0%	3.0%	2.070	-	2.0%	2.0%
Mean	4.5	-	-	4.5	-	-	-	-	4.5	4.5	4.5	4.5	4.5	4.6	4.4	4.6	4.3	4.3	4.5	4.4	4.5	4.5
Std. Dev.	0.7	-	-	0.7	-	-	-	-	0.7	0.7	0.7	0.7	0.8	P 0.7	0.9	P 0.7	0.8	0.9	0.7	0.8	0.7	0.8
5.1.5						+			*	*	0.4		*	*								
Std. Err.	*	-	-		-	-	-	-	*	*	0.1	0.1	*	*	0.1	0.1	0.1	0.2	0.1	0.1	*	

Statistics:

Overlap formulae used

- Column Means:


Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q18. Patient centricity status statements agreement 1-5 scale - long term success - Focusing on patients" needs leads to better business outcomes

					Туре				Confi	dence	Pha	rma: Company	/ size			Gen	graphical loca	tion			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	387	0	0	387	0	0	0	0	165	222	99	43	245	124	85	92	65	22	34	20	190	197
0,10	57.0%	-	-	57.0%	-	-	-	-	63.0%	54.0%	55.0%	54.0%	59.0%	58.0%	53.0%	58.0%	68.0%	58.0%	63.0%	62.0%	60.0%	55.0%
4	190	0	0	190	0	0	0	0	67	123	55	21	114	59	44	49	N 21	12	12	9	94	96
	28.0%	-	-	28.0%	-	-	-	-	26.0%	30.0%	31.0%	27.0%	27.0%	28.0%	28.0%	31.0%	22.0%	32.0%	22.0%	28.0%	29.0%	27.0%
3	71	0	0	71	0	0	0	0	20	51	16	9	46	21	21	13	7	3	6	3	25	46
	11.0%	-		11.0%	-	-	-	-	8.0%	12.0%	9.0%	11.0%	11.0%	10.0%	13.0%	8.0%	7.0%	8.0%	11.0%	9.0%	8.0%	13.0% T
2	10	0	0	10	0	0	0	0	1	9	3	4	3	5	2	3	1	0	1	0	5	5
	1.0%	-	-	1.0%	-	-	=	-	*	2.0%	2.0%	5.0%	1.0%	2.0%	1.0%	2.0%	1.0%	-	2.0%	9	2.0%	1.0%
Strongly disagree 1	3	0	0	3	0	0	0	0	1	2	1	0	2	2	1	0	0	0	0	0	0	3
	*	-	-	*	-	-	-	-	*	*	1.0%	-	*	1.0%	1.0%	-	-	-	-	-	-	1.0%
Don't know or NA	14	0	0	14	0	0	0	0	7	7	6	2	6	3	7	2	1	1	1	0	5	9
	2.0%	-	-	2.0%	-	-	-	-	3.0%	2.0%	3.0%	3.0%	1.0%	1.0%	4.0%	1.0%	1.0%	3.0%	2.0%	-	2.0%	3.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	577	0	0	577	0	0	0	0	232	345	154	64	359	183	129	141	86	34	46	29	284	293
	85.0%	-	-	85.0%	-	-	-	-	89.0%	83.0%	86.0%	81.0%	86.0%	86.0%	81.0%	89.0% N	91.0% N	89.0%	85.0%	91.0%	89.0% U	82.0%
BOTTOM 2 BOX	13	0	0	13	0	0	0	0	2	11	4	4	5	7	3	3	1	0	1	0	5	8
	2.0%	-	-	2.0%	-	-	-	-	1.0%	3.0%	2.0%	5.0%	1.0%	3.0%	2.0%	2.0%	1.0%	-	2.0%	-	2.0%	2.0%
Mean	4.4	-	-	4.4	-	-	-	-	4.6	4.4	4.4	4.3	4.5	4.4	4.4	4.5	4.6	4.5	4.5	4.5	4.5	4.4
Std. Dev.	0.8	-	-	0.8	-	-	-	-	0.7	0.8	0.8	0.9	0.8	0.8	0.8	0.7	N 0.7	0.7	0.8	0.7	0.7	0.8
Chd Fan	*								*	*	0.1	0.1	*	0.1	0.1	0.1	0.1	0.1	0.1	0.1	*	*
Std. Err.	-	-	-	-	-	-	-	-	*	*	0.1	0.1	T	0.1	0.1	0.1	0.1	0.1	0.1	0.1	ļ ,	-

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q18. Patient centricity status statements agreement 1-5 scale - long term success - A long-term focus is key to success with patient-centric efforts

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	435	0	0	435	0	0	0	0	179	256	111	48	276	146	97	97	63	29	38	20	214	221
0,10	64.0%	-	-	64.0%	-	-	-	-	69.0%	62.0%	62.0%	61.0%	66.0%	68.0%	61.0%	61.0%	66.0%	76.0%	70.0%	62.0%	67.0%	62.0%
4	170	0	0	170	0	0	0	0	54	116	49	26	95	55	36	48	24	8	11	8	77	93
	25.0%	-	-	25.0%	-	-	-	-	21.0%	28.0%	27.0%	33.0%	23.0%	26.0%	22.0%	30.0%	25.0%	21.0%	20.0%	25.0%	24.0%	26.0%
3	40	0	0	40	0	0	0	0	16	H 24	8	3	29	7	14	10	3	0	4	2	14	26
	6.0%	-	-	6.0%	-	-	-	-	6.0%	6.0%	4.0%	4.0%	7.0%	3.0%	9.0%	6.0%	3.0%	-	7.0%	6.0%	4.0%	7.0%
2	8	0	0	8	0	0	0	0	3	5	2	1	5	2	M 3	2	1	0	0	1	5	3
	1.0%	-	-	1.0%	-	-	-	-	1.0%	1.0%	1.0%	1.0%	1.0%	1.0%	2.0%	1.0%	1.0%	-	-	3.0%	2.0%	1.0%
Strongly disagree 1	2	0	0	2	0	0	0	0	0	2	2	0	0	1	0	1	0	0	0	0	2	0
	*	-	-	*	-	=	-	9	9	*	1.0%	-	-	*	-	1.0%	÷	9	-	-	1.0%	-
Don't know or NA	20	0	0	20	0	0	0	0	9	11	8	1	11	3	10	1	4	1	1	1	7	13
	3.0%	-	-	3.0%	-	-	-	-	3.0%	3.0%	4.0%	1.0%	3.0%	1.0%	6.0% MO	1.0%	4.0% O	3.0%	2.0%	3.0%	2.0%	4.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	605	0	0	605	0	0	0	0	233	372	160	74	371	201	133	145	87	37	49	28	291	314
	90.0%	-	-	90.0%	-	-	-	-	89.0%	90.0%	89.0%	94.0%	89.0%	94.0% N	83.0%	91.0% N	92.0%	97.0% N	91.0%	88.0%	91.0%	88.0%
BOTTOM 2 BOX	10	0	0	10	0	0	0	0	3	7	4	1	5	3	3	3	1	0	0	1	7	3
	1.0%	-	-	1.0%	-	-	-	-	1.0%	2.0%	2.0%	1.0%	1.0%	1.0%	2.0%	2.0%	1.0%	-	-	3.0%	2.0%	1.0%
Mean	4.6	-	-	4.6	-	-	-	-	4.6	4.5	4.5	4.6	4.6	4.6	4.5	4.5	4.6	4.8	4.6	4.5	4.6	4.6
Std. Dev.	0.7	-	-	0.7	-	-	-	-	0.7	0.7	0.7	0.6	0.7	0.6	0.7	0.7	0.6	NOS 0.4	0.6	0.8	0.7	0.7
	*								*	*			*	*		0.4				0.4	*	*
Std. Err.	*	-	-	-	-	-	-	-	*	*	0.1	0.1	*		0.1	0.1	0.1	0.1	0.1	0.1	-	+ -

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q18. Patient centricity status statements agreement 1-5 scale - long term success - Companies can act in the best interest of patients but I don't believe we can achieve long-term business success by doing so

					Туре				Confi	dence	Pha	ırma: Company	size			Geo	ographical loca	tion			Job tit	itle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		Α	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
							_	_														
Base: Pharma Companies	675 34	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5		0	0	34 5.0%	0	0	-	0	16	18	9	7	18 4.0%	10	5.0%	3	8	1	4	0	11 3.0%	6.0%
	5.0%	-	-	5.0%	-	-	-	-	6.0%	4.0%	5.0%	9.0%	4.0%	5.0%	5.0%	2.0%	8.0% O	3.0%	7.0%	-	3.0%	6.0%
4	78	0	0	78	0	0	0	0	36	42	24	14	40	25	20	16	12	5	6	2	41	37
	12.0%	-	-	12.0%	-	-	-	-	14.0%	10.0%	13.0%	18.0%	10.0%	12.0%	12.0%	10.0%	13.0%	13.0%	11.0%	6.0%	13.0%	10.0%
												L										
3	103	0	0	103	0	0	0	0	36	67	36	11	56	27	29	27	13	1	11	3	42	61
	15.0%	-	-	15.0%	-	-	-	-	14.0%	16.0%	20.0%	14.0%	13.0%	13.0%	18.0%	17.0%	14.0%	3.0%	20.0%	9.0%	13.0%	17.0%
_			_				_	_			L				Q	Q	Q		Q			+
2	201	0	0	201	0	0	0	0	63	138	51	23	127	64	42	53	27	15	16	9	94	107
	30.0%	-	-	30.0%	-	-	-	-	24.0%	33.0% H	28.0%	29.0%	31.0%	30.0%	26.0%	33.0%	28.0%	39.0%	30.0%	28.0%	29.0%	30.0%
Strongly disagree 1	247	0	0	247	0	0	0	0	106	141	56	23	168	86	59	56	32	15	16	18	126	121
	37.0%	-	-	37.0%	-	-	-	-	41.0%	34.0%	31.0%	29.0%	40.0%	40.0%	37.0%	35.0%	34.0%	39.0%	30.0%	56.0%	39.0%	34.0%
													J							NOPR		
Don't know or NA	12	0	0	12	0	0	0	0	4	8	4	1	7	2	2	4	3	1	1	0	5	7
	2.0%	-	-	2.0%	-	-	-	-	2.0%	2.0%	2.0%	1.0%	2.0%	1.0%	1.0%	3.0%	3.0%	3.0%	2.0%	-	2.0%	2.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Signia	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	112	0	0	112	0	0	0	0	52	60	33	21	58	35	28	19	20	6	10	2	52	60
	17.0%	-	-	17.0%	-	-	-	-	20.0%	14.0%	18.0%	27.0%	14.0%	16.0%	18.0%	12.0%	21.0% OS	16.0%	19.0%	6.0%	16.0%	17.0%
BOTTOM 2 BOX	448	0	0	448	0	0	0	0	169	279	107	46	295	150	101	109	59	30	32	27	220	228
BOTTOM 2 BOX	66.0%	-	-	66.0%	-	-	-	-	65.0%	67.0%	59.0%	58.0%	71.0%	70.0%	63.0%	69.0%	62.0%	79.0%	59.0%	84.0%	69.0%	64.0%
	00.070			00.070					03.070	07.070	33.070	30.070	1K	70.070	03.070	03.070	02.070	P P	33.070	NPR	05.070	04.070
Mean	2.2	-	-	2.2	-	-	-	-	2.2	2.2	2.3	2.5	2.1	2.1	2.2	2.1	2.3	2	2.4	1.7	2.1	2.2
											L	L		S	S	S	S		S			
Std. Dev.	1.2	-	-	1.2	-	-	-	-	1.3	1.1	1.2	1.3	1.2	1.2	1.2	1.1	1.3	1.1	1.2	0.9	1.2	1.2
Std. Err.	*	_	_			1		_	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1
Stu. EII.		1 -	-		-	-	-	-	0.1	U.I	U.I	0.2	0.1	0.1	0.1	0.1	U.1	0.2	0.2	0.2	0.1	0.1

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q18. Patient centricity status statements agreement 1-5 scale - long term success - Companies must serve shareholders first

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			loh tit	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	Е	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	57	0	0	57	0	0	0	0	20	37	18	5	34	13	16	14	7	0	7	4	25	32
	8.0%	-	-	8.0%	-	-	-	-	8.0%	9.0%	10.0%	6.0%	8.0%	6.0%	10.0%	9.0%	7.0%	-	13.0%	12.0%	8.0%	9.0%
						_						_			Q			_	Q	Q		
4	92 14.0%	0	-	92 14.0%	0	- 0	0	0	46 18.0%	46 11.0%	35 19.0%	10.0%	49 12.0%	29 14.0%	15 9.0%	30 19.0%	12 13.0%	5 13.0%	9 17.0%	3.0%	49 15.0%	43 12.0%
	14.078	-	_	14.0%	_	-			18.0%	11.0%	13.076	10.0%	12.076	14.076	3.076	NS	13.076	13.0%	17.0%	3.0%	13.0%	12.0/6
3	220	0	0	220	0	0	0	0	87	133	51	37	132	62	51	54	37	14	20	11	119	101
	33.0%	-	-	33.0%	-	-	-	-	33.0%	32.0%	28.0%	47.0%	32.0%	29.0%	32.0%	34.0%	39.0%	37.0%	37.0%	34.0%	37.0%	28.0%
2	165	0	0	165	0	0	0	0	54	111	44	JL 13	108	62	37	38	17	9	12	9	73	92
2	24.0%	-	-	24.0%	-	-	-	-	21.0%	27.0%	24.0%	16.0%	26.0%	29.0%	23.0%	24.0%	18.0%	24.0%	22.0%	28.0%	23.0%	26.0%
														P								
Strongly disagree 1	129	0	0	129	0	0	0	0	50	79	31	10	88	43	37	21	22	9	6	7	50	79
	19.0%	-	-	19.0%	-	-	-	-	19.0%	19.0%	17.0%	13.0%	21.0%	20.0%	23.0%	13.0%	23.0%	24.0%	11.0%	22.0%	16.0%	22.0% T
Don't know or NA	12	0	0	12	0	0	0	0	4	8	1	6	5	5	4	2	0	1	0	0	3	9
	2.0%	-	-	2.0%	-	-	-	-	2.0%	2.0%	1.0%	8.0%	1.0%	2.0%	2.0%	1.0%		3.0%	-	-	1.0%	3.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	JL 79	416	214	160	159	95	38	54	32	319	356
Sigilia	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	149	0	0	149	0	0	0	0	66	83	53	13	83	42	31	44	19	5	16	5	74	75
lor 2 box	22.0%	-	-	22.0%	-	-	-	-	25.0%	20.0%	29.0%	16.0%	20.0%	20.0%	19.0%	28.0%	20.0%	13.0%	30.0%	16.0%	23.0%	21.0%
											KL											
BOTTOM 2 BOX	294 44.0%	0	0	294 44.0%	0	0	0	0	104 40.0%	190	75	23	196 47.0%	105	74 46.0%	59	39	18 47.0%	18	16	123	171
	44.0%	-	-	44.0%	-	=	-	-	40.0%	46.0%	42.0%	29.0%	47.0% K	49.0% OR	46.0%	37.0%	41.0%	47.0%	33.0%	50.0%	39.0%	48.0% T
Mean	2.7	-	-	2.7	-	-	-	-	2.7	2.6	2.8	2.8	2.6	2.6	2.6	2.9	2.6	2.4	3	2.6	2.8	2.6
Std. Dev.	1.2	_	_	1.2	_	-	-	-	1.2	1.2	1.2	1	1.2	1.1	1.2	MNQ 1.1	1.2	1	MNQ 1.2	1.2	1.1	1.2
Stu. Dev.	1.2	1 -	-	1.2	-	-		1	1.2	1.4	1.2	1	1.2	1.1	1.2	1.1	1.2	1	1.2	1.2	1.1	1.2
Std. Err.	*	-	-	*	-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q18. Patient centricity status statements agreement 1-5 scale - long term success - Pharma"s goals are misaligned with serving patients optimally

					Туре				Confi	dence	Pha	rma: Company	size			Gen	graphical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	Е	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	87	0	0	87	0	0	0	0	23	64	23	9	55	30	24	17	11	7	6	2	45	42
Strongly agree 3	13.0%	-	-	13.0%	-	-	-	-	9.0%	15.0%	13.0%	11.0%	13.0%	14.0%	15.0%	11.0%	12.0%	18.0%	11.0%	6.0%	14.0%	12.0%
4	213	0	0	213	0	0	0	0	70	H 143	66	24	123	62	48	59	33	12	22	8	105	108
*	32.0%	-	-	32.0%	-	-	-	-	27.0%	35.0%	37.0%	30.0%	30.0%	29.0%	30.0%	37.0%	35.0%	32.0%	41.0%	25.0%	33.0%	30.0%
_		_				_				Н								_				
3	187 28.0%	-	- 0	187 28.0%	-	0 -	0 -	-	69 26.0%	118 29.0%	48 27.0%	28 35.0%	111 27.0%	54 25.0%	45 28.0%	51 32.0%	24 25.0%	9 24.0%	13 24.0%	14 44.0%	84 26.0%	103 29.0%
																				MP		
2	121 18.0%	- 0	- 0	121 18.0%	0	0	0	0	61 23.0%	60 14.0%	24 13.0%	13 16.0%	84 20.0%	49 23.0%	23 14.0%	23 14.0%	15 16.0%	5 13.0%	6 11.0%	5 16.0%	56 18.0%	65 18.0%
	10.070			10.070					1	11.070	13.070	10.070	J	NO	21.070	11.070	10.070	13.070	11.070	10.070	10.070	10.070
Strongly disagree 1	50	0	0	50	0	0	0	0	33	17	15	3	32	15	13	8	10	3	6	2	23	27
	7.0%	-	-	7.0%	-	-	-	-	13.0%	4.0%	8.0%	4.0%	8.0%	7.0%	8.0%	5.0%	11.0%	8.0%	11.0%	6.0%	7.0%	8.0%
Don't know or NA	17	0	0	17	0	0	0	0	5	12	4	2	11	4	7	1	2	2	1	1	6	11
	3.0%	-	-	3.0%	-	-	-	-	2.0%	3.0%	2.0%	3.0%	3.0%	2.0%	4.0% O	1.0%	2.0%	5.0% O	2.0%	3.0%	2.0%	3.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	300	0	0	300	0	0	0	0	93	207	89	33	178	92	72	76	44	19	28	10	150	150
	44.0%	-	-	44.0%	-	-	-	-	36.0%	50.0% H	49.0%	42.0%	43.0%	43.0%	45.0%	48.0%	46.0%	50.0%	52.0%	31.0%	47.0%	42.0%
BOTTOM 2 BOX	171	0	0	171	0	0	0	0	94	77	39	16	116	64	36	31	25	8	12	7	79	92
	25.0%	-	-	25.0%	-	-	-	-	36.0%	19.0%	22.0%	20.0%	28.0%	30.0% O	22.0%	19.0%	26.0%	21.0%	22.0%	22.0%	25.0%	26.0%
Mean	3.3	-	-	3.3	-	-	-	-	3	3.4	3.3	3.3	3.2	3.2	3.3	3.3	3.2	3.4	3.3	3.1	3.3	3.2
Std. Dev.	1.1	-	-	1.1	-	-	-	-	1.2	H 1.1	1.1	1	1.2	1.2	1.2	1	1.2	1.2	1.2	1	1.1	1.1
Std. Err.	*	-	-	*	-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

tient Centricity Global Benchmarks

Table: 25

Q18. Patient centricity status statements agreement 1-5 scale - long term success - GRID SUMMARY

	When we focus on delivering the best patient outcomes, we will create the best results for patients, healthcare professionals and our companies	Finding the intersection where optimal outcomes for patients, healthcare professionals and pharma companies all coincide is the crucial skill in the pharma, biotech and medical device industry	Focusing on patients" needs leads to better business outcomes	A long-term focus is key to success with patient-centric efforts	Companies can act in the best interest of patients but I don"t believe we can achieve long-term business success by doing so	Companies must serve shareholders first	Pharma''s goals are misaligned with serving patients optimally
	A	В	С	D	E	F	G
Base: Pharma Companies	675	675	675	675	675	675	675
Strongly agree 5	425	422	387	435	34	57	87
Strongly agree 3	63.0%	63.0%	57.0%	64.0%	5.0%	8.0%	13.0%
	CEFG	CEFG	EFG	CEFG	3.070	E	EF
4	179	165	190	170	78	92	213
-	27.0%	24.0%	28.0%	25.0%	12.0%	14.0%	32.0%
	EF	EF EF	EF	EF EF			ABDEF
3	48	51	71	40	103	220	187
	7.0%	8.0%	11.0%	6.0%	15.0%	33.0%	28.0%
			ABD		ABCD	ABCDEG	ABCDE
2	9	14	10	8	201	165	121
	1.0%	2.0%	1.0%	1.0%	30.0%	24.0%	18.0%
					ABCDFG	ABCDG	ABCD
Strongly disagree 1	2	1	3	2	247	129	50
	*	*	*	*	37.0%	19.0%	7.0%

					ABCDFG	ABCDG	ABCD
Don't know or NA	12	22	14	20	12	12	17
	2.0%	3.0%	2.0%	3.0%	2.0%	2.0%	3.0%
		Α		Α			
Sigma	675	675	675	675	675	675	675
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary							
TOP 2 BOX	604	587	577	605	112	149	300
	89.0%	87.0%	85.0%	90.0%	17.0%	22.0%	44.0%
	CEFG	EFG	EFG	CEFG		E	EF
BOTTOM 2 BOX	11	15	13	10	448	294	171
	2.0%	2.0%	2.0%	1.0%	66.0%	44.0%	25.0%
					ABCDFG	ABCDG	ABCD
Mean	4.5	4.5	4.4	4.6	2.2	2.7	3.3
	CEFG	CEFG	EFG	CEFG		Е	EF
Std. Dev.	0.7	0.7	0.8	0.7	1.2	1.2	1.1
Std. Err.	*	*	*	*	*	*	*

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G Minimum Base: 5 (**), Small Base: 15 (*)



Q18. Patient centricity status statements agreement 1-5 scale - long term success - Top 2 Box Summary

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job titl	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower
		Α	В	С	D	Е	F	G	Н	1	J	K	L	М	N	0	P	Q	R	S	T	U
Base: Pharma Companies	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
When we focus on delivering the best patient	604	73	338	604	0	0	n	0	238	366	159	71	374	193	138	148	82	36	48	29	287	317
	89.0%	-	U	89.0%	-	-	-	-	91.0%	88.0%	88.0%	90.0%	90.0%	90.0%	86.0%	93.0%	86.0%	95.0%	89.0%	91.0%	90.0%	89.0%
outcomes, we will create the best results for patients, healthcare professionals and our	85.070	-	_	85.076	-	-	_	-	91.070	88.076	88.070	30.076	30.076	30.076	80.076	93.0% N	80.076	33.076	85.076	91.076	30.076	85.076
Finding the intersection where optimal	587	0	0	587	0	0	0	0	225	362	158	69	360	194	133	142	73	28	49	25	280	307
outcomes for patients, healthcare professionals	87.0%	0	U	87.0%	-	-	-	-	86.0%	87.0%	88.0%	87.0%	87.0%	91.0%	83.0%	89.0%	77.0%	74.0%	91.0%	78.0%	88.0%	86.0%
and pharma companies all coincide is the	87.0%	_		87.0%	_	-	-	_	80.076	87.076	88.076	87.0%	87.0%	NPQS	83.076	PQ	77.078	74.0%	PQ	78.076	88.076	80.076
Focusing on patients' needs leads to better	577	0	0	577	0	0	n	0	232	345	154	64	359	183	129	141	86	34	46	29	284	293
business outcomes	85.0%	-	-	85.0%	-	-	-	-	89.0%	83.0%	86.0%	81.0%	86.0%	86.0%	81.0%	89.0%	91.0%	89.0%	85.0%	91.0%	89.0%	82.0%
business outcomes	03.070			05.070					1	03.070	00.070	01.070	00.070	80.070	01.070	N	N N	65.076	05.070	31.070	11	02.070
A long-term focus is key to success with patient-	605	0	0	605	0	0	0	0	233	372	160	74	371	201	133	145	87	37	49	28	291	314
centric efforts	90.0%	-	-	90.0%	-	-	-	-	89.0%	90.0%	89.0%	94.0%	89.0%	94.0%	83.0%	91.0%	92.0%	97.0%	91.0%	88.0%	91.0%	88.0%
centre enorg				00.071						00.0	001071		00.0.1	N	00.071	N		N	0.1107.1	00.0,1	02.07.	00.07.
Companies can act in the best interest of	112	0	0	112	0	0	0	0	52	60	33	21	58	35	28	19	20	6	10	2	52	60
patients but I don't believe we can achieve long-	17.0%	-	-	17.0%	-	-	-	-	20.0%	14.0%	18.0%	27.0%	14.0%	16.0%	18.0%	12.0%	21.0%	16.0%	19.0%	6.0%	16.0%	17.0%
term business success by doing so												L					OS					
Companies must serve shareholders first	149	0	0	149	0	0	0	0	66	83	53	13	83	42	31	44	19	5	16	5	74	75
,	22.0%	-	-	22.0%	-	-	-	-	25.0%	20.0%	29.0%	16.0%	20.0%	20.0%	19.0%	28.0%	20.0%	13.0%	30.0%	16.0%	23.0%	21.0%
											KL											
Pharma's goals are misaligned with serving	300	0	0	300	0	0	0	0	93	207	89	33	178	92	72	76	44	19	28	10	150	150
patients optimally	44.0%	-	-	44.0%	-	-	-	-	36.0%	50.0%	49.0%	42.0%	43.0%	43.0%	45.0%	48.0%	46.0%	50.0%	52.0%	31.0%	47.0%	42.0%
										Н												

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

Column Proportions:

Column Stested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q18. Patient centricity status statements agreement 1-5 scale - long term success - Bottom 2 Box Summary

					Туре				Confi	dence	Pha	rma: Company	size			Geo	ographical loca	ition			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower
		Α	В	С	D	E	F	G	Н	- 1	J	К	L	М	N	0	Р	Q	R	S	T	U
Base: Pharma Companies	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
When we focus on delivering the best patient	11	0	0	11	0	0	0	0	2	9	5	1	5	3	2	1	2	1	2	1	6	5
outcomes, we will create the best results for	2.0%	-	-	2.0%	-	-	-	-	1.0%	2.0%	3.0%	1.0%	1.0%	1.0%	1.0%	1.0%	2.0%	3.0%	4.0%	3.0%	2.0%	1.0%
patients, healthcare professionals and our																						
Finding the intersection where optimal	15	0	0	15	0	0	0	0	6	9	3	2	10	4	8	2	2	2	1	0	7	8
outcomes for patients, healthcare professionals	2.0%	-	-	2.0%	-	-	-	-	2.0%	2.0%	2.0%	3.0%	2.0%	2.0%	5.0%	1.0%	2.0%	5.0%	2.0%	-	2.0%	2.0%
and pharma companies all coincide is the															0							
Focusing on patients' needs leads to better	13	0	0	13	0	0	0	0	2	11	4	4	5	7	3	3	1	0	1	0	5	8
business outcomes	2.0%	-	-	2.0%	-	-	-	-	1.0%	3.0%	2.0%	5.0%	1.0%	3.0%	2.0%	2.0%	1.0%	-	2.0%	-	2.0%	2.0%
A long-term focus is key to success with patient-	10	0	0	10	0	0	0	0	3	7	4	1	5	3	3	3	1	0	0	1	7	3
centric efforts	1.0%	-	-	1.0%	-	-	-	-	1.0%	2.0%	2.0%	1.0%	1.0%	1.0%	2.0%	2.0%	1.0%	-	-	3.0%	2.0%	1.0%
Companies can act in the best interest of	448	0	0	448	0	0	0	0	169	279	107	46	295	150	101	109	59	30	32	27	220	228
patients but I don't believe we can achieve long-	66.0%	-	-	66.0%	-	-	-	-	65.0%	67.0%	59.0%	58.0%	71.0%	70.0%	63.0%	69.0%	62.0%	79.0%	59.0%	84.0%	69.0%	64.0%
term business success by doing so													JK					Р		NPR		
Companies must serve shareholders first	294	0	0	294	0	0	0	0	104	190	75	23	196	105	74	59	39	18	18	16	123	171
,	44.0%	-	-	44.0%	-	-	-	-	40.0%	46.0%	42.0%	29.0%	47.0%	49.0%	46.0%	37.0%	41.0%	47.0%	33.0%	50.0%	39.0%	48.0%
													K	OR								T
Pharma's goals are misaligned with serving	171	0	0	171	0	0	0	0	94	77	39	16	116	64	36	31	25	8	12	7	79	92
patients optimally	25.0%	-	-	25.0%	-	-	-	-	36.0%	19.0%	22.0%	20.0%	28.0%	30.0%	22.0%	19.0%	26.0%	21.0%	22.0%	22.0%	25.0%	26.0%
														0								


Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

wininum base: 3 (), Jinan base: 12 ()
Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)
Table of Contents



Q18. Patient centricity status statements agreement 1-5 scale - long term success - Mean Summary

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job titl	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower
		Α	В	С	D	Е	F	G	Н	l l	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
When we focus on delivering the best patient	4.5	-	-	4.5	-	-	-	-	4.6	4.5	4.5	4.5	4.6	4.5	4.5	4.6	4.5	4.5	4.6	4.5	4.5	4.5
outcomes, we will create the best results for									1													
Finding the intersection where optimal	4.5	-	-	4.5	-	-	-	-	4.5	4.5	4.5	4.5	4.5	4.6	4.4	4.6	4.3	4.3	4.5	4.4	4.5	4.5
outcomes for patients, healthcare professionals														P		P						
Focusing on patients' needs leads to better	4.4	-	-	4.4	-	-	-	-	4.6	4.4	4.4	4.3	4.5	4.4	4.4	4.5	4.6	4.5	4.5	4.5	4.5	4.4
business outcomes									1								N					
A long-term focus is key to success with patient-	4.6	-	-	4.6	-	-	-	-	4.6	4.5	4.5	4.6	4.6	4.6	4.5	4.5	4.6	4.8	4.6	4.5	4.6	4.6
centric efforts																		NOS				
Companies can act in the best interest of	2.2	-	-	2.2	-	-	-	-	2.2	2.2	2.3	2.5	2.1	2.1	2.2	2.1	2.3	2	2.4	1.7	2.1	2.2
patients but I don't believe we can achieve long-											L	L		S	S	S	S		S			
Companies must serve shareholders first	2.7	-	-	2.7	-	-	-	-	2.7	2.6	2.8	2.8	2.6	2.6	2.6	2.9	2.6	2.4	3	2.6	2.8	2.6
																MNQ			MNQ			
Pharma's goals are misaligned with serving	3.3	-	-	3.3	-	-	-	-	3	3.4	3.3	3.3	3.2	3.2	3.3	3.3	3.2	3.4	3.3	3.1	3.3	3.2
patients optimally										H								1				1

Statistics: Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)

Minimum Base, 3 (*), Sindin Base, 13 (*)

Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

Table of Contents



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I believe in my company"s future

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			loh tit	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	307	0	0	307	0	0	0	0	157	150	93	32	182	91	77	68	42	19	30	16	161	146
	45.0%	-	-	45.0%	-	-	-	- C	60.0%	36.0%	52.0%	41.0%	44.0%	43.0%	48.0%	43.0%	44.0%	50.0%	56.0%	50.0%	50.0%	41.0%
4	212	0	0	212	0	0	0	0	63	149	44	28	140	76	55	45	28	10	11	11	U 96	116
	31.0%	-	-	31.0%	-	-	-	-	24.0%	36.0%	24.0%	35.0%	34.0%	36.0%	34.0%	28.0%	29.0%	26.0%	20.0%	34.0%	30.0%	33.0%
2	100	0	0	100	0	0	0	0	30	70	24	14	62	R 27	21	30	17	7	9	2	38	62
3	15.0%	-	-	15.0%	-	-	-	-	11.0%	17.0%	13.0%	18.0%	15.0%	13.0%	13.0%	19.0%	18.0%	18.0%	17.0%	6.0%	12.0%	17.0%
2	33	0	0	33	0	0	0	0	4	29	8	3	22	14	2	11	3	0	1	2	12	T 21
	5.0%	-	-	5.0%	-	-	-	-	2.0%	7.0%	4.0%	4.0%	5.0%	7.0%	1.0%	7.0%	3.0%	-	2.0%	6.0%	4.0%	6.0%
Channels discount 4	9	0	0	9	0	0	0	0	2	H 7	3	2	4	N 3	0	N 3	1	1	2	0	5	4
Strongly disagree 1	1.0%	-	-	1.0%	-	-	-	-	1.0%	2.0%	2.0%	3.0%	1.0%	1.0%	-	2.0%	1.0%	3.0%	4.0%	-	2.0%	1.0%
Don't know or NA	14	0	0	14	0	0	0	0	5	9	8	0	6	3	5	2	4	N 1	N 1	1	7	7
DOIL CKNOW OF IVA	2.0%	-	-	2.0%	-	-	-	-	2.0%	2.0%	4.0%	-	1.0%	1.0%	3.0%	1.0%	4.0%	3.0%	2.0%	3.0%	2.0%	2.0%
Sigma	675	0	0	675	0	0	0	0	261	414	L 180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	519	0	0	519	0	0	0	0	220	299	137	60	322	167	132	113	70	29	41	27	257	262
	77.0%	-	-	77.0%	-	-	-	-	84.0%	72.0%	76.0%	76.0%	77.0%	78.0%	82.0% O	71.0%	74.0%	76.0%	76.0%	84.0%	81.0% U	74.0%
BOTTOM 2 BOX	42	0	0	42	0	0	0	0	6	36	11	5	26	17	2	14	4	1	3	2	17	25
	6.0%	-	-	6.0%	-	-	-	-	2.0%	9.0% H	6.0%	6.0%	6.0%	8.0% N	1.0%	9.0% N	4.0%	3.0%	6.0%	6.0%	5.0%	7.0%
Mean	4.2	-	-	4.2	-	-	-	-	4.4	4	4.3	4.1	4.2	4.1	4.3	4	4.2	4.2	4.2	4.3	4.3	4.1
Std. Dev.	1	-	-	1	-	-	-	-	0.8	1	1	1	0.9	1	MO 0.8	1	0.9	1	1.1	0.9	U 0.9	1
Std. Err.	*	_	_		_	-	_	_	0.1	*	0.1	0.1	*	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1
56.2					1	+			0.1		0.1	0.1		0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I care about the company"s vision and goals

					Туре				Confi	dence	Pha	arma: Company	size			Geo	ographical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	- 1	J	K	L	M	N	0	Р	Q	R	S	T	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	404	0	0	404	0	0	0	0	186	218	112	49	243	124	92	93	63	29	34	21	211	193
	60.0%	-	-	60.0%	-	-	-	-	71.0%	53.0%	62.0%	62.0%	58.0%	58.0%	58.0%	58.0%	66.0%	76.0%	63.0%	66.0%	66.0%	54.0%
	201	0	0	201	0	0	0	0	54	147	47	23	131	71	49	49	21	MNO 4	13	8	U 84	117
4	30.0%	-	-	30.0%	-	-	-	-	21.0%	36.0%	26.0%	29.0%	31.0%	33.0%	31.0%	31.0%	22.0%	11.0%	24.0%	25.0%	26.0%	33.0%
	30.076	_		30.076	_	-	-	_	21.076	30.0% H	20.076	25.076	31.076	PQ	0	Q Q	22.076	11.0%	24.078	23.076	20.076	33.076
3	44	0	0	44	0	0	0	0	12	32	13	5	26	14	13	11	7	3	3	2	16	28
	7.0%	-	-	7.0%	-	-	-	-	5.0%	8.0%	7.0%	6.0%	6.0%	7.0%	8.0%	7.0%	7.0%	8.0%	6.0%	6.0%	5.0%	8.0%
2	10	0	0	10	0	0	0	0	2	8	2	2	6	1	1	4	0	1	3	0	3	7
	1.0%	-	-	1.0%	-	-	-	-	1.0%	2.0%	1.0%	3.0%	1.0%	*	1.0%	3.0%	-	3.0%	6.0%	-	1.0%	2.0%
																			MNP			
Strongly disagree 1	3	0	0	3	0	0	0	0	1	2	0	0	3	2	0	0	1	0	0	0	0	3
	*	-	-	•	-	-	-	-	*	*	-	-	1.0%	1.0%	-	-	1.0%	-	-	-	-	1.0%
Don't know or NA	13	0	0	13	0	0	0	0	6	7	6	0	7	2	5	2	3	1	1	1	5	8
	2.0%	-	-	2.0%	-	-	-	-	2.0%	2.0%	3.0%	-	2.0%	1.0%	3.0%	1.0%	3.0%	3.0%	2.0%	3.0%	2.0%	2.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Signia	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	605	0	0	605	0	0	0	0	240	365	159	72	374	195	141	142	84	33	47	29	295	310
	90.0%	-	-	90.0%	-	-	-	-	92.0%	88.0%	88.0%	91.0%	90.0%	91.0%	88.0%	89.0%	88.0%	87.0%	87.0%	91.0%	92.0% U	87.0%
BOTTOM 2 BOX	13	0	0	13	0	0	0	0	3	10	2	2	9	3	1	4	1	1	3	0	3	10
	2.0%	=	-	2.0%	-	=	-	-	1.0%	2.0%	1.0%	3.0%	2.0%	1.0%	1.0%	3.0%	1.0%	3.0%	6.0%	-	1.0%	3.0%
																			N			
Mean	4.5	-	-	4.5	-	-	-	-	4.7	4.4	4.5	4.5	4.5	4.5	4.5	4.5	4.6	4.6	4.5	4.6	4.6	4.4
Std. Dev.	0.7	-	-	0.7	-	-	-	-	0.6	0.8	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.8	0.8	0.6	U 0.6	0.8
Std. Err.	*	-	-	*	-	-	-	-	*	*	0.1	0.1	*	*	0.1	0.1	0.1	0.1	0.1	0.1	*	*
Statistics			1																		l	

Statistics:

Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

Minimum Base: 5 (**), Small Base: 15 (*)

Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I am confident my company is making the world a better place

					Туре				Confi	dence	Pha	rma: Company	size			Geo	ographical loca	tion			loh titi	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	279	0	0	279	0	0	0	0	144	135	87	27	165	89	65	66	40	16	21	15	142	137
Strongly agree 3	41.0%	-	-	41.0%	-	-	-	-	55.0%	33.0%	48.0%	34.0%	40.0%	42.0%	41.0%	42.0%	42.0%	42.0%	39.0%	47.0%	45.0%	38.0%
											KL											
4	234 35.0%	0	-	234 35.0%	0	- 0	0	0	82 31.0%	152 37.0%	51 28.0%	29 37.0%	154 37.0%	76 36.0%	56 35.0%	54 34.0%	27 28.0%	13 34.0%	16 30.0%	9 28.0%	112 35.0%	122 34.0%
	33.070			33.070					32.070	37.070	20.070	37.070	J	50.070	33.070	31.070	20.070	31.070	30.070	20.070	33.070	31.070
3	117	0	0	117	0	0	0	0	24	93	30	16	71	32	31	26	25	7	11	8	46	71
	17.0%	-	-	17.0%	-	-	-	-	9.0%	22.0% H	17.0%	20.0%	17.0%	15.0%	19.0%	16.0%	26.0% MO	18.0%	20.0%	25.0%	14.0%	20.0%
2	28	0	0	28	0	0	0	0	6	22	8	5	15	12	4	7	3	1	2	0	11	17
	4.0%	-	-	4.0%	-	-	-	-	2.0%	5.0%	4.0%	6.0%	4.0%	6.0%	2.0%	4.0%	3.0%	3.0%	4.0%	÷	3.0%	5.0%
Strongly disagree 1	10	0	0	10	0	0	0	0	2	8	0	2	8	2	2	4	0	0	3	0	3	7
Strongly disagree 1	1.0%	-	-	1.0%	-	-	-	-	1.0%	2.0%	-	3.0%	2.0%	1.0%	1.0%	3.0%	-	-	6.0%	-	1.0%	2.0%
Dariet Income and NA	7	0	0	7	0	0	0	0	3	4	4	J O	3	3	2	2	0	1	MP 1	0	5	2
Don't know or NA	1.0%	-	-	1.0%	-	-	-	-	1.0%	1.0%	2.0%	-	1.0%	1.0%	1.0%	1.0%	-	3.0%	2.0%	-	2.0%	1.0%
Sigma	675 100.0%	0.0%	0.0%	675 100.0%	0.0%	0.0%	0.0%	0.0%	261 100.0%	414 100.0%	180 100.0%	79 100.0%	416 100.0%	214 100.0%	160 100.0%	159 100.0%	95 100.0%	38 100.0%	54 100.0%	32 100.0%	319 100.0%	356 100.0%
	100.070	0.070	0.070	100.070	0.070	0.070	0.070	0.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070	100.070
Summary																						
TOP 2 BOX	513	0	0	513	0	0	0	0	226	287	138	56	319	165	121	120	67	29	37	24	254	259
	76.0%	-	-	76.0%	-	-	-	-	87.0%	69.0%	77.0%	71.0%	77.0%	77.0%	76.0%	75.0%	71.0%	76.0%	69.0%	75.0%	80.0% U	73.0%
BOTTOM 2 BOX	38	0	0	38	0	0	0	0	8	30	8	7	23	14	6	11	3	1	5	0	14	24
	6.0%	-	-	6.0%	-	-	-	-	3.0%	7.0% H	4.0%	9.0%	6.0%	7.0%	4.0%	7.0%	3.0%	3.0%	9.0%	-	4.0%	7.0%
Mean	4.1	-	-	4.1	-	-	-	-	4.4	3.9	4.2	3.9	4.1	4.1	4.1	4.1	4.1	4.2	3.9	4.2	4.2	4
Std. Dev.	0.9	_	-	0.9	_	-	-	-	0.8	1	K 0.9	1	0.9	0.9	0.9	1	0.9	0.8	1.1	0.8	U 0.9	1
Sta. Dev.	0.9	1	-	0.5	-		-	1	0.0	1	0.5	1	0.5	0.5	0.5	1	0.5	0.0	1.1	0.0	0.5	-
Std. Err.	*	-	-	*	-	-	-	-	0.1	*	0.1	0.1	*	0.1	0.1	0.1	0.1	0.1	0.2	0.1	*	0.1
Statistics:								1														

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I am proud to tell people outside our industry that I work in a pharma, biotech/ medical device company

Base: Pharma Companies 6: Strongly agree 5 34 52: 4 11: 29: 3 7 11: 2 2 2 4. Strongly disagree 1 1 2.0 Don't know or NA 1	75 48 .0% 99 .0%	Patient or Health Charity A 0 0 0	B 0 0	C 675 348 52.0%	D 0 0	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Confi Very confident	Less confident	Small	rma: Company Medium	Large	Global	Europe	North and Central	graphical loca Asia	Africa	South America	Australasia	Department Head or	
Base: Pharma Companies 6: Strongly agree 5 34 52: 4 11: 29: 3 7 11: 2 2 2 4. Strongly disagree 1 1 2.0 Don't know or NA 1	75 48 .0% 99 .0%	A 0 0 -	B 0 0	C 675 348	D 0	(not part of any other group)	·	Health Charity and Patients	confident													
Strongly agree 5 3 3 52 4 11 29 3 7 11 2 2 2 4 Strongly disagree 1 1 2 Don't know or NA 1	48 .0% 99 .0%	0 0 -	0	675 348	0		F	G								America					higher	managers o lower
Strongly agree 5 33 52	48 .0% 99 .0%	0 -	0	348	_	0			Н		J	K	L	М	N	0	Р	Q	R	S	Т	U
Strongly agree 5 33 52	48 .0% 99 .0%	0 -	0	348	_	0																
52. 4 11 29. 3 7 11. 2 2 4. Strongly disagree 1 1 2.0 Don't know or NA 1	.0% 99 .0%	- 0	-		0		0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
4 19 29 3 7 11. 2 2 2 4. Strongly disagree 1 1 2.0 Don't know or NA 1	99 .0%	0	-	52.0%		0	0	0	172	176	104	36	208	110	76	79	59	21	27	19	173	175
29. 3 7 11. 2 2 4. Strongly disagree 1 1 2.0 Don't know or NA 1	.0%				-	-	-	-	66.0%	43.0%	58.0%	46.0%	50.0%	51.0%	48.0%	50.0%	62.0% NO	55.0%	50.0%	59.0%	54.0%	49.0%
3 7 11. 2 2 2 4. Strongly disagree 1 1 2.0 Don't know or NA 1	77		0	199	0	0	0	0	61	138	45	29	125	68	42	52	19	12	17	5	91	108
11. 2			-	29.0%		=	1	-	23.0%	33.0%	25.0%	37.0%	30.0%	32.0%	26.0%	33.0%	20.0%	32.0%	31.0%	16.0%	29.0%	30.0%
11. 2 2 4.										Н				P		P						
2 2 4.4 Strongly disagree 1 1 2.6 Don't know or NA 1 1	.0%	0	0	77	0	0	0	0	19	58	17	12	48	23	23	17	9	2	7	4	36	41
4.0		-	-	11.0%	-	-	-	-	7.0%	14.0%	9.0%	15.0%	12.0%	11.0%	14.0%	11.0%	9.0%	5.0%	13.0%	12.0%	11.0%	12.0%
4.0 4.0	20	0	0	28	0	0	0	0	3	H 25	5	2	21	7	10	7	4	1	2	3	8	20
Strongly disagree 1		-	-	4.0%	-	-	-	-	1.0%	6.0%	3.0%	3.0%	5.0%	3.0%	6.0%	4.0%	4.0%	3.0%	4.0%	9.0%	3.0%	6.0%
2.0 Don't know or NA 1	U%	-	-	4.0%	-	-	-	-	1.0%	6.0% H	3.0%	3.0%	3.0%	3.0%	0.0%	4.0%	4.0%	3.0%	4.0%	9.0%	3.0%	0.0% T
Don't know or NA 1	12	0	0	12	0	0	0	0	2	10	4	0	8	4	5	2	1	1	1	1	4	8
	0%	-	-	2.0%	-	-	-	-	1.0%	2.0%	2.0%	-	2.0%	2.0%	3.0%	1.0%	1.0%	3.0%	2.0%	3.0%	1.0%	2.0%
2.0	11	0	0	11	0	0	0	0	4	7	5	0	6	2	4	2	3	1	0	0	7	4
	0%	9	-	2.0%	-	-	9	-	2.0%	2.0%	3.0%	-	1.0%	1.0%	2.0%	1.0%	3.0%	3.0%	-	-	2.0%	1.0%
Sigma 67	75	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
	47	0	0	547	0	0	0	0	233	314	149	65	333	178	118	131	78	33	44	24	264	283
81.		-	-	81.0%	-	-	-	-	89.0%	76.0%	83.0%	82.0%	80.0%	83.0%	74.0%	82.0%	82.0%	87.0%	81.0%	75.0%	83.0%	79.0%
									1					N								
	10	0	0	40	0	0	0	0	5	35	9	2	29	11	15	9	5	2	3	4	12	28
6.0	0%	-	-	6.0%	-	-	-	-	2.0%	8.0% H	5.0%	3.0%	7.0%	5.0%	9.0%	6.0%	5.0%	5.0%	6.0%	12.0%	4.0%	8.0% T
Mean 4.	1.3	-	-	4.3	-	-	-	-	4.5	4.1	4.4	4.3	4.2	4.3	4.1	4.3	4.4	4.4	4.2	4.2	4.3	4.2
				4.5					1	4.1	7.7	4.5	4.2	4.5	4.1	4.5	N N	4.4	7.2	7.2	U	7.2
Std. Dev. 0.).9	0	9	0.9	=	9	-	-	0.7	1	0.9	0.8	1	0.9	1.1	0.9	0.9	0.9	1	1.2	0.9	1
Std. Err.		-	-		-	-	-	-	*	0.1	0.1	0.1	*	0.1	0.1	0.1	0.1	0.2	0.1	0.2	*	0.1

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I know how to communicate my role such that people outside our industry understand and admire our work

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	268	0	0	268	0	0	0	0	124	144	89	22	157	83	56	58	43	11	23	16	120	148
	40.0%	-	-	40.0%	-	-	-	-	48.0%	35.0%	49.0%	28.0%	38.0%	39.0%	35.0%	36.0%	45.0%	29.0%	43.0%	50.0%	38.0%	42.0%
									1		KL						Q			Q		
4	260 39.0%	- 0	- 0	260 39.0%	- 0	- 0	0	- 0	92 35.0%	168 41.0%	57 32.0%	38 48.0%	165 40.0%	83 39.0%	58 36.0%	70 44.0%	36 38.0%	16 42.0%	19 35.0%	12 38.0%	129 40.0%	131 37.0%
	39.0%	-	-	39.0%	-	-	-	-	35.0%	41.0%	32.0%	48.0%	40.0%	39.0%	36.0%	44.0%	38.0%	42.0%	35.0%	38.0%	40.0%	37.0%
3	88	0	0	88	0	0	0	0	29	59	22	11	55	34	25	16	8	5	6	2	42	46
	13.0%	-	-	13.0%	-	-	-	-	11.0%	14.0%	12.0%	14.0%	13.0%	16.0%	16.0%	10.0%	8.0%	13.0%	11.0%	6.0%	13.0%	13.0%
2	41	0	0	41	0	0	0	0	10	31	6	8	27	9	12	13	6	3	6	1	22	19
_	6.0%	-	-	6.0%	-	-	-	-	4.0%	7.0%	3.0%	10.0%	6.0%	4.0%	8.0%	8.0%	6.0%	8.0%	11.0%	3.0%	7.0%	5.0%
												J							M			
Strongly disagree 1	10	0	0	10	0	0	0	0	3	7	3	0	7	2	6	1	1	2	0	1	2	8
	1.0%	-	-	1.0%	-	=	-	-	1.0%	2.0%	2.0%	-	2.0%	1.0%	4.0%	1.0%	1.0%	5.0% O	-	3.0%	1.0%	2.0%
Don't know or NA	8	0	0	8	0	0	0	0	3	5	3	0	5	3	3	1	1	1	0	0	4	4
	1.0%	-	-	1.0%	-	-	-	-	1.0%	1.0%	2.0%	-	1.0%	1.0%	2.0%	1.0%	1.0%	3.0%	-	-	1.0%	1.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	528	0	0	528	0	0	0	0	216	312	146	60	322	166	114	128	79	27	42	28	249	279
10. 2 50%	78.0%	-	-	78.0%	-	-	-	-	83.0%	75.0%	81.0%	76.0%	77.0%	78.0%	71.0%	81.0%	83.0%	71.0%	78.0%	88.0%	78.0%	78.0%
									I							N	N					
BOTTOM 2 BOX	51	0	0	51	0	0	0	0	13	38	9	8	34	11	18	14	7	5	6	2	24	27
	8.0%	-	-	8.0%	-	=	-	-	5.0%	9.0% H	5.0%	10.0%	8.0%	5.0%	11.0% M	9.0%	7.0%	13.0%	11.0%	6.0%	8.0%	8.0%
Mean	4.1	-	-	4.1	-	-	-	-	4.3	4	4.3	3.9	4.1	4.1	3.9	4.1	4.2	3.8	4.1	4.3	4.1	4.1
									1		KL						NQ					
Std. Dev.	1	-	-	1	-	=	-	-	0.9	1	0.9	0.9	1	0.9	1.1	0.9	0.9	1.1	1	1	0.9	1
Std. Err.	*	-	-	*	-	-	-	-	0.1	*	0.1	0.1	*	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I have posted on Facebook articles or pictures that demonstrate my pride in the good that our industry does

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		Α	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	81	0	0	81	0	0	0	0	40	41	21	6	54	29	18	21	16	4	6	5	36	45
0,1011	12.0%	-	-	12.0%	-	-	-	-	15.0%	10.0%	12.0%	8.0%	13.0%	14.0%	11.0%	13.0%	17.0%	11.0%	11.0%	16.0%	11.0%	13.0%
4	89	0	0	89	0	0	0	0	38	51	25	10	54	26	21	22	14	6	12	3	48	41
	13.0%	-	-	13.0%	-	-	-	-	15.0%	12.0%	14.0%	13.0%	13.0%	12.0%	13.0%	14.0%	15.0%	16.0%	22.0%	9.0%	15.0%	12.0%
3	60	0	0	60	0	0	0	0	24	36	11	14	35	12	18	12	14	3	6	4	24	36
	9.0%	-	-	9.0%	-	*	-	-	9.0%	9.0%	6.0%	18.0%	8.0%	6.0%	11.0% M	8.0%	15.0% M	8.0%	11.0%	12.0%	8.0%	10.0%
2	72	0	0	72	0	0	0	0	30	42	25	7	40	20	13	18	12	7	5	1	38	34
	11.0%	-	-	11.0%	-	-	-	-	11.0%	10.0%	14.0%	9.0%	10.0%	9.0%	8.0%	11.0%	13.0%	18.0%	9.0%	3.0%	12.0%	10.0%
Strongly disagree 1	246	0	0	246	0	0	0	0	81	165	59	28	159	81	67	49	22	12	20	13	113	133
	36.0%	-	-	36.0%	-	-	-	-	31.0%	40.0% H	33.0%	35.0%	38.0%	38.0% P	42.0% OP	31.0%	23.0%	32.0%	37.0%	41.0% P	35.0%	37.0%
Don't know or NA	127	0	0	127	0	0	0	0	48	79	39	14	74	46	23	37	17	6	5	6	60	67
	19.0%	-	-	19.0%	-	-	-	-	18.0%	19.0%	22.0%	18.0%	18.0%	21.0% R	14.0%	23.0% NR	18.0%	16.0%	9.0%	19.0%	19.0%	19.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	170	0	0	170	0	0	0	0	78	92	46	16	108	55	39	43	30	10	18	8	84	86
	25.0%	-	-	25.0%	=	-	-	-	30.0%	22.0%	26.0%	20.0%	26.0%	26.0%	24.0%	27.0%	32.0%	26.0%	33.0%	25.0%	26.0%	24.0%
BOTTOM 2 BOX	318	0	0	318	0	0	0	0	111	207	84	35	199	101	80	67	34	19	25	14	151	167
	47.0%	-	-	47.0%	-	-	-	-	43.0%	50.0%	47.0%	44.0%	48.0%	47.0%	50.0% P	42.0%	36.0%	50.0%	46.0%	44.0%	47.0%	47.0%
Mean	2.4	-	-	2.4	-	-	-	-	2.7	2.3	2.5	2.4	2.4	2.4	2.3	2.6	2.9	2.5	2.6	2.5	2.4	2.4
Std. Dev.	1.5	-	-	1.5	=	-	-	=	1.6	1.5	1.5	1.4	1.6	1.6	1.5	1.6	MN 1.5	1.5	1.5	1.7	1.5	1.5
Std. Err.	0.1	_	-	0.1	_	_	_	_	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.3	0.2	0.3	0.1	0.1
Stu. EII.	0.1	-	-	0.1	 	1 -	-	-	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.5	0.2	0.5	0.1	0.1

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I have posted on Linkedin articles or pictures that demonstrate my pride in the good that our industry does

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ition			Job ti	itle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		Α	В	С	D	Е	F	G	Н	- 1	J	K	L	М	N	0	P	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	112	0	0	112	0	0	0	0	53	59	32	8	72	36	27	27	19	5	11	5	59	53
Strongly agree 3	17.0%	-	-	17.0%	-	-	-	-	20.0%	14.0%	18.0%	10.0%	17.0%	17.0%	17.0%	17.0%	20.0%	13.0%	20.0%	16.0%	18.0%	15.0%
4	109	0	0	109	0	0	0	0	40	69	28	12	69	34	22	32	12	11	8	2	48	61
ľ	16.0%	-	-	16.0%	-	-	-	-	15.0%	17.0%	16.0%	15.0%	17.0%	16.0%	14.0%	20.0%	13.0%	29.0%	15.0%	6.0%	15.0%	17.0%
																		NPS				
3	70	0	0	70	0	0	0	0	28	42	17	11	42	15	22	10	17	5	8	7	29	41
	10.0%	-	-	10.0%	-	-	-	-	11.0%	10.0%	9.0%	14.0%	10.0%	7.0%	14.0%	6.0%	18.0%	13.0%	15.0%	22.0%	9.0%	12.0%
															MO		MO		0	MO		
2	88	0	0	88	0	0	0	0	32	56	27	13	48	27	17	21	13	5	7	4	48	40
	13.0%	-	-	13.0%	-	-	-	-	12.0%	14.0%	15.0%	16.0%	12.0%	13.0%	11.0%	13.0%	14.0%	13.0%	13.0%	12.0%	15.0%	11.0%
Strongly disagree 1	186	0	0	186	0	0	0	0	60	126	48	21	117	65	52	35	18	9	16	8	89	97
	28.0%	-	-	28.0%	-	-	-	-	23.0%	30.0%	27.0%	27.0%	28.0%	30.0%	32.0%	22.0%	19.0%	24.0%	30.0%	25.0%	28.0%	27.0%
										Н				P	OP							
Don't know or NA	110	0	0	110	0	0	0	0	48	62	28	14	68	37	20	34	16	3	4	6	46	64
	16.0%	-	=	16.0%	-	-	-	-	18.0%	15.0%	16.0%	18.0%	16.0%	17.0%	12.0%	21.0% NR	17.0%	8.0%	7.0%	19.0%	14.0%	18.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	221	0	0	221	0	0	0	0	93	128	60	20	141	70	49	59	31	16	19	7	107	114
	33.0%	-	-	33.0%	-	-	-	-	36.0%	31.0%	33.0%	25.0%	34.0%	33.0%	31.0%	37.0%	33.0%	42.0%	35.0%	22.0%	34.0%	32.0%
BOTTOM 2 BOX	274	0	0	274	0	0	0	0	92	182	75	34	165	92	69	56	31	14	23	12	137	137
	41.0%	-	-	41.0%	-	=	-	-	35.0%	44.0% H	42.0%	43.0%	40.0%	43.0%	43.0%	35.0%	33.0%	37.0%	43.0%	38.0%	43.0%	38.0%
Mean	2.8	-	-	2.8	-	-	-	-	3	2.7	2.8	2.6	2.8	2.7	2.7	3	3	2.9	2.8	2.7	2.8	2.8
									1						1							
Std. Dev.	1.6	-	-	1.6	-	-	-	-	1.6	1.5	1.6	1.4	1.6	1.6	1.6	1.6	1.5	1.5	1.6	1.5	1.6	1.5
Std. Err.	0.1	-	-	0.1	-	-	-	-	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.3	0.1	0.1

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - When asked about my profession at a personal social event, I am concerned about how people will react

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job ti	itle/level
	Total	Patient or Health	Suppliers	Pharma	НСР	Pure patient (not part of	Patients only	Patient Health	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central	Asia	Africa	South America	Australasia	Department Head or	Senior managers o
		Charity				any other group)		Charity and Patients								America					higher	lower
		Α	В	С	D	E	F	G	Н	I	J	К	L	М	N	0	P	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	55	0	0	55	0	0	0	0	26	29	24	10	21	18	14	14	9	5	4	2	31	24
	8.0%	-	-	8.0%	=	-	-	=	10.0%	7.0%	13.0% L	13.0% L	5.0%	8.0%	9.0%	9.0%	9.0%	13.0%	7.0%	6.0%	10.0%	7.0%
4	104	0	0	104	0	0	0	0	39	65	26	9	69	27	22	29	13	7	9	2	33	71
	15.0%	-	-	15.0%	-	-	-	-	15.0%	16.0%	14.0%	11.0%	17.0%	13.0%	14.0%	18.0%	14.0%	18.0%	17.0%	6.0%	10.0%	20.0% T
3	93	0	0	93	0	0	0	0	32	61	25	11	57	26	29	14	14	4	8	5	43	50
	14.0%	-	-	14.0%	-	-	-		12.0%	15.0%	14.0%	14.0%	14.0%	12.0%	18.0% O	9.0%	15.0%	11.0%	15.0%	16.0%	13.0%	14.0%
2	140	0	0	140	0	0	0	0	48	92	37	18	85	57	24	33	20	5	11	4	75	65
4	21.0%	-	-	21.0%	-	-	-	-	18.0%	22.0%	21.0%	23.0%	20.0%	27.0%	15.0%	21.0%	21.0%	13.0%	20.0%	12.0%	24.0%	18.0%
Strongly disagree 1	275	0	0	275	0	0	0	0	112	163	63	31	181	N 86	68	67	34	17	22	19	132	143
Strongry disagree 1	41.0%	-	-	41.0%	-	-	-	-	43.0%	39.0%	35.0%	39.0%	44.0%	40.0%	42.0%	42.0%	36.0%	45.0%	41.0%	59.0%	41.0%	40.0%
Don't know or NA	8	0	0	8	0	0	0	0	4	4	5	0	3	0	3	2	5	0	0	MP 0	5	3
	1.0%	-	-	1.0%	-	-	-		2.0%	1.0%	3.0%	-	1.0%	-	2.0% M	1.0%	5.0%	-	-	-	2.0%	1.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	M 95	38	54	32	319	356
Signia	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	159	0	0	159	0	0	0	0	65	94	50	19	90	45	36	43	22	12	13	4	64	95
	24.0%	-	-	24.0%	-	-	-	-	25.0%	23.0%	28.0%	24.0%	22.0%	21.0%	22.0%	27.0%	23.0%	32.0% S	24.0%	12.0%	20.0%	27.0% T
BOTTOM 2 BOX	415	0	0	415	0	0	0	0	160	255	100	49	266	143	92	100	54	22	33	23	207	208
	61.0%	-	-	61.0%	-	-	-	-	61.0%	62.0%	56.0%	62.0%	64.0%	67.0%	58.0%	63.0%	57.0%	58.0%	61.0%	72.0%	65.0%	58.0%
Mean	2.3	-	-	2.3	-	-	-	-	2.3	2.3	2.5	2.4	2.2	2.2	2.3	2.3	2.4	2.4	2.3	1.9	2.2	2.3
Std. Dev.	1.4	-	-	1.4	-	-	-	-	1.4	1.3	1.4	1.4	1.3	1.3	1.4	1.4	1.4	1.5	1.4	1.3	1.3	1.4
Std. Err.	0.1	_	_	0.1	-	-	-	-	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - Helping patients is my primary motivation for working in the pharma/biotech/med device industry

					Туре				Confi	dence	Pha	rma: Company	, size			Geo	ographical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	E	F	G	Н	- 1	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	310	0	0	310	0	0	0	0	142	168	90	33	187	104	66	78	50	13	22	10	140	170
Strongly agree 5	46.0%	-	-	46.0%	-	-	-	-	54.0%	41.0%	50.0%	42.0%	45.0%	49.0%	41.0%	49.0%	53.0%	34.0%	41.0%	31.0%	44.0%	48.0%
	40.070			40.076					34.070	41.070	30.070	42.070	45.070	45.0%	41.070	45.070	QS	34.0%	41.070	31.070	44.070	40.070
4	223	0	0	223	0	0	0	0	82	141	60	30	133	73	58	49	26	16	15	12	111	112
	33.0%	-	-	33.0%	-	-	-	-	31.0%	34.0%	33.0%	38.0%	32.0%	34.0%	36.0%	31.0%	27.0%	42.0%	28.0%	38.0%	35.0%	31.0%
2	82	0	0	82	0	0	0	0	25	57	18	q	55	22	18	17	14	7	11	6	43	39
	12.0%	-	-	12.0%	-	-	-	-	10.0%	14.0%	10.0%	11.0%	13.0%	10.0%	11.0%	11.0%	15.0%	18.0%	20.0%	19.0%	13.0%	11.0%
	12.070			12.070					10.070	14.070	10.070	11.070	13.070	10.070	11.070	11.070	13.070	10.070	MO	15.070	13.070	11.070
2	34	0	0	34	0	0	0	0	5	29	7	5	22	6	10	12	2	1	4	2	14	20
l .	5.0%	-	-	5.0%	-	-	-	-	2.0%	7.0%	4.0%	6.0%	5.0%	3.0%	6.0%	8.0%	2.0%	3.0%	7.0%	6.0%	4.0%	6.0%
										Н						M						
Strongly disagree 1	16	0	0	16	0	0	0	0	4	12	2	2	12	5	6	2	1	0	2	1	7	9
	2.0%	-	-	2.0%	-	-	-	-	2.0%	3.0%	1.0%	3.0%	3.0%	2.0%	4.0%	1.0%	1.0%	-	4.0%	3.0%	2.0%	3.0%
Don't know or NA	10	0	0	10	0	0	0	0	3	7	3	0	7	4	2	1	2	1	0	1	4	6
	1.0%	-	-	1.0%	-	-	-	-	1.0%	2.0%	2.0%	-	2.0%	2.0%	1.0%	1.0%	2.0%	3.0%	-	3.0%	1.0%	2.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Sigilia	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	533	0	0	533	0	0	0	0	224	309	150	63	320	177	124	127	76	29	37	22	251	282
	79.0%	-	-	79.0%	-	-	-	-	86.0%	75.0%	83.0%	80.0%	77.0%	83.0% R	78.0%	80.0%	80.0%	76.0%	69.0%	69.0%	79.0%	79.0%
BOTTOM 2 BOX	50	0	0	50	0	0	0	0	9	41	9	7	34	11	16	14	3	1	6	3	21	29
	7.0%	-	-	7.0%	-	-	-	-	3.0%	10.0%	5.0%	9.0%	8.0%	5.0%	10.0%	9.0%	3.0%	3.0%	11.0%	9.0%	7.0%	8.0%
										Н					P							
Mean	4.2	-	-	4.2	-	-	-	-	4.4	4	4.3	4.1	4.1	4.3	4.1	4.2	4.3	4.1	3.9	3.9	4.2	4.2
Std. Dev.	1	-	_	1	_	-	_	-	0.9	1.1	0.9	1	1	RS 0.9	1.1	1	0.9	0.8	1.1	1	1	1
Stu. Dev.	1	1 -	1 -	1	1	+ -	-	1 -	0.5	1.1	0.5	1	1	0.5	1.1	1	0.5	0.0	1.1	1	1	
Std. Err.	*	-	-		-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.1	0.1

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I communicate why I work in the pharma/ biotech/ med device industry to my customers

					Туре				Confi	dence	Pha	rma: Company	size			Geo	ographical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	E	F	G	Н	ı	J	K	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	220	0	0	220	0	0	0	0	108	112	72	16	132	72	55	51	29	7	19	6	107	113
	33.0%	-	-	33.0%	-	-	-	-	41.0%	27.0%	40.0%	20.0%	32.0%	34.0%	34.0%	32.0%	31.0%	18.0%	35.0%	19.0%	34.0%	32.0%
4	222	0	0	222	0	0	0	0	76	146	K 51	34	K 137	77	Q 40	53	34	13	15	16	108	114
4	33.0%	-	-	33.0%	-	-	-	-	29.0%	35.0%	28.0%	43.0%	33.0%	36.0%	25.0%	33.0%	36.0%	34.0%	28.0%	50.0%	34.0%	32.0%
	33.0%	-	-	33.0%	-	-	-	-	29.0%	33.0%	28.0%	43.0%	33.0%	36.0% N	25.0%	33.0%	30.0%	34.0%	28.0%	30.0% NR	34.0%	32.0%
3	102	0	0	102	0	0	0	0	34	68	26	12	64	29	26	24	14	6	10	5	42	60
3	15.0%	-	-	15.0%	-	-	-	-	13.0%	16.0%	14.0%	15.0%	15.0%	14.0%	16.0%	15.0%	15.0%	16.0%	19.0%	16.0%	13.0%	17.0%
	13.070			15.070					15.070	10.070	11.070	13.070	15.070	21.070	10.070	13.070	15.070	10.070	15.070	10.070	15.070	17.070
2	62	0	0	62	0	0	0	0	21	41	16	11	35	15	17	19	9	6	5	3	29	33
	9.0%	-	-	9.0%	-	-	-	-	8.0%	10.0%	9.0%	14.0%	8.0%	7.0%	11.0%	12.0%	9.0%	16.0%	9.0%	9.0%	9.0%	9.0%
Strongly disagree 1	32	0	0	32	0	0	0	0	10	22	6	2	24	7	11	7	3	4	5	2	15	17
	5.0%	-	-	5.0%	-	-	-	-	4.0%	5.0%	3.0%	3.0%	6.0%	3.0%	7.0%	4.0%	3.0%	11.0%	9.0%	6.0%	5.0%	5.0%
																		MP				
Don't know or NA	37	0	0	37	0	0	0	0	12	25	9	4	24	14	11	5	6	2	0	0	18	19
	5.0%	-	-	5.0%	-	-	-	-	5.0%	6.0%	5.0%	5.0%	6.0%	7.0%	7.0%	3.0%	6.0%	5.0%	-	-	6.0%	5.0%
															R							
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary	442	0	0	442	0	0	0	0	184	258	123	50	269	149	95	104	63	20	34	22	215	227
TOP 2 BOX	65.0%	0	0	65.0%	-		-	0	70.0%	62.0%	68.0%	63.0%	65.0%	70.0%	59.0%	65.0%	66.0%	53.0%	63.0%	69.0%	67.0%	227 64.0%
	65.0%	-	-	65.0%	-	-	-	-	70.0%	62.0%	68.0%	63.0%	65.0%	70.0% NQ	59.0%	65.0%	66.0%	53.0%	63.0%	69.0%	67.0%	64.0%
BOTTOM 2 BOX	94	0	0	94	0	0	0	0	31	63	22	13	59	22	28	26	12	10	10	5	44	50
BOTTOWI 2 BOX	14.0%	-	-	14.0%	-	-	-	-	12.0%	15.0%	12.0%	16.0%	14.0%	10.0%	18.0%	16.0%	13.0%	26.0%	19.0%	16.0%	14.0%	14.0%
	14.076			14.076	_	-		_	12.076	13.0%	12.076	10.076	14.076	10.076	M	10.0%	13.076	MP	15.0%	10.076	14.076	14.076
Mean	3.8	-	-	3.8	-	-	_	-	4	3.7	4	3.7	3.8	4	3.7	3.8	3.9	3.4	3.7	3.7	3.9	3.8
**************************************	5.5			5.0					i	5.7		5.7	5.0	0	3.7	0	0	5.1	5.7	J.,	5.5	3.0
Std. Dev.	1.1	-	-	1.1	-	-	-	-	1.1	1.2	1.1	1.1	1.2	1.1	1.3	1.2	1.1	1.3	1.3	1.1	1.1	1.2
																						1
Std. Err.	*	-	-		-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - I feel trusted and admired by my customers / stakeholders

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	170	0	0	170	0	0	0	0	87	83	61	21	88	52	32	38	31	11	17	9	79	91
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	25.0%	-	-	25.0%	-	-	-	-	33.0%	20.0%	34.0%	27.0%	21.0%	24.0%	20.0%	24.0%	33.0%	29.0%	31.0%	28.0%	25.0%	26.0%
	275	0	0	275			0	0	104	474	L	24	176	87	64	71	N 2C	44	16	14	134	141
4	41.0%	-	-	41.0%	- 0	0 -	-	-	104 40.0%	171 41.0%	68 38.0%	31 39.0%	42.0%	41.0%	40.0%	45.0%	36 38.0%	11 29.0%	16 30.0%	44.0%	42.0%	40.0%
																R						
3	136	0	0	136	0	0	0	0	46	90	26	17	93	45	29	32	23	9	12	5	66	70
	20.0%	-	-	20.0%	-	-	-	-	18.0%	22.0%	14.0%	22.0%	22.0%	21.0%	18.0%	20.0%	24.0%	24.0%	22.0%	16.0%	21.0%	20.0%
2	43	0	0	43	0	0	0	0	11	32	12	5	26	12	13	10	0	3	7	2	21	22
	6.0%	-	-	6.0%	-	-	-	-	4.0%	8.0%	7.0%	6.0%	6.0%	6.0%	8.0%	6.0%	-	8.0%	13.0%	6.0%	7.0%	6.0%
		_					_	_				_		P	P	P		P	P	P		
Strongly disagree 1	15	0	0	15	0	0	0	0	*	14 3.0%	3	0	12	5	7	1	2	4	1	3.0%	6	9
	2.0%	-	-	2.0%	-	-	-	-	-	3.0% H	2.0%	-	3.0%	2.0%	4.0% O	1.0%	2.0%	11.0% MOP	2.0%	3.0%	2.0%	3.0%
Don't know or NA	36	0	0	36	0	0	0	0	12	24	10	5	21	13	15	7	3	0	1	1	13	23
	5.0%	-	-	5.0%	-	-	-	-	5.0%	6.0%	6.0%	6.0%	5.0%	6.0%	9.0%	4.0%	3.0%	-	2.0%	3.0%	4.0%	6.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	445	0	0	445	0	0	0	0	191	254	129	52	264	139	96	109	67	22	33	23	213	232
	66.0%	-	-	66.0%	-	-	-	-	73.0%	61.0%	72.0%	66.0%	63.0%	65.0%	60.0%	69.0%	71.0%	58.0%	61.0%	72.0%	67.0%	65.0%
BOTTOM 2 BOX	58	0	0	58	0	0	0	0	12	46	15	5	38	17	20	11	2	7	8	3	27	31
BOTTOW 2 BOX	9.0%	-	-	9.0%	-	-	-	-	5.0%	11.0%	8.0%	6.0%	9.0%	8.0%	12.0%	7.0%	2.0%	18.0%	15.0%	9.0%	8.0%	9.0%
										Н				P	P			MOP	P			
Mean	3.8	-	-	3.8	-	-	-	-	4.1	3.7	4 I	3.9	3.8	3.8	3.7	3.9	4 NQ	3.6	3.8	3.9	3.8	3.8
Std. Dev.	1	-	-	1	-	-	-	-	0.9	1	1	0.9	1	1	1.1	0.9	0.9	1.3	1.1	1	1	1
Std. Err.	*	_	_		_	-	_	-	0.1	0.1	0.1	0.1	*	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1
566. 211.					 	+	 		0.1	0.1	0.1	0.1		0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - My customers would say that I help improve patient care

					Туре				Confi	dence	Pha	rma: Company	size			Geo	ographical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	E	F	G	Н	I I	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Strongly agree 5	201	0	0	201	0	0	0	0	103	98	67	17	117	69	37	50	29	11	18	8	95	106
	30.0%	-	-	30.0%	-	-	-	-	39.0%	24.0%	37.0%	22.0%	28.0%	32.0%	23.0%	31.0%	31.0%	29.0%	33.0%	25.0%	30.0%	30.0%
									ı		KL											
I ⁴	266	0	0	266	0	0	0	0	104	162	60	36	170	84	66	66	35	13	15	16	127	139
	39.0%	-	-	39.0%	-	-	-	-	40.0%	39.0%	33.0%	46.0%	41.0%	39.0%	41.0%	42.0%	37.0%	34.0%	28.0%	50.0%	40.0%	39.0%
																				R		
3	126	0	0	126	0	0	0	0	32	94	30	15	81	32	33	28	22	9	15	5	57	69
	19.0%	-	-	19.0%	-	-	-	-	12.0%	23.0%	17.0%	19.0%	19.0%	15.0%	21.0%	18.0%	23.0%	24.0%	28.0%	16.0%	18.0%	19.0%
										Н									M			
2	25	0	0	25	0	0	0	0	6	19	5	3	17	7	6	5	1	3	5	2	9	16
	4.0%	-	-	4.0%	-	-	-	-	2.0%	5.0%	3.0%	4.0%	4.0%	3.0%	4.0%	3.0%	1.0%	8.0%	9.0%	6.0%	3.0%	4.0%
																		P	OP			
Strongly disagree 1	9	0	0	9	0	0	0	0	0	9	3	0	6	4	4	0	0	0	0	0	6	3
	1.0%	-	-	1.0%	-	-	-	-	-	2.0%	2.0%	-	1.0%	2.0%	2.0%	-	-	-	-	-	2.0%	1.0%
										Н					0							
Don't know or NA	48	0	0	48	0	0	0	0	16	32	15	8	25	18	14	10	8	2	1	1	25	23
	7.0%	-	-	7.0%	-	-	-	-	6.0%	8.0%	8.0%	10.0%	6.0%	8.0%	9.0%	6.0%	8.0%	5.0%	2.0%	3.0%	8.0%	6.0%
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary					-		-	_														
TOP 2 BOX	467	0	0	467	0	0	0	0	207	260	127	53	287	153	103	116	64	24	33	24	222	245
	69.0%	-	-	69.0%	-	-	-	-	79.0%	63.0%	71.0%	67.0%	69.0%	71.0%	64.0%	73.0%	67.0%	63.0%	61.0%	75.0%	70.0%	69.0%
					_											_			_			
BOTTOM 2 BOX	34	0	0	34	0	0	0	0	6	28	8	3	23	11	10	5	1	3	5	2	15	19
	5.0%	-	-	5.0%	-	-	-	-	2.0%	7.0%	4.0%	4.0%	6.0%	5.0%	6.0%	3.0%	1.0%	8.0%	9.0%	6.0%	5.0%	5.0%
										Н					P			P	OP			
Mean	4	-	-	4	-	-	-	-	4.2	3.8	4.1	3.9	4	4.1	3.9	4.1	4.1	3.9	3.9	4	4	4
Ctd David	0.0	+	+	0.0	-	-			1	0.0	0.0	0.0	0.0	0.0	0.0	N	0.0	0.0	-	0.0	0.0	
Std. Dev.	0.9	-	-	0.9	-	-	-	-	0.8	0.9	0.9	0.8	0.9	0.9	0.9	0.8	0.8	0.9	1	0.8	0.9	0.9
Cad For	*	+	+	*	-	-			*	*	0.4	0.4	*	0.1	0.1	0.1	0.4	0.2	0.1	0.3	0.1	*
Std. Err.	-	-	-	-	-	-	-	-	-	-	0.1	0.1	-	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	+
Ctatistics		1	1																			

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

Table: 41

Q19. Company related statements agreement 1-5 scale - I am proud/Pride - GRID SUMMARY

	I believe in my company"s future	I care about the company"s vision and goals	company is making the world a better place	I am proud to tell people outside our industry that I work in a pharma, biotech/ medical device company	to communicat e my role such that people outside our industry understand and admire our work	I have posted on Facebook articles or pictures that demonstrate my pride in the good that our industry does	on Linkedin articles or pictures that demonstrate my pride in the good that our industry does	about my profession at a personal social event, I am concerned about how people will react	Helping patients is my primary motivation for working in the pharma/biot ech/med device industry	I communicat e why I work in the pharma/ biotech/ med device industry to my customers	I feel trusted and admired by my customers / stakeholders	My customers would say that I help improve patient care
	Α	В	С	D	Е	F	G	Н		J	K	L
Base: Pharma Companies	675	675	675	675	675	675	675	675	675	675	675	675
Strongly agree 5	307	404	279	348	268	81	112	55	310	220	170	201
Strongly agree 3	45.0%	60.0%	41.0%	52.0%	40.0%	12.0%	17.0%	8.0%	46.0%	33.0%	25.0%	30.0%
	CEFGHJKL	ACDEFGHIJKL	FGHJKL	ACEFGHIJKL	FGHJKL	H	FH	0.070	EFGHJKL	FGHK	FGH	FGHK
4	212	201	234	199	260	89	109	104	223	222	275	266
	31.0%	30.0%	35.0%	29.0%	39.0%	13.0%	16.0%	15.0%	33.0%	33.0%	41.0%	39.0%
	FGH	FGH	BDFGH	FGH	ABDFGHIJ				FGH	FGH	ABCDFGHIJ	ABDFGHIJ
3	100	44	117	77	88	60	70	93	82	102	136	126
	15.0%	7.0%	17.0%	11.0%	13.0%	9.0%	10.0%	14.0%	12.0%	15.0%	20.0%	19.0%
	BDFG		BDEFGI	В	BF		В	BFG	BF	BDFG	ABDEFGHIJ	ABDEFGHI
2	33	10	28	28	41	72	88	140	34	62	43	25
	5.0%	1.0%	4.0%	4.0%	6.0%	11.0%	13.0%	21.0%	5.0%	9.0%	6.0%	4.0%
	В		В	В	BL	ABCDEIKL	ABCDEIJKL	ABCDEFGIJKL	В	ABCDEIKL	BL	В
Strongly disagree 1	9	3	10	12	10	246	186	275	16	32	15	9
	1.0%	*	1.0%	2.0%	1.0%	36.0%	28.0%	41.0%	2.0%	5.0%	2.0%	1.0%
	В		В	В		ABCDEGIJKL	ABCDEIJKL	ABCDEGIJKL	В	ABCDEIKL	В	
Don't know or NA	14	13	7	11	8	127	110	8	10	37	36	48
	2.0%	2.0%	1.0%	2.0%	1.0%	19.0%	16.0%	1.0%	1.0%	5.0%	5.0%	7.0%
	С					ABCDEGHIJKL	ABCDEHIJKL			ABCDEHI	ABCDEHI	ABCDEHI
Sigma	675	675	675	675	675	675	675	675	675	675	675	675
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary												
TOP 2 BOX	519	605	513	547	528	170	221	159	533	442	445	467
	77.0%	90.0%	76.0%	81.0%	78.0%	25.0%	33.0%	24.0%	79.0%	65.0%	66.0%	69.0%
	FGHJKL	ACDEFGHIJKL	FGHJKL	ACFGHJKL	FGHJKL		FH		FGHJKL	FGH	FGH	FGH

BOTTOM 2 BOX	42	13	38	40	51	318	274	415	50	94	58	34
	6.0%	2.0%	6.0%	6.0%	8.0%	47.0%	41.0%	61.0%	7.0%	14.0%	9.0%	5.0%
	В		В	В	BL	ABCDEGIJKL	ABCDEIJKL	ABCDEFGIJKL	BL	ABCDEIKL	BCDL	В
Mean	4.2	4.5	4.1	4.3	4.1	2.4	2.8	2.3	4.2	3.8	3.8	4
	FGHJKL	ACDEFGHIJKL	FGHJKL	ACEFGHIJKL	FGHJKL		FH		FGHJKL	FGH	FGH	FGHJK
Std. Dev.	1	0.7	0.9	0.9	1	1.5	1.6	1.4	1	1.1	1	0.9
Std. Err.	*	*	*	*	*	0.1	0.1	0.1	*	*	*	*

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G/H/I/J/K/L Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G/H/I/J/K/L Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - Top 2 Box Summary

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ition			Job tit	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower
		A	В	С	D	E	F	G	н	I	J	K	L	М	N	0	P	Q	R	S	Т	U
Danie Dhamas Camanailea	4202	72	250	675	100	70	422	442	207	895	180	70	44.6	24.4	460	150	0.5	20	54	22	240	250
Base: Pharma Companies	1282	73	358	675	106		123	143	387			79	416	214	160	159	95	38		32	319	356
I believe in my company's future	519	0	0	519 77.0%	0	0	0	0	220 84.0%	299	137	60 76.0%	322 77.0%	167 78.0%	132 82.0%	113	70	29	41 76.0%	27	257	262
	77.0%	-	-	77.0%	-	9	-	-	84.0%	72.0%	76.0%	76.0%	77.0%	78.0%	82.0% O	71.0%	74.0%	76.0%	76.0%	84.0%	81.0% U	74.0%
Lanca de contrata de contrata de la contrata del contrata de la contrata de la contrata del contrata de la contrata del contrata de la contrata de la contrata de la contrata del contrata de la contrata del contrata de la contrata del contrata del contrata del contrata del contrata de la contrata del contrata del contrat	605	0	0	605	0	0	0		240	365	159	72	374	195	141	142	84	33	47	29	295	240
I care about the company's vision and goals		-	-	90.0%	- 0	0	-	0	92.0%	88.0%		91.0%	90.0%		88.0%			87.0%	87.0%		92.0%	310
	90.0%	-	-	90.0%	-	-	-	-	92.0%	88.0%	88.0%	91.0%	90.0%	91.0%	88.0%	89.0%	88.0%	87.0%	87.0%	91.0%	92.0% U	87.0%
I am confident my company is making the	513	0	0	513	0	0	0	0	226	287	138	56	319	165	121	120	67	29	37	24	254	259
world a better place	76.0%	-	-	76.0%	-	-	-	-	87.0%	69.0%	77.0%	71.0%	77.0%	77.0%	76.0%	75.0%	71.0%	76.0%	69.0%	75.0%	80.0%	73.0%
, , , , , , , , , , , , , , , , , , ,									ı												U	
I am proud to tell people outside our industry	547	0	0	547	0	0	0	0	233	314	149	65	333	178	118	131	78	33	44	24	264	283
that I work in a pharma, biotech/ medical	81.0%	-	-	81.0%	-	-	-	-	89.0%	76.0%	83.0%	82.0%	80.0%	83.0%	74.0%	82.0%	82.0%	87.0%	81.0%	75.0%	83.0%	79.0%
device company														N								
I know how to communicate my role such that	528	0	0	528	0	0	0	0	216	312	146	60	322	166	114	128	79	27	42	28	249	279
people outside our industry understand and	78.0%	-	-	78.0%	-	-	-	-	83.0%	75.0%	81.0%	76.0%	77.0%	78.0%	71.0%	81.0%	83.0%	71.0%	78.0%	88.0%	78.0%	78.0%
admire our work									1							N	N					
I have posted on Facebook articles or pictures	170	0	0	170	0	0	0	0	78	92	46	16	108	55	39	43	30	10	18	8	84	86
that demonstrate my pride in the good that our	25.0%	-	-	25.0%	-	-	-	-	30.0%	22.0%	26.0%	20.0%	26.0%	26.0%	24.0%	27.0%	32.0%	26.0%	33.0%	25.0%	26.0%	24.0%
industry does									1													
I have posted on Linkedin articles or pictures	221	0	0	221	0	0	0	0	93	128	60	20	141	70	49	59	31	16	19	7	107	114
that demonstrate my pride in the good that our	33.0%	-	-	33.0%	-	-	-	-	36.0%	31.0%	33.0%	25.0%	34.0%	33.0%	31.0%	37.0%	33.0%	42.0%	35.0%	22.0%	34.0%	32.0%
industry does																						
When asked about my profession at a personal	159	0	0	159	0	0	0	0	65	94	50	19	90	45	36	43	22	12	13	4	64	95
social event, I am concerned about how people	24.0%	-	-	24.0%	-	-	-	-	25.0%	23.0%	28.0%	24.0%	22.0%	21.0%	22.0%	27.0%	23.0%	32.0%	24.0%	12.0%	20.0%	27.0%
will react																		S				T
Helping patients is my primary motivation for	533	0	0	533	0	0	0	0	224	309	150	63	320	177	124	127	76	29	37	22	251	282
working in the pharma/biotech/med device	79.0%	-	-	79.0%	-	-	-	-	86.0%	75.0%	83.0%	80.0%	77.0%	83.0%	78.0%	80.0%	80.0%	76.0%	69.0%	69.0%	79.0%	79.0%
industry														R								
I communicate why I work in the pharma/	442	0	0	442	0	0	0	0	184	258	123	50	269	149	95	104	63	20	34	22	215	227
biotech/ med device industry to my customers	65.0%	-	-	65.0%	-	-	-	-	70.0%	62.0%	68.0%	63.0%	65.0%	70.0%	59.0%	65.0%	66.0%	53.0%	63.0%	69.0%	67.0%	64.0%
														NQ								
I feel trusted and admired by my customers /	445	0	0	445	0	0	0	0	191	254	129	52	264	139	96	109	67	22	33	23	213	232
stakeholders	66.0%	-	-	66.0%	-	-	-	-	73.0%	61.0%	72.0%	66.0%	63.0%	65.0%	60.0%	69.0%	71.0%	58.0%	61.0%	72.0%	67.0%	65.0%
My customers would say that I help improve	467	0	0	467	0	0	0	0	207	260	127	53	287	153	103	116	64	24	33	24	222	245
patient care	69.0%	-	-	69.0%	-	-	-	-	79.0%	63.0%	71.0%	67.0%	69.0%	71.0%	64.0%	73.0%	67.0%	63.0%	61.0%	75.0%	70.0%	69.0%
patient care	03.070			03.070		+			, 5.070	03.070	, 1.070	37.070	03.070	71.070	3.7.070	7 3.070	37.070	33.070	01.070	75.070	70.070	55.070

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

Column Fose: 3 (), Since Section 2 (), Column Fose: 6 (), Column Fose: 6 (), A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - Bottom 2 Box Summary

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ition			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	(not part of	Patients only	Patient Health Charity and	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or
		Charity				any other group)		Patients								America					nigher	lower
						g.oup/		rations														
		A	В	С	D	E	F	G	Н	l l	J	K	L	М	N	0	P	Q	R	S	Т	U
Base: Pharma Companies	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
I believe in my company's future	42	0	0	42	0	0	0	0	6	36	11	5	26	17	2	14	4	1	3	2	17	25
i believe in my company stature	6.0%	-	-	6.0%	-	-	-	-	2.0%	9.0%	6.0%	6.0%	6.0%	8.0%	1.0%	9.0%	4.0%	3.0%	6.0%	6.0%	5.0%	7.0%
	0.070			0.070					2.070	H	0.070	0.070	0.070	N	1.070	N.	4.070	3.070	0.070	0.070	3.070	7.070
I care about the company's vision and goals	13	0	0	13	0	0	0	0	3	10	2	2	9	3	1	4	1	1	3	0	3	10
reare about the company 5 vision and goals	2.0%	-	-	2.0%	-	-	-	-	1.0%	2.0%	1.0%	3.0%	2.0%	1.0%	1.0%	3.0%	1.0%	3.0%	6.0%	-	1.0%	3.0%
										,		0.0,1				0.0.1			N			0.07.
I am confident my company is making the	38	0	0	38	0	0	0	0	8	30	8	7	23	14	6	11	3	1	5	0	14	24
world a better place	6.0%	-	-	6.0%	-	-	-	-	3.0%	7.0%	4.0%	9.0%	6.0%	7.0%	4.0%	7.0%	3.0%	3.0%	9.0%	-	4.0%	7.0%
										Н												
I am proud to tell people outside our industry	40	0	0	40	0	0	0	0	5	35	9	2	29	11	15	9	5	2	3	4	12	28
that I work in a pharma, biotech/ medical	6.0%	-	-	6.0%	-	-	-	-	2.0%	8.0%	5.0%	3.0%	7.0%	5.0%	9.0%	6.0%	5.0%	5.0%	6.0%	12.0%	4.0%	8.0%
device company										Н												T
I know how to communicate my role such that	51	0	0	51	0	0	0	0	13	38	9	8	34	11	18	14	7	5	6	2	24	27
people outside our industry understand and	8.0%	-	-	8.0%	-	-	-	-	5.0%	9.0%	5.0%	10.0%	8.0%	5.0%	11.0%	9.0%	7.0%	13.0%	11.0%	6.0%	8.0%	8.0%
admire our work										Н					M							
I have posted on Facebook articles or pictures	318	0	0	318	0	0	0	0	111	207	84	35	199	101	80	67	34	19	25	14	151	167
that demonstrate my pride in the good that our	47.0%	-	-	47.0%	-	-	-	-	43.0%	50.0%	47.0%	44.0%	48.0%	47.0%	50.0%	42.0%	36.0%	50.0%	46.0%	44.0%	47.0%	47.0%
industry does															P							
I have posted on Linkedin articles or pictures	274	0	0	274	0	0	0	0	92	182	75	34	165	92	69	56	31	14	23	12	137	137
that demonstrate my pride in the good that our	41.0%	-	-	41.0%	-	-	-	-	35.0%	44.0%	42.0%	43.0%	40.0%	43.0%	43.0%	35.0%	33.0%	37.0%	43.0%	38.0%	43.0%	38.0%
industry does										Н												
When asked about my profession at a personal	415	0	0	415	0	0	0	0	160	255	100	49	266	143	92	100	54	22	33	23	207	208
social event, I am concerned about how people	61.0%	-	-	61.0%	-	-	-	-	61.0%	62.0%	56.0%	62.0%	64.0%	67.0%	58.0%	63.0%	57.0%	58.0%	61.0%	72.0%	65.0%	58.0%
will react																						
Helping patients is my primary motivation for	50	0	0	50	0	0	0	0	9	41	9	7	34	11	16	14	3	1	6	3	21	29
working in the pharma/biotech/med device	7.0%	-	-	7.0%	-	-	-	-	3.0%	10.0%	5.0%	9.0%	8.0%	5.0%	10.0%	9.0%	3.0%	3.0%	11.0%	9.0%	7.0%	8.0%
industry										Н					P							
I communicate why I work in the pharma/	94	0	0	94	0	0	0	0	31	63	22	13	59	22	28	26	12	10	10	5	44	50
biotech/ med device industry to my customers	14.0%	-	-	14.0%	-	-	-	-	12.0%	15.0%	12.0%	16.0%	14.0%	10.0%	18.0%	16.0%	13.0%	26.0%	19.0%	16.0%	14.0%	14.0%
															M			MP				<u> </u>
I feel trusted and admired by my customers /	58	0	0	58	0	0	0	0	12	46	15	5	38	17	20	11	2	7	8	3	27	31
stakeholders	9.0%	-	-	9.0%	-	-	-	-	5.0%	11.0%	8.0%	6.0%	9.0%	8.0%	12.0%	7.0%	2.0%	18.0%	15.0%	9.0%	8.0%	9.0%
						1	ļ			Н		ļ		P	P			MOP	P	ļ		
My customers would say that I help improve	34	0	0	34	0	0	0	0	6	28	8	3	23	11	10	5	1	3	5	2	15	19
patient care	5.0%	-	-	5.0%	-	-	-	-	2.0%	7.0%	4.0%	4.0%	6.0%	5.0%	6.0%	3.0%	1.0%	8.0%	9.0%	6.0%	5.0%	5.0%
Ctatistics.										Н					P			P	OP			


Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

Column Fose: 3 (), Since Section 2 (), Column Fose: 6 (), Column Fose: 6 (), A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)



Q19. Company related statements agreement 1-5 scale - I am proud/Pride - Mean Summary

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ition			Job tit	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower
		Α	В	С	D	E	F	G	Н	1	J	К	L	M	N	0	Р	Q	R	S	T	U
Base: Pharma Companies	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
I believe in my company's future	4.2	-	-	4.2	-	-	-	-	4.4	4	4.3	4.1	4.2	4.1	4.3	4	4.2	4.2	4.2	4.3	4.3	4.1
									_						MO						U	
I care about the company's vision and goals	4.5	-	-	4.5	-	-	-	-	4.7	4.4	4.5	4.5	4.5	4.5	4.5	4.5	4.6	4.6	4.5	4.6	4.6	4.4
										2.0		2.0	4.1								U	
I am confident my company is making the	4.1	9	-	4.1	-	-	-	-	4.4	3.9	4.2	3.9	4.1	4.1	4.1	4.1	4.1	4.2	3.9	4.2	4.2	4
world a better place I am proud to tell people outside our industry	4.3		_	4.3			-	_	4.5	4.1	4.4	4.3	4.2	4.3	4.1	4.3	4.4	4.4	4.2	4.2	4.3	4.2
	4.3	-	-	4.3	-	-	-	-	4.5	4.1	4.4	4.3	4.2	4.3	4.1	4.3	4.4 N	4.4	4.2	4.2	4.3	4.2
that I work in a pharma, biotech/ medical I know how to communicate my role such that	4.1			4.1	_	_	-	_	4.3	4	4.3	3.9	4.1	4.1	3.9	4.1	4.2	3.8	4.1	4.3	4.1	4.1
people outside our industry understand and	4.1	1 -	-	4.1	-	-	-	-	4.5	4	KI.	5.9	4.1	4.1	5.9	4.1	NQ	3.0	4.1	4.3	4.1	4.1
I have posted on Facebook articles or pictures	2.4	_		2.4	_	_	_	_	2.7	2.3	2.5	2.4	2.4	2.4	2.3	2.6	2.9	2.5	2.6	2.5	2.4	2.4
_ · ·	2.4	1 -	-	2.4	-	-	-	-	2.7	2.3	2.5	2.4	2.4	2.4	2.3	2.0	MN	2.5	2.0	2.5	2.4	2.4
that demonstrate my pride in the good that our I have posted on Linkedin articles or pictures	2.8	_	_	2.8	_	_	_	-	3	2.7	2.8	2.6	2.8	2.7	2.7	3	3	2.9	2.8	2.7	2.8	2.8
that demonstrate my pride in the good that our	2.0	-	-	2.0	-		-	_	1	2.7	2.0	2.0	2.0	2.7	2.7	3		2.5	2.0	2.7	2.0	2.0
When asked about my profession at a personal	2.3	_	_	2.3	_	_	-	-	2.3	2.3	2.5	2.4	2.2	2.2	2.3	2.3	2.4	2.4	2.3	1.9	2.2	2.3
social event. I am concerned about how people	2.3			2.3					2.3	2.3	1	2.4	2.2	2.2	2.5	2.5	2.4	2.4	2.3	1.5	2.2	2.3
Helping patients is my primary motivation for	4.2	_	_	4.2	_	_	_	-	4.4	4	4.3	4.1	4.1	4.3	4.1	4.2	4.3	4.1	3.9	3.9	4.2	4.2
working in the pharma/biotech/med device	4.2			4.2					1	-	7.5	4.1	4.1	RS	4.1	7.2	NRS	4.1	3.3	3.5	7.2	4.2
I communicate why I work in the pharma/	3.8	_	_	3.8	-	_	-	-	4	3.7	4	3.7	3.8	4	3.7	3.8	3.9	3.4	3.7	3.7	3.9	3.8
biotech/ med device industry to my customers	5.0			5.0					i	3.7		3.7	5.0	0	5.7	0	Q	5	3.7	3.7	5.5	5.0
I feel trusted and admired by my customers /	3.8	-	-	3.8	-	-	-	-	4.1	3.7	4	3.9	3.8	3.8	3.7	3.9	4	3.6	3.8	3.9	3.8	3.8
stakeholders	2.0			2.0					1		Ĺ	5.5	2.0	3.0	3.7	2.3	NQ.	5.0	2.0	2.5	2.0	5.0
My customers would say that I help improve	4	-	-	4	-	-	-	-	4.2	3.8	4.1	3.9	4	4.1	3.9	4.1	4.1	3.9	3.9	4	4	4
patient care									I.							N						

Statistics: Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Column Fesce (2/n), And (2/n), An



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Patients' trust affected if they were to secretly observe a typical day in that department

Patient or Patient or Sopplies Patient or Patient or Patient or Patient or Charity and Patient or Charity and Patient or Charity and Patient or Charity and Patient Ch						Туре				Confi	dence	Pha	ırma: Company	size			.Ged	ographical loca	tion			Job tit	tle/level
Base Pharma Companies		Total	Health	Suppliers	Pharma		(not part of any other	Patients only	Health Charity and	Very	Less				Global	Europe	North and Central				Australasia	Department Head or	
Significantly increase 5 259 0 0 259 0 0 0 0 118 141 66 29 164 93 50 63 31 13 17 15 128 128 136			А	В	С	D	E	F	G	Н	ı	J	K	L	М	N	0	P	Q	R	S	Т	U
Significantly increase 5 259 0 0 259 0 0 0 0 118 141 66 29 164 93 50 63 31 13 17 15 128 128 138																							
Sightly increase 4 191			-	_		0																	356
Sightly increase 191	Significantly increase 5		0	0		0	-	-	-														131
Sightly increase 4		38.0%	-	-	38.0%	-	-	-	-	45.0%	34.0%	37.0%	37.0%	39.0%		31.0%	40.0%	33.0%	34.0%	31.0%	47.0%	40.0%	37.0%
Neither increase or decrease 3	Cli-bab. In-annual 4	404		0	101	0	0		0	7.0	445	F.4	24	116		40	40	26	42	45		01	100
Neither increase or decrease 3 117 0 0 0 117 0 0 0 0 34 83 30 14 73 30 36 28 17 3 11 9 50 17 9 17 9 17 9 17 9 17 9 18 9 17 9 18 9 18	Slightly increase 4					_			-												-		28.0%
170% - - 170% - - 170% - - 130% 200% 170% 180% 180% 180% 180% 180% 180% 180% 200% 280% 180% 200% 280% 180% 200% 280% 180% 200% 280% 180% 280% 280% 180% 280%		20.070			20.070					23.070	20.070	30.070	27.070	20.070	25.070	30.070	25.070	27.070	32.070	20.070	15.070	23.070	20.070
Sightly decrease 2	Neither increase or decrease 3	117	0	0	117	0	0	0	0	34	83	30	14	73	30	36	28	17	3	11	9	50	67
Significantly decrease 2		17.0%	-	-	17.0%	-	-	-	-	13.0%	20.0%	17.0%	18.0%	18.0%	14.0%	22.0%	18.0%	18.0%	8.0%	20.0%	28.0%	16.0%	19.0%
Total Contract Tota											Н					MQ					MQ		
Significantly decrease 1 35	Slightly decrease 2		0	0		0	0	0	0									•					20
Significantly decrease 1 35 0 0 35 0 0 0 35 0 0 0 9 26 8 4 23 8 7 10 5 2 4 0 11 5.0% 5.0% 3.0% 6.0% 4.0% 5.0% 6.0% 4.0% 4.0% 6.0% 5.0% 5.0% 5.0% 7.0% - 3.0% I don't know 28 0 0 28 0 0 0 0 13 15 10 3 15 6 10 5 9 3 2 0 14 4.0% 4.0% 5.0% 4.0% 6.0% 4.0% 4.0% 3.0% 6.0% 3.0% 9.0% 8.0% 4.0% - 4.0% Sigma 675 0 0 0 675 0 0 0 0 0 261 414 180 79 416 214 160 159 95 38 54 32 319 100.0% 0.0% 0.0% 100		7.0%	-	-	7.0%	-	-	-	-	4.0%		7.0%	10.0%	6.0%	7.0%	6.0%	8.0%	7.0%	13.0%	9.0%	6.0%	8.0%	6.0%
Sometimen Some			_	_		_		_	_						_			_	_	_			
Idon't know 28	Significantly decrease 1		-			_	-	-	-			0				,		-	_		-		24
A.0% - -		5.0%	-	-	5.0%	-	-	-	-	3.0%	6.0%	4.0%	5.0%	6.0%	4.0%	4.0%	6.0%	5.0%	5.0%	7.0%	-	3.0%	7.0%
Sigma 675 0 0 0 675 0 0 0 0 261 414 180 79 416 214 160 159 95 38 54 32 319 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 1	I don't know	28	0	0	28	0	0	0	0	13	15	10	3	15	6	10	5	9	3	2	0	14	14
Sigma 675 0 0 0 675 0 0 0 0 261 414 180 79 416 214 160 159 95 38 54 32 319 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 10		4.0%	-	-	4.0%	-	-	-	-	5.0%	4.0%	6.0%	4.0%	4.0%	3.0%	6.0%	3.0%	9.0%	8.0%	4.0%	-	4.0%	4.0%
100.0% 0.0% 0.0% 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%																		MO					
Summary TOP 2 BOX 450 0 0 450 0 0 0 0 194 256 120 50 280 155 98 103 57 25 32 21 219 67.0% 67.0% 74.0% 62.0% 67.0% 63.0% 67.0% 72.0% 61.0% 65.0% 60.0% 66.0% 59.0% 66.0% 69.0% BOTTOM 2 BOX 80 0 0 80 0 0 0 0 0 20 60 20 12 48 23 16 23 12 7 9 2 36 12.0% 12.0% 8.0% 14.0% 11.0% 15.0% 12.0% 11.0% 10.0% 14.0% 13.0% 18.0% 17.0% 6.0% 11.0% Mean 3.9 3.9 4.1 3.8 3.9 3.8 3.9 4 3.8 3.9 3.8 3.8 3.7 4.1 4 Std. Dev. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Sigma	675		0		0	0										159						356
TOP 2 BOX 450 0 0 450 0 0 0 0 0 0 194 256 120 50 280 155 98 103 57 25 32 21 219 67.0% 67.0% 67.0% 69.		100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
TOP 2 BOX 450 0 0 450 0 0 0 0 0 0 194 256 120 50 280 155 98 103 57 25 32 21 219 67.0% 67.0% 67.0% 69.																							
67.0% 67.0% 74.0% 62.0% 67.0% 63.0% 67.0% 72.0% 61.0% 65.0% 60.0% 66.0% 59.0% 66.0% 69.0% 69.0% 69.0% 60.0% 67		450	0	0	450	0	0	0	0	104	25.0	120	50	200	455	00	102		25	22	24	240	231
BOTTOM 2 BOX	TOP 2 BOX					-	-	-	-														65.0%
BOTTOM 2 BOX 80 0 0 80 0 0 0 0 0 0 20 60 20 12 48 23 16 23 12 7 9 2 36 12.0% 12.0% 8.0% 14.0% 11.0% 15.0% 12.0% 11.0% 10.0% 14.0% 13.0% 18.0% 17.0% 6.0% 11.0% Mean 3.9 3.9 4.1 3.8 3.9 3.8 3.9 4 3.8 3.9 3.8 3.9 3.8 3.7 4.1 4 Std. Dev. 1.2 1.2 1.2 1 1.2 1.1 1.2 1.1 1.2 1.2 1.1 1.1 1.2 1.2		67.0%	-	-	67.0%	-	-	-	-	74.0%	62.0%	67.0%	65.0%	67.0%		01.0%	65.0%	60.0%	00.0%	39.0%	00.0%	69.0%	05.0%
12.0% - 12.0% 8.0% 14.0% 11.0% 15.0% 12.0% 10.0% 14.0% 13.0% 18.0% 17.0% 6.0% 11.0% Mean 3.9 3.9 4.1 3.8 3.9 3.8 3.9 4 3.8 3.9 3.8 3.9 3.8 3.7 4.1 4 Std. Dev. 1.2 1.2 1 1.2 1.1 1.2 1.2 1.1 1.1 1.2 1.2 1.2 1	ROTTOM 2 ROX	80	0	0	80	0	0	0	0	20	60	20	12	48		16	23	12	7	q	2	36	44
Mean 3.9 3.9 4.1 3.8 3.9 3.8 3.9 4 3.8 3.9 3.8 3.7 4.1 4 Std. Dev. Std. Dev. 1.2 1.2 1 1.2 1.1 1.2 1.2 1.1 1.1 1.2 1.2 1.2 1	BOTTOM E BOX		-			_	-	-	-											-	_		12.0%
Std. Dev. 1.2 1.2 1 1.2 1.1 1.2 1.2 1.1 1.1 1.2 1.2 1.2 1											Н												
Std. Dev. 1.2 1.2 1 1.2 1.1 1.2 1.2 1.1 1.1 1.2 1.2 1.2 1	Mean	3.9	-	-	3.9	-	-	-	-	4.1	3.8	3.9	3.8	3.9	-	3.8	3.9	3.8	3.8	3.7	4.1	4	3.9
	0.1.0						1							4.0	- 1			4.0			+		+
Std. Err. * * 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.2	Std. Dev.	1.2	-	-	1.2	-	-	-	-	1	1.2	1.1	1.2	1.2	1.1	1.1	1.2	1.2	1.2	1.2	1	1.1	1.2
pto.err. - - - - - - - - -	Chil F									0.1	0.1	0.1	0.4	0.4	0.1	0.1	0.1	0.4	0.2	0.2	0.3	0.1	- 0.1
	Sta. Err.	-	-	-	-	-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1

Statistics:

Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Clinical - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	arma: Company	size			Geo	ographical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н		J	К	L	М	N	0	P	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - Clinical	43	0	0	43	0	0	0	0	11	32	17	1	25	28	7	8	2	0	0	0	23	20
Significantly increase 5	18 42.0%	-	-	18 42.0%	0 -	-	0 -	-	5 45.0% *	13 41.0%	8 47.0%	0 - **	10 40.0%	12 43.0%	2 29.0%	2 25.0%	2 100.0%	0 -	0 -	0 -	9 39.0%	9 45.0%
Slightly increase 4	12 28.0%	0 -	0 -	12 28.0%	0 -	0 -	0 -	0 -	2 18.0%	10 31.0%	4 24.0%	0 - **	8 32.0%	7 25.0%	3 43.0%	4 50.0%	0 - **	0 -	0 -	0 -	5 22.0%	7 35.0%
Neither increase or decrease 3	8 19.0%	0 -	0 -	8 19.0%	0 -	0 -	0 -	0 -	2 18.0%	6 19.0%	4 24.0%	0	4 16.0%	6 21.0%	1 14.0%	1 12.0%	0 -	0 -	0 -	0 -	5 22.0%	3 15.0%
Slightly decrease 2	9.0%	0 -	0 -	4 9.0%	0 -	0 -	0 -	0 -	9.0%	3 9.0%	1 6.0%	1 100.0%	2 8.0%	3 11.0%	1 14.0%	1 12.0%	0 -	0 -	0 -	0 -	3 13.0%	1 5.0%
Significantly decrease 1	0	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0	0 -	0	0	0 -	0 -	0	0 -	0 -	0 -
I don't know	2.0%	0 -	0 -	1 2.0%	0 -	0 -	0 -	0 -	1 9.0%	0	0 -	0 -	1 4.0%	0 -	0	0	0 -	0 -	0 -	0 -	1 4.0%	0 -
Sigma	43 100.0%	0 0.0%	0	43 100.0%	0 0.0%	0	0 0.0%	0 0.0%	* 11 100.0%	32 100.0%	17 100.0%	1 100.0%	25 100.0%	28 100.0%	7 100.0%	* 8 100.0%	** 2 100.0%	0 0.0%	0 0.0%	0	23 100.0%	20 100.0%
Summary																						
TOP 2 BOX	30 70.0%	0 -	-	30 70.0%	0 -	-	0 -	-	7 64.0% *	23 72.0%	12 71.0%	0 - **	18 72.0%	19 68.0%	5 71.0%	6 75.0% *	2 100.0% **	0 -	0	0 -	14 61.0%	16 80.0%
BOTTOM 2 BOX	9.0%	0 -	0	9.0%	0 -	0	0 -	0 -	9.0%	3 9.0%	1 6.0%	1 100.0%	2 8.0%	3 11.0%	1 14.0%	1 12.0%	0 - **	0 -	0	0	3 13.0%	1 5.0%
Mean	4	-	-	4	-	-	-	-	4.1	4	4.1	2	4.1	4	3.9	3.9	5	-	-	-	3.9	4.2
Std. Dev.	1	-	-	1	-	-	-	-	1.1	1	1	-	1	1.1	1.1	1	-	-	-	-	1.1	0.9
Std. Err.	0.2	-	-	0.2	-	-	-	-	0.3	0.2	0.2	-	0.2	0.2	0.4	0.4	-	-	-	-	0.2	0.2

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Corporate Affairs - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - Corporate Affairs	17	0	0	17	0	0	0	0	8	9	6	4	7	8	3	1	5	1	2	0	11	6
Significantly increase 5	11 65.0%	0 -	0 -	11 65.0%	0 -	-	0 -	0 -	4 50.0% *	7 78.0% *	4 67.0% *	1 25.0%	6 86.0% *	7 88.0% *	0 - **	1 100.0% **	3 60.0% *	0 - **	0 - **	0 -	8 73.0% *	3 50.0% *
Slightly increase 4	4 24.0%	0 -	0 -	4 24.0%	0 -	0 -	0 -	0 -	2 25.0% *	2 22.0% *	2 33.0%	1 25.0%	1 14.0%	0 -	1 33.0% **	0 -	1 20.0%	0 -	2 100.0%	0 -	2 18.0%	2 33.0%
Neither increase or decrease 3	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 - *	0 - *	0	0 - *	0 -	0 - **	0 -	0 - *	0 - **	0 - **	0 -	0 -	0 -
Slightly decrease 2	0	0 -	0 -	0 -	0 -	0 -	0	0	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
Significantly decrease 1	1 6.0%	0 -	0 -	1 6.0%	0 -	0 -	0 -	0 -	1 12.0%	0 -	0	1 25.0%	0 -	0 -	1 33.0%	0 -	0 -	0 -	0 -	0 -	0 -	1 17.0%
I don't know	1 6.0%	0 -	0 -	1 6.0%	0 -	0 -	0 -	0	1 12.0%	0 -	0	1 25.0%	0 -	1 12.0%	1 33.0%	0 -	1 20.0%	1 100.0%	0 -	0	1 9.0%	0 -
Sigma	17 100.0%	0	0 0.0%	17 100.0%	0	0	0	0	* 8 100.0%	9 100.0%	6 100.0%	4 100.0%	7 100.0%	* 8 100.0%	** 3 100.0%	1 100.0%	* 5 100.0%	** 1 100.0%	** 2 100.0%	0 0.0%	* 11 100.0%	6 100.0%
Summary																						
TOP 2 BOX	15 88.0%	0 -	0 -	15 88.0%	0 -	0 -	0 -	0 -	6 75.0% *	9 100.0% *	6 100.0%	2 50.0%	7 100.0% *	7 88.0%	1 33.0% **	1 100.0% **	4 80.0% *	0 - **	2 100.0% **	0 -	10 91.0%	5 83.0%
ВОТТОМ 2 ВОХ	1 6.0%	0 -	0 -	1 6.0%	0 -	0 -	0 -	0 -	1 12.0%	0 -	0 -	1 25.0%	0 -	0 -	1 33.0% **	0 -	0 -	0 -	0 -	0 -	0 -	1 17.0%
Mean	4.5	-	-	4.5	-	-	-	-	4.1	4.8	4.7	3.3	4.9	5	2.5	5	4.8	-	4	-	4.8	4
Std. Dev.	1	-	-	1	-	-	-	-	1.5	0.4	0.5	2.1	0.4	-	2.1	-	0.5	-	-	-	0.4	1.5
Std. Err.	0.3	-	-	0.3	-	-	-	-	0.6	0.1	0.2	1.2	0.1	-	1.5	-	0.2	-	-	-	0.1	0.6

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Government Affairs or Public Affairs - Patients" trust affected if they were to secretly observe a typical day in that department

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - Government Affairs or Public Affairs	9	0	0	9	0	0	0	0	4	5	2	0	7	0	5	0	4	1	0	0	4	5
Significantly increase 5	4 44.0%	0 -	0 -	4 44.0%	0 -	0 -	0 -	-	2 50.0% **	2 40.0%	0 - **	-	4 57.0%	0 -	4 80.0%	-	0 - **	0 - **	-	0 -	2 50.0% **	2 40.0%
Slightly increase 4	3 33.0%	0 -	0 -	3 33.0%	0 -	0 -	0 -	0	1 25.0%	2 40.0%	1 50.0%	0 -	2 29.0%	0 -	1 20.0%	0 -	2 50.0%	1 100.0%	0 -	0	2 50.0%	1 20.0%
Neither increase or decrease 3	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
Slightly decrease 2	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
Significantly decrease 1	1 11.0%	0 -	0 -	1 11.0%	0 -	0 -	0 -	0 -	1 25.0%	0	1 50.0%	0 -	0 -	0 -	0	0 -	1 25.0%	0 -	0 -	0 -	0	1 20.0%
don't know	1 11.0%	0 -	0 -	1 11.0%	0 -	0 -	0 -	0 -	0 -	1 20.0%	0 -	0 -	1 14.0%	0 -	0 -	0 -	** 1 25.0%	0 -	0 -	0 -	0 -	1 20.0%
Sigma	9 100.0%	0	0	9 100.0%	0	0 0.0%	0	0	4 100.0%	5 100.0%	** 2 100.0%	0	7 100.0%	0	5 100.0%	0 0.0%	** 4 100.0%	** 1 100.0%	0	0	** 4 100.0%	5 100.0%
Summary																						
TOP 2 BOX	7 78.0%	0 -	0 -	7 78.0%	0 -	0 -	0	0 -	3 75.0%	4 80.0%	1 50.0%	0 -	6 86.0%	0 -	5 100.0%	0 -	2 50.0% **	1 100.0%	0 -	0 -	4 100.0%	3 60.0%
BOTTOM 2 BOX	1 11.0%	0 -	0 -	1 11.0%	0 -	0 -	0	0 -	1 25.0%	0 -	1 50.0% **	0	0 -	0	0 -	0 -	1 25.0% **	0 - **	0 -	0 -	0 - **	1 20.0%
Mean	4.1	-	-	4.1	-	-	-	-	3.8	4.5	2.5	-	4.7	-	4.8	-	3	4	-	-	4.5	3.8
Std. Dev.	1.4	-	-	1.4	-	-	-	-	1.9	0.6	2.1	-	0.5	-	0.4	-	1.7	-	-	-	0.6	1.9
Std. Err.	0.5	-	-	0.5	-	-	-	-	0.9	0.3	1.5	-	0.2	=	0.2	-	1	-	-	-	0.3	0.9

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Health Economics and Outcomes Research - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	ırma: Company	size			Geo	graphical loca	tion			Job tit	itle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	E	F	G	Н	- 1	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - Health Economics and Outcomes Research	16	0	0	16	0	0	0	0	7	9	4	0	12	9	2	4	1	1	0	1	12	4
Significantly increase 5	10 62.0%	-	0 -	10 62.0%	0 -	-	-	0 -	5 71.0% *	5 56.0% *	2 50.0% **	-	8 67.0%	5 56.0%	2 100.0% **	2 50.0% **	1 100.0%	1 100.0% **	-	1 100.0%	6 50.0%	4 100.0% **
Slightly increase 4	4 25.0%	0 -	0 -	4 25.0%	0 -	0 -	0	0 -	1 14.0% *	3 33.0% *	2 50.0% **	0	2 17.0%	3 33.0%	0 - **	1 25.0% **	0 - **	0 - **	0 -	0 - **	4 33.0%	0 - **
Neither increase or decrease 3	1 6.0%	0 -	0 -	1 6.0%	0 -	0 -	0 -	0 -	1 14.0%	0 -	0 -	0	1 8.0%	0 -	0	1 25.0%	0	0 -	0 -	0 -	1 8.0%	0 -
Slightly decrease 2	0	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0	0	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
Significantly decrease 1	1 6.0%	0	0 -	1 6.0%	0 -	0 -	0 -	0 -	0 -	* 1 11.0%	0 -	0 -	1 8.0%	1 11.0%	0 -	0 -	0 -	0 -	0 -	0 -	1 8.0%	0 -
I don't know	0	0 -	0	0	0	0	0	0	0 -	0	0	0	0	0	0 -	0 -	0	0 -	0 -	0	0 -	0 -
Sigma	16 100.0%	0	0	16 100.0%	0	0	0	0	* 7 100.0%	* 9 100.0%	** 4 100.0%	0	12 100.0%	9	** 2 100.0%	** 4 100.0%	** 1 100.0%	** 1 100.0%	0	** 1 100.0%	12 100.0%	** 4 100.0%
Summary	200.075	0.0.0	0.0.1	300.010	3.0.0		0.0,1	0.07.			200.0.0	0.0,0			2001011	200.071		300.0.0	0.07.			
TOP 2 BOX	14 88.0%	0 -	0 -	14 88.0%	0	0 -	0	0	6 86.0%	8 89.0%	4 100.0%	0	10 83.0%	8 89.0%	2 100.0%	3 75.0%	1 100.0% **	1 100.0% **	0 -	1 100.0%	10 83.0%	4 100.0% **
ВОТТОМ 2 ВОХ	1 6.0%	0 -	0 -	1 6.0%	0 -	0 -	0 -	0 -	0 -	1 11.0%	0	0	1 8.0%	1 11.0%	0 -	0	0 -	0 -	0 -	0 -	1 8.0%	0 -
Mean	4.4	-	-	4.4	-	-	-	-	4.6	4.2	4.5	-	4.3	4.2	5	4.2	5	5	-	5	4.2	5
Std. Dev.	1.1	-	-	1.1	-	-	-	-	0.8	1.3	0.6	-	1.2	1.3	-	1	-	-	-	-	1.2	-
Std. Err.	0.3	-	-	0.3	-	-	-	-	0.3	0.4	0.3	-	0.4	0.4	-	0.5	-	-	-	-	0.3	-

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - HR - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	rma: Company	size			Geo	ographical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	1	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - HR	3	0	0	3	0	0	0	0	1	2	1	0	2	1	0	1	1	0	0	0	2	1
Significantly increase 5	1 33.0%	0 -	0 -	1 33.0%	0 -	0 -	0 -	0 -	0 -	1 50.0% **	0 - **	0 -	1 50.0% **	0 -	0 -	0 - **	1 100.0% **	0 -	0 -	0 -	1 50.0% **	0 -
Slightly increase 4	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 - **	0 - **	0	0 - **	0 -	0 -	0 - **	0 - **	0 -	0 -	0 -	0 - **	0 -
Neither increase or decrease 3	1 33.0%	0 -	0 -	1 33.0%	0 -	0 -	0	0 -	0	1 50.0%	1 100.0%	0	0 -	0 -	0 -	1 100.0%	0 -	0 -	0 -	0 -	1 50.0%	0 -
Slightly decrease 2	0 -	0 -	0 -	0 -	0 -	0	0	0	0	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -
Significantly decrease 1	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -
I don't know	1 33.0%	0 -	0 -	1 33.0%	0 -	0 -	0 -	0 -	1 100.0%	0 -	0 -	0	1 50.0%	1 100.0%	0 -	0 -	0 -	0 -	0 -	0 -	0 -	1 100.0%
Sigma	3 100.0%	0	0	3 100.0%	0.0%	0 0.0%	0	0 0.0%	1 100.0%	2 100.0%	1 100.0%	0	2 100.0%	1 100.0%	0 0.0%	1 100.0%	1 100.0%	0 0.0%	0 0.0%	0	2 100.0%	1 100.0%
Summary																						
TOP 2 BOX	1 33.0%	0 -	0 -	1 33.0%	-	-	0 -	-	0 -	1 50.0% **	- **	-	1 50.0% **	0 - **	0 -	0 - **	1 100.0% **	-	-	0 -	1 50.0%	- **
ВОТТОМ 2 ВОХ	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 - **	0 - **	0	0 - **	0 -	0 -	0 - **	0 - **	0 -	0 -	0 -	0 - **	0 - **
Mean	4	-	-	4	-	-	-	-	-	4	3	-	5	-	-	3	5	-	-	-	4	-
Std. Dev.	1.4	-	-	1.4	-	-	-	-	-	1.4	**	-	**	-	-	**	**	-	-	-	1.4	-
Std. Err.	1	-	-	1	-	-	-	-	-	1	_	_	-	-	-	_	-	-	-	-	1	-

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - IT - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	I	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - IT	13	0	0	13	0	0	0	0	7	6	1	1	11	4	4	5	2	1	0	0	6	7
Significantly increase 5	2 15.0%	0 -	0	2 15.0%	0 -	0 -	0	0	2 29.0%	0 - *	0 -	1 100.0% **	1 9.0%	0 - **	1 25.0% **	2 40.0%	0 - **	0 - **	0 -	0 -	2 33.0%	0 - *
Slightly increase 4	6 46.0%	0 -	0 -	6 46.0%	0 -	0 -	0 -	0 -	3 43.0%	3 50.0%	0	0	6 55.0%	2 50.0%	1 25.0%	2 40.0%	0 -	1 100.0%	0 -	0 -	3 50.0%	3 43.0%
Neither increase or decrease 3	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
Slightly decrease 2	1 8.0%	0 -	0 -	1 8.0%	0 -	0 -	0 -	0 -	0 -	1 17.0%	0 -	0 -	1 9.0%	** 1 25.0%	0 -	0 -	0 -	** 0 - **	0 -	0 -	0 -	1 14.0%
Significantly decrease 1	1 8.0%	0 -	0 -	1 8.0%	0 -	0 -	0 -	0 -	0 -	1 17.0%	0	0	1 9.0%	1 25.0%	0	0 -	0 -	0	0 -	0 -	0 -	1 14.0%
I don't know	3 23.0%	0 -	0 -	3 23.0%	0 -	0 -	0	0	* 2 29.0%	* 1 17.0%	** 1 100.0%	0 -	2 18.0%	0 -	** 2 50.0%	1 20.0%	** 2 100.0%	0 -	0 -	0 -	* 1 17.0%	* 2 29.0%
Sigma	13 100.0%	0 0.0%	0	13 100.0%	0	0	0	0	* 7 100.0%	* 6 100.0%	** 1 100.0%	** 1 100.0%	11 100.0%	** 4 100.0%	** 4 100.0%	5 100.0%	** 2 100.0%	** 1 100.0%	0 0.0%	0	6 100.0%	7 100.0%
Summary																						
TOP 2 BOX	8 62.0%	0 -	0 -	8 62.0%	0 -	0 -	0 -	0 -	5 71.0%	3 50.0% *	0 - **	1 100.0%	7 64.0%	2 50.0%	2 50.0%	4 80.0%	0 - **	1 100.0%	0 -	0 -	5 83.0% *	3 43.0%
ВОТТОМ 2 ВОХ	2 15.0%	0 -	0 -	2 15.0%	0 -	0 -	0	0	0 -	2 33.0%	0	0	2 18.0%	2 50.0%	0	0 -	0 -	0	0 -	0 -	0 -	2 29.0%
Mean	3.7	-	-	3.7	-	=	-	-	* 4.4 *	3 *	**	5	3.6	2.8	** 4.5 **	4.5	**	** 4 **	-	=	* 4.4 *	3
Std. Dev.	1.3	-	-	1.3	-	-	-	-	0.5	1.4		-	1.2	1.5	0.7	0.6	-	-	-	-	0.5	1.4
Std. Err.	0.4	-	-	0.4	-	-	-	-	0.2	0.6	-	-	0.4	0.8	0.5	0.3	-	-	-	-	0.2	0.6

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Manufacturing - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	arma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - Manufacturing	12	0	0	12	0	0	0	0	3	9	4	1	7	8	1	1	3	1	0	1	8	4
Significantly increase 5	7 58.0%	-	-	7 58.0%	0 -	-	-	-	1 33.0% **	6 67.0%	2 50.0% **	1 100.0% **	4 57.0%	7 88.0%	0 - **	0 -	0 - **	0 - **	0 -	0 - **	5 62.0%	2 50.0% **
Slightly increase 4	4 33.0%	0 -	0 -	4 33.0%	0 -	0 -	0 -	0 -	1 33.0%	3 33.0%	1 25.0%	0 - **	3 43.0%	1 12.0%	1 100.0%	0 -	3 100.0% **	1 100.0%	0 -	1 100.0%	3 38.0%	1 25.0%
Neither increase or decrease 3	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -	0 -	0	0	0 -	0 -	0	0 -	0 -
Slightly decrease 2	1 8.0%	0 -	0 -	1 8.0%	0 -	0 -	0 -	0 -	1 33.0%	0 -	1 25.0%	0 -	0 -	0 -	0 -	1 100.0%	0 -	0 -	0 -	0	0 -	1 25.0%
Significantly decrease 1	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0	0 -	0 -
I don't know	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
Sigma	12 100.0%	0	0	12 100.0%	0 0.0%	0	0	0 0.0%	** 3 100.0%	9 100.0%	** 4 100.0%	** 1 100.0%	7 100.0%	8 100.0%	** 1 100.0%	** 1 100.0%	** 3 100.0%	** 1 100.0%	0 0.0%	** 1 100.0%	8 100.0%	** 4 100.0%
Summary																						
TOP 2 BOX	11 92.0%	0 -	0 -	11 92.0%	0 -	0 -	0 -	0 -	2 67.0%	9 100.0%	3 75.0%	1 100.0%	7 100.0%	8 100.0%	1 100.0%	0 - **	3 100.0% **	1 100.0%	0 -	1 100.0%	8 100.0%	3 75.0% **
ВОТТОМ 2 ВОХ	1 8.0%	0 -	0 -	1 8.0%	0 -	0 -	0	0	1 33.0%	0 -	1 25.0%	0 -	0	0 -	0 -	1 100.0%	0 -	0 -	0 -	0 -	0 -	1 25.0% **
Mean	4.4	-	-	4.4	-	-	-	-	3.7	4.7	4	5	4.6	4.9	4	2	4	4	-	4	4.6	4
Std. Dev.	0.9	-	-	0.9	-	-	-	-	1.5	0.5	1.4	-	0.5	0.4	-	-	-	-	-	-	0.5	1.4
Std. Err.	0.3	-	÷	0.3	-	-	-	-	0.9	0.2	0.7	-	0.2	0.1	-	-	-	-	-	-	0.2	0.7

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Market Access - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Ph	arma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		Α	В	С	D	E	F	G	Н	1	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - Market Access	41	0	0	41	0	0	0	0	20	21	10	1	30	4	12	14	4	6	7	3	17	24
Significantly increase 5	16 39.0%	0 -	0 -	16 39.0%	0 -	0 -	0 -	0 -	11 55.0%	5 24.0%	5 50.0% *	0 -	11 37.0%	1 25.0% **	4 33.0% *	3 21.0% *	0 - **	3 50.0% *	29.0%	1 33.0% **	8 47.0%	8 33.0%
Slightly increase 4	10 24.0%	0 -	0 -	10 24.0%	0 -	0 -	0 -	0 -	4 20.0%	6 29.0%	1 10.0%	1 100.0%	8 27.0%	2 50.0% **	3 25.0%	6 43.0%	1 25.0% **	1 17.0%	2 29.0%	1 33.0%	5 29.0%	5 21.0%
Neither increase or decrease 3	9 22.0%	0 -	0 -	9 22.0%	0 -	0 -	0 -	0 -	4 20.0%	5 24.0%	3 30.0%	0	6 20.0%	1 25.0%	3 25.0%	2 14.0%	2 50.0% **	0 -	1 14.0%	0	3 18.0%	6 25.0%
Slightly decrease 2	3 7.0%	0 -	0 -	3 7.0%	0 -	0 -	0 -	0	0 -	3 14.0%	1 10.0%	0 -	2 7.0%	0 -	1 8.0%	2 14.0%	1 25.0%	1 17.0%	1 14.0%	1 33.0%	1 6.0%	2 8.0%
Significantly decrease 1	2 5.0%	0 -	0 -	2 5.0%	0 -	0 -	0	0 -	1 5.0%	1 5.0%	0	0 -	2 7.0%	0 -	0	1 7.0%	0 -	1 17.0%	1 14.0%	0	0 -	2 8.0%
I don't know	2.0%	0 -	0 -	1 2.0%	0 -	0 -	0 -	0 -	0 -	1 5.0%	0	0 -	1 3.0%	0	1 8.0%	0 -	0 -	0	0	0 -	0 -	1 4.0%
Sigma	41 100.0%	0	0	41 100.0%	0 0.0%	0	0	0	20 100.0%	21 100.0%	10 100.0%	** 1 100.0%	30 100.0%	** 4 100.0%	12 100.0%	* 14 100.0%	** 4 100.0%	6 100.0%	7 100.0%	** 3 100.0%	17 100.0%	24 100.0%
Summary																						
TOP 2 BOX	26 63.0%	0 -	-	26 63.0%	0 -	-	0 -	-	15 75.0%	11 52.0%	6 60.0%	1 100.0% **	19 63.0%	3 75.0% **	7 58.0%	9 64.0% *	1 25.0% **	4 67.0% *	4 57.0%	2 67.0% **	13 76.0%	13 54.0%
BOTTOM 2 BOX	5 12.0%	0 -	0 -	5 12.0%	0 -	0 -	0 -	0 -	1 5.0%	4 19.0%	1 10.0%	0 -	4 13.0%	0 - **	1 8.0%	3 21.0%	1 25.0% **	2 33.0%	2 29.0%	1 33.0%	1 6.0%	4 17.0%
Mean	3.9	-	-	3.9	-	-	-	-	4.2	3.6	4	4	3.8	4	3.9	3.6	3	3.7	3.4	3.7	4.2	3.7
Std. Dev.	1.2	-	-	1.2	-	-	-	-	1.1	1.2	1.2	-	1.2	0.8	1	1.2	0.8	1.8	1.5	1.5	1	1.3
Std. Err.	0.2	-	-	0.2	-	-	-	-	0.2	0.3	0.4	-	0.2	0.4	0.3	0.3	0.4	0.7	0.6	0.9	0.2	0.3

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Market Research - Patients' trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	ırma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н		J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - Market Research	23	0	0	23	0	0	0	0	8	15	4	4	15	9	8	3	2	1	3	0	9	14
Significantly increase 5	8 35.0%	-	0 -	8 35.0%	0 -	0 -	0 -	0 -	4 50.0% *	4 27.0%	0 - **	1 25.0% **	7 47.0%	3 33.0%	3 38.0%	0 -	0 -	0 - **	1 33.0% **	0 -	1 11.0%	7 50.0%
Slightly increase 4	10 43.0%	0 -	0 -	10 43.0%	0 -	0 -	0 -	0 -	4 50.0% *	6 40.0%	1 25.0%	3 75.0%	6 40.0%	4 44.0%	3 38.0%	2 67.0%	2 100.0%	1 100.0% **	1 33.0%	0 -	6 67.0%	4 29.0%
Neither increase or decrease 3	3 13.0%	0 -	0 -	3 13.0%	0 -	0 -	0 -	0 -	0 -	3 20.0%	3 75.0%	0 -	0 -	1 11.0%	1 12.0%	1 33.0%	0	0 -	1 33.0% **	0 -	1 11.0%	2 14.0%
Slightly decrease 2	1 4.0%	0 -	0 -	1 4.0%	0 -	0 -	0 -	0 -	0 -	1 7.0%	0 -	0 -	1 7.0%	1 11.0%	0	0	0	0 -	0 -	0 -	0 -	1 7.0%
Significantly decrease 1	1 4.0%	0 -	0 -	1 4.0%	0 -	0 -	0	0 -	0 -	1 7.0%	0	0 -	1 7.0%	0 -	1 12.0%	0	0	0 -	0 -	0 -	1 11.0%	0 -
I don't know	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0	0	0	0 -	0 -	0 -	0	0 -
Sigma	23 100.0%	0 0.0%	0	23 100.0%	0.0%	0	0 0.0%	0	* 8 100.0%	15 100.0%	4 100.0%	4 100.0%	15 100.0%	9 100.0%	* 8 100.0%	3 100.0%	2 100.0%	1 100.0%	3 100.0%	0	9 100.0%	14 100.0%
Summary																						
TOP 2 BOX	18 78.0%	0 -	-	18 78.0%	0 -	-	-	0 -	8 100.0% *	10 67.0%	1 25.0% **	4 100.0% **	13 87.0%	7 78.0% *	6 75.0%	2 67.0% **	2 100.0%	1 100.0% **	2 67.0% **	0 -	7 78.0% *	11 79.0%
ВОТТОМ 2 ВОХ	9.0%	0 -	0 -	9.0%	0 -	0 -	0 -	0 -	0 - *	2 13.0%	0 -	0 - **	2 13.0%	1 11.0%	1 12.0%	0 -	0 -	0 - **	0 - **	0 -	1 11.0%	1 7.0% *
Mean	4	-	-	4	-	-	-	-	4.5	3.7	3.2	4.2	4.1	4	3.9	3.7	4	4	4	-	3.7	4.2
Std. Dev.	1	-	-	1	-	-	-	-	0.5	1.2	0.5	0.5	1.2	1	1.4	0.6	-	-	1	-	1.1	1
Std. Err.	0.2	-	-	0.2	-	-	-	-	0.2	0.3	0.2	0.2	0.3	0.3	0.5	0.3	-	-	0.6	÷	0.4	0.3

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Marketing - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н		J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - Marketing	157	0	0	157	0	0	0	0	62	95	45	22	90	35	34	32	30	13	18	9	84	73
Significantly increase 5	45 29.0%	-	0 -	45 29.0%	0 -	0 -	0 -	0 -	19 31.0%	26 27.0%	16 36.0%	5 23.0%	24 27.0%	13 37.0%	7 21.0%	9 28.0%	6 20.0%	3 23.0% *	4 22.0%	4 44.0% *	29 35.0%	16 22.0%
Slightly increase 4	42 27.0%	0 -	0 -	42 27.0%	0 -	0 -	0 -	0 -	21 34.0%	21 22.0%	16 36.0%	3 14.0%	23 26.0%	6 17.0%	14 41.0% MO	4 12.0%	9 30.0%	6 46.0% MO*	4 22.0%	1 11.0%	24 29.0%	18 25.0%
Neither increase or decrease 3	39 25.0%	0 -	0 -	39 25.0%	0 -	0 -	0 -	0 -	10 16.0%	29 31.0%	6 13.0%	9 41.0%	24 27.0%	12 34.0%	10 29.0%	9 28.0%	6 20.0%	0 -	5 28.0%	4 44.0%	17 20.0%	22 30.0%
Slightly decrease 2	13 8.0%	0 -	0 -	13 8.0%	0 -	0 -	0 -	0 -	5 8.0%	H 8 8.0%	4 9.0%	3 14.0%	6 7.0%	Q 1 3.0%	Q 0 -	Q 5 16.0%	4 13.0%	2 15.0%	3 17.0%	Q* 0 -	9 11.0%	4 5.0%
Significantly decrease 1	13 8.0%	0 -	0 -	13 8.0%	0 -	0 -	0 -	0 -	4 6.0%	9 9.0%	1 2.0%	2 9.0%	10 11.0%	3 9.0%	2 6.0%	N 4 12.0%	N 3 10.0%	N* 0	N 1 6.0%	0 -	3 4.0%	10 14.0%
I don't know	5 3.0%	0 -	0 -	5 3.0%	0 -	0 -	0 -	0 -	3 5.0%	2 2.0%	2 4.0%	0 -	3 3.0%	0 -	1 3.0%	1 3.0%	2 7.0%	* 2 15.0%	1 6.0%	0 -	2 2.0%	T 3 4.0%
Sigma	157 100.0%	0	0	157 100.0%	0	0	0	0 0.0%	62 100.0%	95 100.0%	45 100.0%	22 100.0%	90 100.0%	35 100.0%	34 100.0%	32 100.0%	30 100.0%	M* 13 100.0%	18 100.0%	9 100.0%	84 100.0%	73 100.0%
Summary																						
TOP 2 BOX	87 55.0%	0 -	0 -	87 55.0%	0 -	0 -	0 -	0 -	40 65.0%	47 49.0%	32 71.0% KL	8 36.0%	47 52.0%	19 54.0%	21 62.0%	13 41.0%	15 50.0%	9 69.0%	8 44.0%	5 56.0% *	53 63.0% U	34 47.0%
ВОТТОМ 2 ВОХ	26 17.0%	0 -	0 -	26 17.0%	0 -	0 -	0	0	9 15.0%	17 18.0%	5 11.0%	5 23.0%	16 18.0%	4 11.0%	2 6.0%	9 28.0%	7 23.0%	2 15.0%	4 22.0%	0 -	12 14.0%	14 19.0%
Mean	3.6	-	-	3.6	-	-	-	-	3.8	3.5	4 KL	3.3	3.5	3.7	3.7	N 3.3	3.4	3.9	3.4	4	3.8 U	3.4
Std. Dev.	1.2	-	-	1.2	-	-	-	-	1.2	1.3	1.1	1.2	1.3	1.3	1	1.4	1.3	1	1.2	1	1.1	1.3
Std. Err.	0.1	-	-	0.1	-	-	-	-	0.2	0.1	0.2	0.3	0.1	0.2	0.2	0.3	0.2	0.3	0.3	0.3	0.1	0.2

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Medical Affairs - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	ırma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - Medical Affairs	74	0	0	74	0	0	0	0	22	52	13	9	52	20	17	19	14	3	6	5	38	36
Significantly increase 5	31 42.0%	0 -	-	31 42.0%	0 -	0 -	0 -	0 -	12 55.0%	19 37.0%	4 31.0%	4 44.0%	23 44.0%	7 35.0%	4 24.0%	10 53.0%	8 57.0% *	2 67.0% **	2 33.0% *	3 60.0% *	16 42.0%	15 42.0%
Slightly increase 4	23 31.0%	0 -	0 -	23 31.0%	0 -	0 -	0	0 -	4 18.0%	19 37.0%	5 38.0%	3 33.0%	15 29.0%	9 45.0%	7 41.0%	2 11.0%	2 14.0% *	0 - **	2 33.0%	0 -	9 24.0%	14 39.0%
Neither increase or decrease 3	12 16.0%	0 -	0 -	12 16.0%	0 -	0 -	0	0 -	5 23.0%	7 13.0%	1 8.0%	1 11.0%	10 19.0%	2 10.0%	0 4 24.0%	5 26.0%	3 21.0%	1 33.0%	1 17.0%	2 40.0%	8 21.0%	4 11.0%
Slightly decrease 2	3 4.0%	0 -	0 -	3 4.0%	0 -	0 -	0 -	0 -	0	3 6.0%	0	1 11.0%	2 4.0%	0 -	0 -	2 11.0%	0 -	0 -	1 17.0%	0 -	3 8.0%	0 -
Significantly decrease 1	3 4.0%	0 -	0 -	3 4.0%	0 -	0 -	0 -	0 -	0 -	3 6.0%	2 15.0%	0	1 2.0%	1 5.0%	2 12.0%	0 -	0 -	0	0 -	0 -	0 -	3 8.0%
I don't know	3.0%	0 -	0 -	2 3.0%	0 -	0 -	0 -	0 -	1 5.0%	1 2.0%	L* 1 8.0%	0	1 2.0%	1 5.0%	0 -	0 -	* 1 7.0%	0 -	0 -	0 -	2 5.0%	0 -
Sigma	74 100.0%	0	0	74 100.0%	0	0	0	0	22 100.0%	52 100.0%	13 100.0%	9 100.0%	52 100.0%	20 100.0%	17 100.0%	19 100.0%	* 14 100.0%	** 3 100.0%	6 100.0%	* 5 100.0%	38 100.0%	36 100.0%
Summary																						
TOP 2 BOX	54 73.0%	0 -	0 -	54 73.0%	0 -	0 -	0 -	0 -	16 73.0%	38 73.0%	9 69.0%	7 78.0%	38 73.0%	16 80.0%	11 65.0%	12 63.0%	10 71.0%	2 67.0%	4 67.0%	3 60.0% *	25 66.0%	29 81.0%
ВОТТОМ 2 ВОХ	6 8.0%	0 -	0 -	6 8.0%	0 -	0 -	0	0	0	6 12.0%	2 15.0%	1 11.0%	3 6.0%	1 5.0%	2 12.0%	2 11.0%	0 -	0 -	1 17.0%	0 -	3 8.0%	3 8.0%
Mean	4.1	-	-	4.1	-	-	-	-	4.3	3.9	3.8	4.1	4.1	4.1	3.6	4.1	4.4	4.3	3.8	4.2	4.1	4.1
Std. Dev.	1.1	-	-	1.1	-	-	-	-	0.9	1.1	1.4	1.1	1	1	1.2	1.1	0.9	1.2	1.2	1.1	1	1.1
Std. Err.	0.1	-	-	0.1	=	-	-	-	0.2	0.2	0.4	0.4	0.1	0.2	0.3	0.3	0.2	0.7	0.5	0.5	0.2	0.2

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Operations and Finance - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	rma: Company	, size			Geo	graphical loc	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	т	U
Base: Pharma Companies based on Q22 - Operations and Finance	15	0	0	15	0	0	0	0	5	10	6	2	7	5	1	6	0	1	2	0	7	8
Significantly increase 5	2 13.0%	0 -	0 -	2 13.0%	0 -	0 -	0 -	0	1 20.0%	1 10.0%	1 17.0%	0 -	1 14.0%	0 -	0 -	1 17.0%	0	0 -	1 50.0% **	0 -	2 29.0%	0 - *
Slightly increase 4	4 27.0%	0 -	0 -	4 27.0%	0 -	0 -	0 -	0 -	3 60.0%	1 10.0%	1 17.0%	0	3 43.0%	40.0%	0	2 33.0%	0 -	0 -	0 -	0 -	2 29.0%	2 25.0%
Neither increase or decrease 3	3 20.0%	0 -	0 -	3 20.0%	0 -	0 -	0 -	0 -	1 20.0%	2 20.0%	1 17.0%	2 100.0%	0 -	1 20.0%	1 100.0%	1 17.0%	0 -	0 -	0 -	0 -	1 14.0%	2 25.0%
Slightly decrease 2	2 13.0%	0	0	2 13.0%	0 -	0 -	0	0	0 -	2 20.0%	0	0	2 29.0%	2 40.0%	0	0 -	0	0 -	0 -	0 -	1 14.0%	1 12.0%
Significantly decrease 1	3 20.0%	0 -	0 -	3 20.0%	0 -	0 -	0 -	0 -	0 -	3 30.0%	2 33.0%	0	1 14.0%	0 -	0	1 17.0%	0 -	1 100.0%	1 50.0%	0 -	1 14.0%	2 25.0%
I don't know	1 7.0%	0 -	0 -	1 7.0%	0 -	0 -	0 -	0 -	0 -	1 10.0%	1 17.0%	0	0 -	0 -	0	1 17.0%	0	0 -	0 -	0	0	1 12.0%
Sigma	15 100.0%	0	0	15 100.0%	0	0	0	0	* 5 100.0%	* 10 100.0%	6 100.0%	** 2 100.0%	* 7 100.0%	* 5 100.0%	** 1 100.0%	6 100.0%	0	** 1 100.0%	** 2 100.0%	0	7 100.0%	* 8 100.0%
Summary																						
TOP 2 BOX	6 40.0%	0 -	0 -	6 40.0%	0 -	0 -	0 -	0 -	4 80.0%	2 20.0%	2 33.0%	0 -	4 57.0%	2 40.0%	0 - **	3 50.0%	0 -	0 -	1 50.0% **	0	4 57.0%	2 25.0%
ВОТТОМ 2 ВОХ	5 33.0%	0 -	0 -	5 33.0%	0 -	0 -	0 -	0	0 -	5 50.0% *	2 33.0%	0 -	3 43.0% *	2 40.0% *	0 -	1 17.0%	0	1 100.0% **	1 50.0% **	0 -	2 29.0%	3 38.0% *
Mean	3	-	-	3	-	-	-	-	4	2.4	2.8	3	3.1	3 *	3	3.4	-	1 **	3	-	3.4	2.6
Std. Dev.	1.4	-	-	1.4	-	-	-	-	0.7	1.4	1.8	-	1.5	1	-	1.5	-	-	2.8	÷	1.5	1.3
Std. Err.	0.4	-	-	0.4	-	-	-	-	0.3	0.5	0.8	-	0.6	0.4	-	0.7	-	-	2	-	0.6	0.5


Statistics:

Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Patient Affairs or Patient Advocacy - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Ph:	arma: Company	r siza			Geo	graphical loca	tion			loh tit	tle/level
	Total	Patient or	Suppliers	Pharma	HCP	Bure nationt	Patients only	Patient	Very	Less	Small	Medium	Large	Global	Europe	North and	Asia	Africa	South	Australasia		
	Total	Health Charity	эцррпета	Filailia	ncr	(not part of any other group)	Patients only	Health Charity and Patients	confident	confident	Siliali	Wiedluiii	Large	Global	Lurope	Central America	Asia	Airica	America	Australasia	Head or higher	managers of lower
		Α	В	С	D	E	F	G	Н	- 1	J	K	L	М	N	0	P	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - Patient Affairs or Patient Advocacy	20	0	0	20	0	0	0	0	12	8	6	4	10	10	3	7	1	0	0	1	7	13
Significantly increase 5	13 65.0%	0	0	13 65.0%	0	0	0	0	9 75.0%	4 50.0%	4 67.0%	3 75.0%	60.0%	7 70.0%	2 67.0%	5 71.0%	0	0	0	1 100.0%	4 57.0%	9 69.0%
	03.076		-	03.070	-	-	-	-	*	*	*	**	*	*	**	*	**	-	_	**	*	*
Slightly increase 4	6	0	0	6	0	0	0	0	3	3	1	1	4	3	1	2	0	0	0	0	3	3
	30.0%	-	-	30.0%	-	-	-	-	25.0%	38.0%	17.0%	25.0%	40.0%	30.0%	33.0%	29.0%	**	-	-	**	43.0%	23.0%
Neither increase or decrease 3	1	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	1
	5.0%	-	-	5.0%	-	-	-	-	-	12.0%	17.0%	-	-	-	-	-	100.0%	-	-	-	-	8.0%
Slightly decrease 2	0	0	0	0	0	0	0	0	*	*	*	0	*	*	**	*	0	0	0	**	*	*
Slightly decrease 2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
									*	*	*	**	*	*	**	*	**			**	*	*
Significantly decrease 1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	-	-	-	-	-	-	-	-	*	*	*	**	*	*	**	*	**	-	-	**	*	*
I don't know	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	-	-	-	-	-	-	-	-	*			**	*		**		**	-	-	**	*	*
Sigma	20	0	0	20	0	0	0	0	12	8	6	4	10	10	3	7	1	0	0	1	7	13
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	19	0	0	19	0	0	0	0	12	7	5	4	10	10	3	7	0	0	0	1	7	12
	95.0%	-	-	95.0%	-	-	-	-	100.0%	88.0%	83.0%	100.0%	100.0%	100.0%	100.0%	100.0%	**	-	-	100.0%	100.0%	92.0%
BOTTOM 2 BOX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	•	-	-	-	-	-
Maria	4.6			4.6					*	*	*	**	*	*	**	*	**			**	*	*
Mean	4.6	-	-	4.6	-	-	-	-	4.8 *	4.4 *	4.5 *	4.8	4.6 *	4.7 *	4.7	4.7 *	3	-	-	5	4.6 *	4.6 *
Std. Dev.	0.6	-	-	0.6	-	-	-	-	0.5	0.7	0.8	0.5	0.5	0.5	0.6	0.5	-	-	-	-	0.5	0.7
Std. Err.	0.1	-	-	0.1	-	-	-	-	0.1	0.3	0.3	0.2	0.2	0.2	0.3	0.2	-	-	-	-	0.2	0.2

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)
Table of Contents



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - R&D pre-clinical - Patients' trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	arma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - R&D pre-clinical	20	0	0	20	0	0	0	0	10	10	12	2	6	13	3	4	0	0	1	0	10	10
Significantly increase 5	7 35.0%	-	0 -	7 35.0%	-	0 -	0	0 -	5 50.0% *	2 20.0%	4 33.0%	1 50.0% **	2 33.0% *	5 38.0%	1 33.0% **	2 50.0% **	0 -	0 -	0 - **	-	4 40.0%	3 30.0% *
Slightly increase 4	8 40.0%	0 -	0 -	8 40.0%	0 -	0 -	0 -	0 -	3 30.0%	5 50.0% *	7 58.0%	0 -	1 17.0%	6 46.0%	1 33.0%	1 25.0%	0	0 -	0 -	0	4 40.0%	4 40.0% *
Neither increase or decrease 3	2 10.0%	0 -	0 -	2 10.0%	0 -	0 -	0 -	0 -	1 10.0%	1 10.0%	0	0 -	33.0%	1 8.0%	0 -	0 -	0 -	0 -	1 100.0% **	0 -	2 20.0%	0 -
Slightly decrease 2	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
Significantly decrease 1	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
I don't know	3 15.0%	0 -	0 -	3 15.0%	0 -	0 -	0	0	1 10.0%	2 20.0%	1 8.0%	1 50.0%	1 17.0%	1 8.0%	1 33.0%	1 25.0%	0	0 -	0 -	0 -	0 -	3 30.0%
Sigma	20 100.0%	0	0	20 100.0%	0	0	0	0	* 10 100.0%	* 10 100.0%	12 100.0%	** 2 100.0%	6 100.0%	13 100.0%	** 3 100.0%	** 4 100.0%	0	0	1 100.0%	0 0.0%	10 100.0%	10 100.0%
Summary																						_
TOP 2 BOX	15 75.0%	-	0 -	15 75.0%	0 -	-	0 -	0 -	8 80.0% *	7 70.0% *	11 92.0%	1 50.0% **	3 50.0% *	11 85.0%	2 67.0% **	3 75.0% **	0 -	0 -	0 - **	0 -	8 80.0% *	7 70.0% *
ВОТТОМ 2 ВОХ	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 - *	0 - *	0 - *	0 - **	0 - *	0 -	0 - **	0 -	0 -	0 -	0 - **	0 -	0 - *	0 -
Mean	4.3	-	-	4.3	-	-	-	-	4.4	4.1	4.4	5	4 *	4.3	4.5	4.7	-	-	3	-	4.2	4.4
Std. Dev.	0.7	-	-	0.7	-	-	-	-	0.7	0.6	0.5	-	1	0.7	0.7	0.6	-	-	-	-	0.8	0.5
Std. Err.	0.2	-	-	0.2	÷	-	-	-	0.2	0.2	0.2	-	0.4	0.2	0.5	0.3	-	-	-	-	0.2	0.2

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - R&D clinical - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		Α	В	С	D	E	F	G	н	_	J	K	L	М	N	0	P	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - R&D clinical	55	0	0	55	0	0	0	0	22	33	10	6	39	34	6	9	4	1	4	0	24	31
Significantly increase 5	18 33.0%	0 -	0 -	18 33.0%	0 -	0 -	0 -	-	8 36.0%	10 30.0%	0 - *	4 67.0% J*	14 36.0%	12 35.0%	33.0%	4 44.0% *	1 25.0% **	0 - **	1 25.0% **	0 -	8 33.0%	10 32.0%
Slightly increase 4	16 29.0%	0 -	0 -	16 29.0%	0 -	0 -	0	0 -	7 32.0%	9 27.0%	4 40.0%	1 17.0%	11 28.0%	11 32.0%	1 17.0%	1 11.0%	1 25.0%	0 -	2 50.0%	0 -	8 33.0%	8 26.0%
Neither increase or decrease 3	7 13.0%	0 -	0 -	7 13.0%	0 -	0 -	0 -	0 -	2 9.0%	5 15.0%	* 3 30.0%	0 -	4 10.0%	3 9.0%	1 17.0%	* 2 22.0%	** 1 25.0%	** 1 100.0%	0 -	0 -	2 8.0%	5 16.0%
Slightly decrease 2	9	0 -	0	9 16.0%	0 -	0 -	0 -	0 -	3 14.0%	6 18.0%	* 2 20.0%	1 17.0%	6 15.0%	6 18.0%	1 17.0%	2 22.0%	0 -	0 -	0 -	0 -	4 17.0%	5 16.0%
Significantly decrease 1	3 5.0%	0 -	0	3 5.0%	0	0 -	0	0	1 5.0%	2 6.0%	* 1 10.0%	0	2 5.0%	1 3.0%	0	0	** 1 25.0%	0 -	** 1 25.0%	0	1 4.0%	2 6.0%
I don't know	2 4.0%	0	0	2 4.0%	0	0	0	0	1 5.0%	1 3.0%	0	0	2 5.0%	1 3.0%	* 1 17.0%	0	0	0 -	0 -	0	1 4.0%	1 3.0%
Sigma	55 100.0%	0	0	55 100.0%	0	0	0	0	22	33 100.0%	* 10 100.0%	* 6 100.0%	39 100.0%	34 100.0%	* 6 100.0%	* 9 100.0%	** 4 100.0%	** 1 100.0%	** 4 100.0%	0	24	31 100.0%
Summary																						
TOP 2 BOX	34 62.0%	-	-	34 62.0%	-	-	-	-	15 68.0%	19 58.0%	40.0%	5 83.0%	25 64.0%	23 68.0%	3 50.0% *	5 56.0% *	2 50.0% **	0 - **	3 75.0% **	-	16 67.0%	18 58.0%
BOTTOM 2 BOX	12 22.0%	0 -	0 -	12 22.0%	0 -	0 -	0	0 -	4 18.0%	8 24.0%	3 30.0%	1 17.0%	8 21.0%	7 21.0%	1 17.0%	2 22.0%	1 25.0% **	0 - **	1 25.0% **	0 -	5 21.0%	7 23.0%
Mean	3.7	-	-	3.7	-	-	-	-	3.9	3.6	3	4.3 J*	3.8	3.8	3.8	3.8	3.2	3	3.5	-	3.8	3.6
Std. Dev.	1.3	-	-	1.3	-	-	-	-	1.2	1.3	1.1	1.2	1.3	1.2	1.3	1.3	1.7	-	1.7	-	1.2	1.3
Std. Err.	0.2	-	-	0.2	-	-		-	0.3	0.2	0.3	0.5	0.2	0.2	0.6	0.4	0.9	-	0.9	-	0.3	0.2

Statistics:

Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)
Table of Contents



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Regulatory Affairs - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	arma: Company	size			Geo	graphical loca	ation			loh ti	itle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	Е	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - Regulatory Affairs	11	0	0	11	0	0	0	0	6	5	1	3	7	4	3	4	0	0	0	0	0	11
Significantly increase 5	5 45.0%	0 -	0 -	5 45.0%	0 -	0 -	0 -	0 -	2 33.0% *	3 60.0% *	0 - **	1 33.0%	4 57.0%	2 50.0% **	1 33.0% **	2 50.0%	-	0 -	0 -	0 -	0	5 45.0%
Slightly increase 4	4 36.0%	0 -	0 -	4 36.0%	0 -	0 -	0 -	0 -	3 50.0%	1 20.0%	0 -	2 67.0%	29.0%	2 50.0%	0 -	2 50.0%	0 -	0 -	0 -	0 -	0 -	4 36.0%
Neither increase or decrease 3	2 18.0%	0	0	2 18.0%	0	0 -	0	0	* 1 17.0%	* 1 20.0%	** 1 100.0%	0 -	1 14.0%	0 -	** 2 67.0%	0	0 -	0	0	0 -	0	2 18.0%
Slightly decrease 2	0	0	0	0	0	0 -	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Significantly decrease 1	0	0	0	0	0	0	0	0	* 0	* 0	**	**	0	**	**	0	0	0	0	0	0	0
I don't know	0	0	0	0	0	0	0	0	*	*	**	**	0	**	**	**	0	0	0	- 0	0	0
	-	-	-	-	-	-	-	-	*	*	**	**	-	**	**	**	-	-	-	-	-	-
Sigma	11 100.0%	0.0%	0.0%	11 100.0%	0.0%	0.0%	0.0%	0.0%	6 100.0%	5 100.0%	100.0%	3 100.0%	7 100.0%	100.0%	3 100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	11 100.0%
Summary																						
TOP 2 BOX	9 82.0%	-	-	9 82.0%	0 -	-	-	-	5 83.0% *	4 80.0% *	0 - **	3 100.0%	6 86.0%	4 100.0%	1 33.0%	4 100.0%	-	-	0 -	-	-	9 82.0%
ВОТТОМ 2 ВОХ	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0	0 -	0 - **	0 -	0 -	0 -	0 -	0	0 -
Mean	4.3	-	-	4.3	-	-	-	-	* 4.2 *	4.4	3	4.3	4.4	4.5 **	** 3.7 **	4.5	-	-	-	-	-	4.3
Std. Dev.	0.8	-	-	0.8	-	-	-	-	0.8	0.9	-	0.6	0.8	0.6	1.2	0.6	-	-	-	-	-	0.8
I .	1	1	1	1	1	1	1	1	1	1		1	1	1	1	1		1	1	1		0.2

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Sales - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	ırma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	1	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - Sales	93	0	0	93	0	0	0	0	35	58	23	15	55	4	34	27	16	5	8	10	31	62
Significantly increase 5	32 34.0%	0 -	0 -	32 34.0%	0 -	0 -	0 -	0 -	16 46.0%	16 28.0%	7 30.0%	6 40.0%	19 35.0%	0 - **	10 29.0%	12 44.0%	6 38.0%	1 20.0% *	4 50.0%	3 30.0% *	8 26.0%	24 39.0%
Slightly increase 4	27 29.0%	0 -	0 -	27 29.0%	0 -	0 -	0 -	0 -	10 29.0%	17 29.0%	7 30.0%	4 27.0%	16 29.0%	1 25.0% **	8 24.0%	10 37.0%	4 25.0%	1 20.0%	2 25.0%	3 30.0% *	8 26.0%	19 31.0%
Neither increase or decrease 3	17 18.0%	0 -	0 -	17 18.0%	0 -	0 -	0 -	0 -	6 17.0%	11 19.0%	3 13.0%	2 13.0%	12 22.0%	0 - **	9 26.0%	7.0%	2 12.0%	1 20.0% *	1 12.0%	3 30.0% *	3 10.0%	14 23.0%
Slightly decrease 2	8 9.0%	0 -	0 -	8 9.0%	0 -	0 -	0 -	0 -	1 3.0%	7 12.0%	3 13.0%	2 13.0%	3 5.0%	1 25.0%	6 18.0%	0 -	2 12.0%	2 40.0% O*	0 -	1 10.0%	4 13.0%	4 6.0%
Significantly decrease 1	4 4.0%	0 -	0 -	4 4.0%	0 -	0 -	0	0	1 3.0%	3 5.0%	0	7.0%	3 5.0%	1 25.0%	0	3 11.0%	0	0 -	0 -	0 -	3 10.0%	1 2.0%
I don't know	5 5.0%	0 -	0 -	5 5.0%	0 -	0 -	0	0	1 3.0%	4 7.0%	3 13.0%	0	2 4.0%	1 25.0%	1 3.0%	0 -	2 12.0%	0 -	1 12.0%	0 -	5 16.0%	0 -
Sigma	93 100.0%	0	0	93 100.0%	0 0.0%	0 0.0%	0	0	35 100.0%	58 100.0%	23 100.0%	15 100.0%	55 100.0%	4 100.0%	34 100.0%	27 100.0%	16 100.0%	5 100.0%	8 100.0%	10 100.0%	U 31 100.0%	62 100.0%
Summary																						
TOP 2 BOX	59 63.0%	0 -	0 -	59 63.0%	-	-	0 -	0 -	26 74.0%	33 57.0%	14 61.0%	10 67.0%	35 64.0%	1 25.0% **	18 53.0%	22 81.0% N	10 62.0%	2 40.0% *	6 75.0%	6 60.0% *	16 52.0%	43 69.0%
ВОТТОМ 2 ВОХ	12 13.0%	0 -	0 -	12 13.0%	0 -	0 -	0 -	0 -	2 6.0%	10 17.0%	3 13.0%	3 20.0%	6 11.0%	2 50.0% **	6 18.0%	3 11.0%	2 12.0%	2 40.0% *	0 -	1 10.0% *	7 23.0%	5 8.0%
Mean	3.9	-	-	3.9	-	-	-	-	4.1	3.7	3.9	3.8	3.8	2.3	3.7	4	4	3.2	4.4	3.8	3.5	4
Std. Dev.	1.2	-	-	1.2	-	-	-	-	1	1.2	1.1	1.3	1.2	1.5	1.1	1.3	1.1	1.3	0.8	1	1.4	1
Std. Err.	0.1	-	-	0.1	-	-	-	-	0.2	0.2	0.2	0.3	0.2	0.9	0.2	0.2	0.3	0.6	0.3	0.3	0.3	0.1


Statistics:

Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Training - Patients" trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	ırma: Company	size			Geo	graphical loca	ition			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	т	U
Base: Pharma Companies based on Q22 - Training	5	0	0	5	0	0	0	0	2	3	1	0	4	0	2	2	2	2	1	1	2	3
Significantly increase 5	4 80.0%	0 -	0 -	4 80.0%	0 -	0 -	0 -	-	2 100.0%	2 67.0% **	1 100.0% **	-	3 75.0% **	0 -	2 100.0% **	2 100.0% **	1 50.0% **	2 100.0% **	1 100.0% **	1 100.0% **	2 100.0% **	2 67.0% **
Slightly increase 4	0 -	0 -	0	0	0 -	0 -	0 -	0 -	0	0 -	0 - **	0 -	0 -	0 -	0 -	0 -	0 - **	0 -	0 - **	0 -	0 -	0 -
Neither increase or decrease 3	1 20.0%	0 -	0 -	1 20.0%	0 -	0 -	0 -	0 -	0 -	1 33.0%	0 -	0 -	1 25.0%	0 -	0 -	0 -	1 50.0% **	0 -	0 -	0 -	0	1 33.0%
Slightly decrease 2	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0	0 -	0 -	0 -	0	0 -	0	0 -	0 -	0 -	0	0 -	0 -
Significantly decrease 1	0	0 -	0 -	0 -	0	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0	0 -	0 -
I don't know	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -
Sigma	5 100.0%	0	0	5 100.0%	0	0	0	0 0.0%	2 100.0%	3 100.0%	1 100.0%	0	4 100.0%	0	** 2 100.0%	** 2 100.0%	** 2 100.0%	** 2 100.0%	** 1 100.0%	1 100.0%	2 100.0%	3 100.0%
Summary																						
TOP 2 BOX	4 80.0%	0 -	0 -	4 80.0%	-	0 -	0 -	0 -	2 100.0%	2 67.0% **	1 100.0% **	-	3 75.0% **	-	2 100.0% **	2 100.0%	1 50.0% **	2 100.0% **	1 100.0% **	1 100.0% **	2 100.0% **	2 67.0% **
BOTTOM 2 BOX	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 - **	0 -	0 -	0 -	0 -	0 -	0 - **	0 - **	0 - **	0 -	0 -	0 -
Mean	4.6	-	-	4.6	-	-	-	-	5	4.3	5	-	4.5	-	5	5	4	5	5	5	5	4.3
Std. Dev.	0.9	-	-	0.9	-	-	-	-	-	1.2	-	-	1	-	-	-	1.4	-	-	-	-	1.2
Std. Err.	0.4	-	-	0.4	-	-	-	-	-	0.7	-	-	0.5	-	-	-	1	-	-	-	-	0.7

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q23. Patients' trust affected if they were to secretly observe a typical day in that department. 1-5 scale - Other (please specify) - Patients' trust affected if they were to secretly observe a typical day in that department

					Туре				Confi	dence	Pha	ırma: Company	size			Geo	graphical loca	ation			Job tit	itle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies based on Q22 - Other (please specify)	48	0	0	48	0	0	0	0	16	32	14	4	30	18	15	12	4	1	2	1	24	24
Significantly increase 5	25 52.0%	-	-	25 52.0%	-	0 -	-	0 -	10 62.0%	15 47.0%	8 57.0% *	1 25.0%	16 53.0%	12 67.0%	5 33.0%	6 50.0%	2 50.0% **	1 100.0% **	1 50.0% **	1 100.0% **	13 54.0%	12 50.0%
Slightly increase 4	8 17.0%	0 -	0 -	8 17.0%	0 -	0 -	0 -	0 -	4 25.0%	4 12.0%	1 7.0%	2 50.0%	5 17.0%	3 17.0%	3 20.0%	1 8.0% *	1 25.0% **	0 - **	0 - **	0 - **	3 12.0%	5 21.0%
Neither increase or decrease 3	11 23.0%	0 -	0 -	11 23.0%	0 -	0 -	0 -	0 -	1 6.0%	10 31.0%	3 21.0%	0	8 27.0%	3 17.0%	4 27.0%	3 25.0%	1 25.0%	0 -	1 50.0%	0	6 25.0%	5 21.0%
Slightly decrease 2	0	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0	0 -	0 -
Significantly decrease 1	2 4.0%	0 -	0 -	2 4.0%	0 -	0 -	0 -	0 -	0 -	2 6.0%	1 7.0%	0	1 3.0%	0 -	1 7.0%	1 8.0%	0 -	0 -	0 -	0	1 4.0%	1 4.0%
I don't know	2 4.0%	0 -	0 -	2 4.0%	0 -	0 -	0 -	0 -	1 6.0%	1 3.0%	* 1 7.0%	** 1 25.0%	0 -	0 -	2 13.0%	* 1 8.0%	0 -	0 -	0 -	0 -	1 4.0%	1 4.0%
Sigma	48 100.0%	0	0	48 100.0%	0	0	0	0	16 100.0%	32 100.0%	* 14 100.0%	4 100.0%	30 100.0%	18 100.0%	15 100.0%	* 12 100.0%	** 4 100.0%	** 1 100.0%	** 2 100.0%	** 1 100.0%	24 100.0%	24 100.0%
Summary																						
TOP 2 BOX	33 69.0%	0 -	0 -	33 69.0%	-	-	0 -	0 -	14 88.0%	19 59.0%	9 64.0%	3 75.0%	21 70.0%	15 83.0%	8 53.0%	7 58.0% *	3 75.0% **	1 100.0%	1 50.0%	1 100.0%	16 67.0%	17 71.0%
ВОТТОМ 2 ВОХ	2 4.0%	0 -	0 -	2 4.0%	0 -	0 -	0 -	0 -	0 -	2 6.0%	7.0%	0 -	3.0%	0 -	1 7.0%	1 8.0%	0 -	0 -	0 -	0 -	1 4.0%	1 4.0%
Mean	4.2	-	-	4.2	-	-	-	-	4.6	4	4.2	4.3	4.2	4.5	3.8	4	4.2	5	4	5	4.2	4.2
Std. Dev.	1.1	-	-	1.1	8.	-	-	-	0.6	1.2	1.3	0.6	1.1	0.8	1.2	1.3	1	-	1.4	-	1.1	1.1
Std. Err.	0.2	-	-	0.2	-	-	-	-	0.2	0.2	0.4	0.3	0.2	0.2	0.3	0.4	0.5	-	1	-	0.2	0.2

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q26. Training people to behave in patient-focused ways in your department

					Type				Confi	dence	Pha	rma: Company	/ size			Geo	graphical loca	tion			Job titl	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower
		А	В	С	D	E	F	G	Н	1	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
We know exactly what and how to teach this to our people.	146 22.0%	-	-	146 22.0%	-	-	-	-	66 25.0%	80 19.0%	48 27.0%	15 19.0%	83 20.0%	41 19.0%	30 19.0%	37 23.0%	26 27.0% R	10 26.0%	7 13.0%	10 31.0% R	66 21.0%	80 22.0%
We are actively looking for what and how to teach this to our people.	355 53.0%	0 -	0 -	355 53.0%	0 -	0 -	0 -	0 -	160 61.0%	195 47.0%	86 48.0%	48 61.0%	221 53.0%	119 56.0%	82 51.0%	77 48.0%	50 53.0%	18 47.0%	31 57.0%	15 47.0%	172 54.0%	183 51.0%
We don't know what or how to teach this to our people.	108 16.0%	0 -	0 -	108 16.0%	0 -	0 -	0 -	0 -	23 9.0%	85 21.0% H	27 15.0%	11 14.0%	70 17.0%	29 14.0%	32 20.0%	29 18.0%	15 16.0%	7 18.0%	9 17.0%	6 19.0%	54 17.0%	54 15.0%
This is not on our radar.	66 10.0%	0 -	0 -	66 10.0%	0 -	0 -	0 -	0 -	12 5.0%	54 13.0% H	19 11.0%	5 6.0%	42 10.0%	25 12.0% P	16 10.0%	16 10.0%	4 4.0%	3 8.0%	7 13.0%	1 3.0%	27 8.0%	39 11.0%
Sigma	675 100.0%	0.0%	0.0%	675 100.0%	0 0.0%	0.0%	0 0.0%	0.0%	261 100.0%	414 100.0%	180 100.0%	79 100.0%	416 100.0%	214 100.0%	160 100.0%	159 100.0%	95 100.0%	38 100.0%	54 100.0%	32 100.0%	319 100.0%	356 100.0%

Statistics:

Overlap formulae used

- Column Means:

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

Table of Contents



Q35. Change as a result from organization's patient-focused efforts (trust) - Employee engagement

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job titl	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		Α	В	С	D	E	F	G	Н	_	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
			-			-																
Significantly increased 5	160	0	0	160	0	0	0	0	84	76	53	17	90	47	35	43	20	9	18	11	77	83
	24.0%	-	-	24.0%	-	-	-	-	32.0%	18.0%	29.0%	22.0%	22.0%	22.0%	22.0%	27.0%	21.0%	24.0%	33.0%	34.0%	24.0%	23.0%
									ı		L											<u> </u>
Slightly increased 4	267	0	0	267	0	0	0	0	104	163	57	35	175	86	66	51	47	19	22	12	136	131
	40.0%	-	-	40.0%	-	-	-	-	40.0%	39.0%	32.0%	44.0%	42.0%	40.0%	41.0%	32.0%	49.0%	50.0%	41.0%	38.0%	43.0%	37.0%
													J				0	0				
Neither increased or decreased 3	142	0	0	142	0	0	0	0	45	97	42	19	81	41	37	39	15	4	8	4	62	80
	21.0%	-	-	21.0%	-	-	-	-	17.0%	23.0%	23.0%	24.0%	19.0%	19.0%	23.0%	25.0%	16.0%	11.0%	15.0%	12.0%	19.0%	22.0%
Slightly decreased 2	28	0	0	28	0	0	0	0	7	21	6	2	20	10	5	8	3	4	3	3	17	11
Signary accreased 2	4.0%	-	-	4.0%	-	-	-	-	3.0%	5.0%	3.0%	3.0%	5.0%	5.0%	3.0%	5.0%	3.0%	11.0%	6.0%	9.0%	5.0%	3.0%
	4.070			4.070					3.070	3.070	3.070	3.070	3.070	3.070	3.070	3.070	3.070	NP	0.070	3.070	3.070	3.070
Significantly decreased 1	14	0	0	14	0	0	0	0	3	11	5	1	8	6	1	5	2	1	1	0	6	8
Significantly decreased 1	2.0%	-	-	2.0%	-	-	-	-	1.0%	3.0%	3.0%	1.0%	2.0%	3.0%	1.0%	3.0%	2.0%	3.0%	2.0%	-	2.0%	2.0%
	2.0%	-	-	2.0%	-	-	-	-	1.0%	3.0%	3.0%	1.0%	2.0%	3.0%	1.0%	3.0%	2.0%	3.0%	2.0%	-	2.0%	2.0%
I don't know	64	0	0	64	0	0	0	0	18	46	17	5	42	24	16	13	8	1	2	2	21	43
	9.0%	-	-	9.0%	-	-	-	-	7.0%	11.0%	9.0%	6.0%	10.0%	11.0%	10.0%	8.0%	8.0%	3.0%	4.0%	6.0%	7.0%	12.0%
																						T
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
	200.070	0.0	0.0,1		0.07.	0.0.1		0.0.1														
Summary																						
TOP 2 BOX	427	0	0	427	0	0	0	0	188	239	110	52	265	133	101	94	67	28	40	23	213	214
	63.0%	-	-	63.0%	-	-	-	-	72.0%	58.0%	61.0%	66.0%	64.0%	62.0%	63.0%	59.0%	71.0%	74.0%	74.0%	72.0%	67.0%	60.0%
	03.070			03.070					1	50.070	01.070	00.070	01.070	02.070	03.070	33.070	72.070	7 1.070	0	72.070	07.070	00.070
BOTTOM 2 BOX	42	0	0	42	0	0	0	0	10	32	11	3	28	16	6	13	5	5	4	3	23	19
BOTTOWIZ BOX	6.0%	-	-	6.0%	-	-	-	-	4.0%	8.0%	6.0%	4.0%	7.0%	7.0%	4.0%	8.0%	5.0%	13.0%	7.0%	9.0%	7.0%	5.0%
	0.0%	-	-	0.0%	-	-	-	-	4.0%	8.0% H	0.0%	4.0%	7.0%	7.0%	4.0%	8.0%	5.0%	13.0% N	7.0%	9.0%	7.0%	5.0%
Mean	3.9		_	3.9	_		_	_	4.1	3.7	3.9	3.9	3.9	3.8	3.9	3.8	3.9	3.8	4	4	3.9	3.9
Ivieali	3.9	-	-	5.9	-	-	-	-	4.1	3.7	3.9	3.9	3.9	3.0	5.9	3.6	3.9	5.0	4	4	3.9	5.9
Std. Dev.	0.9	_	_	0.9	-	-	-	-	0.9	0.9	1	0.8	0.9	1	0.8	1	0.9	1	1	1	0.9	0.9
Stu. Dev.	0.9	-	-	0.9	-	-	-	-	0.9	0.9	1	0.8	0.9	1	0.8	1	0.9	1	1	1	0.9	0.9
Chil For	*	-	-		1	1		1	0.1	*	0.4	0.4	*	0.1	0.1	0.1	0.4	0.2	0.1	0.2	0.1	0.1
Std. Err.	-	-	-	-	-	-	-	-	0.1	-	0.1	0.1		0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1
			1]]			1			1]]]	L

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q35. Change as a result from organization's patient-focused efforts (trust) - Employee attraction/retention

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		Α	В	С	D	E	F	G	Н	- 1	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Significantly increased 5	111	0	0	111	0	0	0	0	64	47	42	15	54	28	24	27	18	6	16	8	55	56
	16.0%	-	-	16.0%	-	-	-	-	25.0%	11.0%	23.0%	19.0%	13.0%	13.0%	15.0%	17.0%	19.0%	16.0%	30.0%	25.0%	17.0%	16.0%
									l l		L								MNO			
Slightly increased 4	201	0	0	201	0	0	0	0	82	119	51	16	134	61	52	41	36	15	13	11	114	87
	30.0%	-	-	30.0%	-	-	-	-	31.0%	29.0%	28.0%	20.0%	32.0%	29.0%	32.0%	26.0%	38.0%	39.0%	24.0%	34.0%	36.0%	24.0%
													K				0				U	
Neither increased or decreased 3	204	0	0	204	0	0	0	0	75	129	49	33	122	69	50	46	24	10	16	9	92	112
	30.0%	-	-	30.0%	-	-	-	-	29.0%	31.0%	27.0%	42.0%	29.0%	32.0%	31.0%	29.0%	25.0%	26.0%	30.0%	28.0%	29.0%	31.0%
												JL										
Slightly decreased 2	37	0	0	37	0	0	0	0	9	28	9	5	23	8	7	16	6	1	2	2	15	22
	5.0%	-	-	5.0%	-	-	-	-	3.0%	7.0%	5.0%	6.0%	6.0%	4.0%	4.0%	10.0%	6.0%	3.0%	4.0%	6.0%	5.0%	6.0%
																MN						
Significantly decreased 1	18	0	0	18	0	0	0	0	4	14	6	2	10	6	3	7	0	1	3	0	9	9
	3.0%	-	-	3.0%	-	-	-	-	2.0%	3.0%	3.0%	3.0%	2.0%	3.0%	2.0%	4.0%	-	3.0%	6.0%	-	3.0%	3.0%
			_					_								P		_	P	_		
I don't know	104	0	0	104	0	0	0	0	27	77	23	8	73	42	24	22	11	5	4	2	34	70
	15.0%	-	-	15.0%	-	-	-	-	10.0%	19.0%	13.0%	10.0%	18.0%	20.0%	15.0%	14.0%	12.0%	13.0%	7.0%	6.0%	11.0%	20.0%
					_			_		Н				R								T
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Commence																						
Summary TOP 2 BOX	312	0	0	312	0	0	0	0	146	166	93	31	188	89	76	68	54	21	29	19	169	143
TOP 2 BOX	46.0%	-	-	46.0%	-	-	-	-	56.0%	40.0%	52.0%	39.0%	45.0%	42.0%	48.0%	43.0%	57.0%	55.0%	54.0%	59.0%	53.0%	40.0%
	40.0%	-	-	46.0%	-	-	-	-	30.0%	40.0%	52.0%	39.0%	45.0%	42.0%	46.0%	43.0%	37.0% MO	33.0%	54.0%	39.0%	33.0% U	40.0%
BOTTOM 2 BOX	55	0	0	55	0	0	0	0	13	42	15	7	33	14	10	23	6	2	5	2	24	31
BOTTOW 2 BOX	8.0%	-	-	8.0%	-	-	-	-	5.0%	10.0%	8.0%	9.0%	8.0%	7.0%	6.0%	14.0%	6.0%	5.0%	9.0%	6.0%	8.0%	9.0%
	8.076	-	-	8.0%	-	-	-	-	5.0%	10.0% H	8.0%	9.0%	8.0%	7.0%	0.0%	14.0% MNP	0.0%	5.0%	9.0%	0.0%	8.0%	9.0%
Mean	3.6	_	_	3.6	-	-		_	3.8	3.5	3.7	3.5	3.6	3.6	3.6	3.5	3.8	3.7	3.7	3.8	3.7	3.6
ivicali	3.0	-	-	3.0	-	-	-	-	3.6 I	3.3	3.7	3.3	3.0	3.0	3.0	3.3	0	3.7	3.7	3.0	3.7	3.0
Std. Dev.	1	_	_	1	-	-	-	-	0.9	1	1	1	0.9	0.9	0.9	1.1	0.9	0.9	1.1	0.9	1	1
5ta. 5ct.				1					0.5	1	1	1	3.5	3.5	5.5	2.1	0.5	0.5	2.1	3.5	_	1
Std. Err.	*	-	-		-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1
		+	 		-	-		l	0.1	0.1	0.1	0.1	0.1	U.1	0.1	U.1	0.1	0.2	V.2	V.2	0.1	0.1

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

Minimum Base: 5 (**), Small Base: 15 (*)

Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q35. Change as a result from organization's patient-focused efforts (trust) - Patient outcomes

Total				Type							irma: Company										tle/level
10.0	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
	Α	В	С	D	E	F	G	Н		J	K	L	М	N	0	Р	Q	R	S	Т	U
675	0	0	675	0	0	0	0	261	414	190	70	416	214	160	150	QE.	20	EA	22	210	356
		-			-	-					-		-					-	-		78
				-															-		22.0%
20.076	-	-	20.076	-	-	-	_	28.076	13.0%	20.0%	23.076	18.076	10.076	18.076	22.076	20.076	24.076		28.076	18.076	22.076
239	0	0	239	0	0	0	0	101	138	44	26	169	78	60	56	34	10		q	116	123
35.0%	-	-	35.0%	-	-	-	-	39.0%	33.0%	24.0%	33.0%	41.0%	36.0%	38.0%	35.0%	36.0%	26.0%	30.0%	28.0%	36.0%	35.0%
137	0	0	137	0	0	0	0	41	96	12	20	J 75	//1	32	32	17	9	1/1	7	73	64
	-					-											-				18.0%
20.070			20.070					10.070	H	25.070	23.070	10.070	15.0%	20.070	20.070	10.070	24.070	20.070	22.070	25.070	10.070
14	0	0	14	0	0	0	0	4		3	2	9	4	4	4	1	2	2	1	9	5
2.0%	-	-	2.0%	-	-	ž.	-	2.0%	2.0%	2.0%	3.0%	2.0%	2.0%	2.0%	3.0%	1.0%	5.0%	4.0%	3.0%	3.0%	1.0%
5	0	0	5	0	0	0	0	1	4	5	0	0	1	2	1	0	2	0	0	3	2
1.0%	-	-	1.0%	-	-	-	-	*	1.0%	3.0%	-	-	*	1.0%	1.0%	-	5.0%	-	-	1.0%	1.0%
143	0	0	143	0	0	0	0	40	103	40	13	90	55	33	31	24	6	5	6	59	84
21.0%	-	-	21.0%	-	-	-	-	15.0%	25.0%	22.0%	16.0%	22.0%	26.0%	21.0%	19.0%	25.0%	16.0%	9.0%	19.0%	18.0%	24.0%
									Н				R			R					
				_	_	-															356
100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
376	0	0	376	0	0	0	0	175	201	90	44	242	113	89	91	53	19	33	18	175	201
56.0%	-	9	56.0%	-	-	-	-	67.0%	49.0%	50.0%	56.0%	58.0%	53.0%	56.0%	57.0%	56.0%	50.0%	61.0%	56.0%	55.0%	56.0%
19	0	0	19	0	0	0	0	5	14	8	2	9	5	6	5	1	4	2	1	12	7
3.0%	-	-	3.0%	-	-	-	-	2.0%	3.0%	4.0%	3.0%	2.0%	2.0%	4.0%	3.0%	1.0%	11.0%	4.0%	3.0%	4.0%	2.0%
3.9	-	1	3.9	-	-	1	-	4.1	3.8	3.9	3.9	3.9	3.9	3.9	3.9	4	3.7	4	4	3.8	4
								1													T
0.8	-	-	0.8	-	-	-	-	0.8	0.8	1	0.8	0.7	0.8	0.9	0.8	0.8	1.1	0.9	0.9	0.9	0.8
*	_	_		-	_	-	_	0.1	*	0.1	0.1	*	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	*
	137 20.0% 14 2.0% 5 1.0% 143 21.0% 675 100.0% 376 56.0% 19 3.0%	Charity A 675 0 137 0 20.0% - 239 35.0% - 137 0 20.0% - 137 0 20.0% - 14 0 2.0% - 5 0 1.0% - 143 0 21.0% - 675 0 100.0% 0.0% 376 0 56.0% - 19 0 3.0% - 3.9 - 0.8 -	Charity	Charity A B C 675 0 0 675 137 0 0 137 20.0% 20.0% 239 0 0 239 35.0% 35.0% 137 0 0 137 20.0% 20.0% 14 0 0 14 2.0% 20.0% 5 0 0 5 1.0% 1.0% 143 0 0 143 21.0% 10.0% 675 0 0 675 100.0% 0.0% 100.0% 376 0 0 376 56.0% 56.0% 19 0 0 19 3.0% 3.0% 3.9 3.9	Charity A B C D 675 0 0 675 0 137 0 0 137 0 20.0% - - 20.0% - - - 20.0% - - 239 0 0 239 0 35.0% - - 35.0% - 137 0 0 137 0 20.0% - - 20.0% - 14 0 0 14 0 2.0% - - 20.0% - 5 0 0 5 0 1.0% - - 1.0% - 143 0 0 143 0 21.0% - - 21.0% - 675 0 0 675 0 100.0% 0.0% 0.0% 100.0% 0.0% <t< td=""><td>Charity A B C D E 675 0 0 675 0 0 137 0 0 137 0 0 20.0% 20.0% 239 0 0 239 0 0 35.0% 35.0% 137 0 0 137 0 0 20.0% 20.0% 137 0 0 137 0 0 20.0% 20.0% 137 0 0 137 0 0 20.0% 20.0% 14 0 0 14 0 0 20.0% 20.0% 5 0 0 5 0 0 1.0% 10.0% 143 0 0 143 0 0 21.0% 21.0% 675 0 0 675 0 0 675 0 0 675 0 0 100.0% 0.0% 0.0% 0.0% 376 0 0 376 0 0 376 0 0 0 376 0 0 376 0 0 0 19 0 0 3.0% 30.0% 19 0 0 19 0 0 0 3.0% 30.0%</td><td>Charity A B C D E F 675 0 0 675 0 0 0 0 137 0 0 0 137 0 0 0 22.0% 20.0% 239 0 0 0 239 0 0 0 35.0% 35.0% 137 0 0 137 0 0 0 137 0 0 0 0 20.0% 20.0% 137 0 0 0 137 0 0 0 20.0% 20.0% 14 0 0 14 0 0 0 0 2.0% 2.0% 5 0 0 5 0 0 0 0 1.0% 1.0% 143 0 0 143 0 0 0 143 0 0 0 21.0% 21.0% 675 0 0 675 0 0 0 675 0 0 675 0 0 0 675 0 0 0 675 0 0 0 100.0% 0.0% 0.0% 0.0% 0.0% 376 0 0 376 0 0 0 376 0 0 376 0 0 0 376 0 0 376 0 0 0 376 0 0 0 19 0 0 0 3.0% 3.0%</td><td> Charity</td><td> Charity</td><td> Charity Charity and Patients Charity and Ch</td><td> Charity</td><td> Charity A B C D E F G H I J K </td><td> Charity and Patients</td><td> Charity Regoup Charity and Patients Charity and Patients Regoup Regoup </td><td> Charity</td><td> Charity Charity and Char</td><td> Charity</td><td> Charity Charity and Petitents Charity and Petite</td><td> Chairity A B C D E F G H 1 J K L M N O P Q R </td><td> Charity</td><td> Carify Carify Charles Charles and prough Patients Charles and prough Patients Carify Carify </td></t<>	Charity A B C D E 675 0 0 675 0 0 137 0 0 137 0 0 20.0% 20.0% 239 0 0 239 0 0 35.0% 35.0% 137 0 0 137 0 0 20.0% 20.0% 137 0 0 137 0 0 20.0% 20.0% 137 0 0 137 0 0 20.0% 20.0% 14 0 0 14 0 0 20.0% 20.0% 5 0 0 5 0 0 1.0% 10.0% 143 0 0 143 0 0 21.0% 21.0% 675 0 0 675 0 0 675 0 0 675 0 0 100.0% 0.0% 0.0% 0.0% 376 0 0 376 0 0 376 0 0 0 376 0 0 376 0 0 0 19 0 0 3.0% 30.0% 19 0 0 19 0 0 0 3.0% 30.0%	Charity A B C D E F 675 0 0 675 0 0 0 0 137 0 0 0 137 0 0 0 22.0% 20.0% 239 0 0 0 239 0 0 0 35.0% 35.0% 137 0 0 137 0 0 0 137 0 0 0 0 20.0% 20.0% 137 0 0 0 137 0 0 0 20.0% 20.0% 14 0 0 14 0 0 0 0 2.0% 2.0% 5 0 0 5 0 0 0 0 1.0% 1.0% 143 0 0 143 0 0 0 143 0 0 0 21.0% 21.0% 675 0 0 675 0 0 0 675 0 0 675 0 0 0 675 0 0 0 675 0 0 0 100.0% 0.0% 0.0% 0.0% 0.0% 376 0 0 376 0 0 0 376 0 0 376 0 0 0 376 0 0 376 0 0 0 376 0 0 0 19 0 0 0 3.0% 3.0%	Charity	Charity	Charity Charity and Patients Charity and Ch	Charity	Charity A B C D E F G H I J K	Charity and Patients	Charity Regoup Charity and Patients Charity and Patients Regoup Regoup	Charity	Charity Charity and Char	Charity	Charity Charity and Petitents Charity and Petite	Chairity A B C D E F G H 1 J K L M N O P Q R	Charity	Carify Carify Charles Charles and prough Patients Charles and prough Patients Carify Carify

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q35. Change as a result from organization's patient-focused efforts (trust) - Health care professionals trust in us

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	E	F	G	Н	ı	J	K	L	M	N	0	Р	Q	R	S	Т	U
			0	CDE	0		0		261		400	70	***	244	460	450	0.5	38	54	32	240	255
Base: Pharma Companies Significantly increased 5	675 169	0	0	675 169	0	0	0	0	88	414 81	180 59	79 29	416 81	214 39	160 42	159 44	95 27	38 11	19	13	319 82	356 87
significantly increased 5									34.0%		33.0%											24.0%
	25.0%	-	-	25.0%	-	-	-	-	34.0%	20.0%	33.0%	37.0%	19.0%	18.0%	26.0%	28.0% M	28.0% M	29.0%	35.0% M	41.0% M	26.0%	24.0%
lightly increased 4	229	0	0	229	0	0	0	0	87	142	52	25	152	73	59	46	33	12	16	5	109	120
ingitaly increases in	34.0%	-	-	34.0%	-	-	-	-	33.0%	34.0%	29.0%	32.0%	37.0%	34.0%	37.0%	29.0%	35.0%	32.0%	30.0%	16.0%	34.0%	34.0%
													0071	S	S		S	02.07.1	00.07.		0.110,10	0.10,0
Neither increased or decreased 3	148	0	0	148	0	0	0	0	47	101	36	15	97	49	36	41	19	6	11	8	76	72
	22.0%	-	-	22.0%	-	-	-	-	18.0%	24.0%	20.0%	19.0%	23.0%	23.0%	22.0%	26.0%	20.0%	16.0%	20.0%	25.0%	24.0%	20.0%
Slightly decreased 2	22	0	0	22	0	0	0	0	8	14	7	2	13	6	4	5	3	4	2	3	10	12
	3.0%	-	-	3.0%	-	-	1	-	3.0%	3.0%	4.0%	3.0%	3.0%	3.0%	2.0%	3.0%	3.0%	11.0%	4.0%	9.0%	3.0%	3.0%
																		MNOP				
Significantly decreased 1	8	0	0	8	0	0	0	0	1	7	2	2	4	2	2	3	2	1	1	0	5	3
	1.0%	-	-	1.0%	-	-	-	-	*	2.0%	1.0%	3.0%	1.0%	1.0%	1.0%	2.0%	2.0%	3.0%	2.0%	-	2.0%	1.0%
don't know	99	0	0	99	0	0	0	0	30	69	24	6	69	45	17	20	11	4	5	3	37	62
	15.0%	-	-	15.0%	-	-	1	-	11.0%	17.0%	13.0%	8.0%	17.0%	21.0%	11.0%	13.0%	12.0%	11.0%	9.0%	9.0%	12.0%	17.0%
													K	NOPR								Т
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary	200			200					475	222	444		222	440	404			20	25	4.0	404	207
FOP 2 BOX	398 59.0%	0	0	398 59.0%	0	0	0	0	175 67.0%	223 54.0%	111 62.0%	54 68.0%	233 56.0%	112 52.0%	101	90	60	23	35 65.0%	18 56.0%	191 60.0%	207 58.0%
	59.0%	-	-	59.0%	-	-	-	-	67.0%	54.0%	62.0%	68.U%	56.0%	52.0%	63.0% M	57.0%	63.0%	61.0%	65.0%	56.0%	60.0%	58.0%
SOTTOM 2 BOX	30	0	0	30	0	0	0	0	9	21	9	4	17	8	6	8	5	5	3	3	15	15
OTTOWIZ BOX	4.0%	-	-	4.0%	-	-	-	-	3.0%	5.0%	5.0%	5.0%	4.0%	4.0%	4.0%	5.0%	5.0%	13.0%	6.0%	9.0%	5.0%	4.0%
	4.070			1.070					5.070	3.370	5.070	3.070	1.070	1.070	1.070	3.070	5.070	MN	0.070	5.070	3.070	4.070
Mean	3.9	-	-	3.9	-	-		-	4.1	3.8	4	4.1	3.8	3.8	3.9	3.9	4	3.8	4	4	3.9	3.9
									1		L											
Std. Dev.	0.9	-	-	0.9	-	-	-	-	0.9	0.9	1	1	0.9	0.9	0.9	1	1	1.1	1	1.1	0.9	0.9
Std. Err.	*	-	-		-	-	-	-	0.1	*	0.1	0.1	*	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1
		1	†	†	l			 	0.1		0.1	0.1		0.1	0.1	0.1	0.1	U.L	0.1	0.2	0.1	0.2

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q35. Change as a result from organization's patient-focused efforts (trust) - Patients and patient advocacy groups trust in us

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job tit	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		Senior managers o lower
		Α	В	С	D	E	F	G	Н	- 1	J	K	L	M	N	0	P	Q	R	S	T	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Significantly increased 5	149	0	0	149	0	0	0	0	73	76	51	18	80	46	34	39	21	6	15	6	79	70
	22.0%	-	-	22.0%	-	-	-	-	28.0%	18.0%	28.0% L	23.0%	19.0%	21.0%	21.0%	25.0%	22.0%	16.0%	28.0%	19.0%	25.0%	20.0%
Slightly increased 4	243	0	0	243	0	0	0	0	99	144	54	32	157	81	60	55	34	13	17	6	106	137
	36.0%	-	-	36.0%	-	-	-	-	38.0%	35.0%	30.0%	41.0%	38.0%	38.0%	38.0%	35.0%	36.0%	34.0%	31.0%	19.0%	33.0%	38.0%
														S	S							
Neither increased or decreased 3	142	0	0	142	0	0	0	0	45	97	39	16	87	38	34	36	21	9	12	10	74	68
	21.0%	-	-	21.0%	-	-	-	-	17.0%	23.0%	22.0%	20.0%	21.0%	18.0%	21.0%	23.0%	22.0%	24.0%	22.0%	31.0%	23.0%	19.0%
Slightly decreased 2	18	0	0	18	0	0	0	0	6	12	6	1	11	4	4	6	2	1	4	2	12	6
Signay decreased 2	3.0%	-	-	3.0%	-	-	-	-	2.0%	3.0%	3.0%	1.0%	3.0%	2.0%	2.0%	4.0%	2.0%	3.0%	7.0% M	6.0%	4.0%	2.0%
Significantly decreased 1	11	0	0	11	0	0	0	0	3	8	5	1	5	3	3	3	2	3	0	0	7	4
	2.0%	-	-	2.0%	-	-	-	-	1.0%	2.0%	3.0%	1.0%	1.0%	1.0%	2.0%	2.0%	2.0%	8.0% MNOR	-	-	2.0%	1.0%
I don't know	112	0	0	112	0	0	0	0	35	77	25	11	76	42	25	20	15	6	6	8	41	71
	17.0%	-	-	17.0%	-	-	-	-	13.0%	19.0%	14.0%	14.0%	18.0%	20.0%	16.0%	13.0%	16.0%	16.0%	11.0%	25.0%	13.0%	20.0% T
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	392	0	0	392	0	0	0	0	172	220	105	50	237	127	94	94	55	19	32	12	185	207
	58.0%	-	-	58.0%	-	-	-	-	66.0%	53.0%	58.0%	63.0%	57.0%	59.0% S	59.0% S	59.0% S	58.0% S	50.0%	59.0%	38.0%	58.0%	58.0%
BOTTOM 2 BOX	29	0	0	29	0	0	0	0	9	20	11	2	16	7	7	9	4	4	4	2	19	10
	4.0%	-	-	4.0%	-	-	-	-	3.0%	5.0%	6.0%	3.0%	4.0%	3.0%	4.0%	6.0%	4.0%	11.0% M	7.0%	6.0%	6.0%	3.0%
Mean	3.9	-	-	3.9	-	-	-	-	4	3.8	3.9	4	3.9	3.9	3.9	3.9	3.9	3.6	3.9	3.7	3.9	3.9
Std. Dev.	0.9	-	-	0.9	-	-	-	-	0.9	0.9	1	0.8	0.9	Q 0.9	0.9	0.9	0.9	1.1	1	1	1	0.8
Std. Err.	*	-	-		-	-	-	-	0.1	*	0.1	0.1	*	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	*
Ctatistics														1	1			1	1	1		

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q35. Change as a result from organization's patient-focused efforts (trust) - Payors, health system bureaucrats and government bodies trust in us

					Туре				Confi	dence	Pha	rma: Company	/ size			Geo	graphical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	Е	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
		0		81		_	0	0		38	24	10	416	214			14	7	9	4	37	44
Significantly increased 5	81		0		0	0			43 16.0%						16	25			_			12.0%
	12.0%	-	-	12.0%	-	-	-	-	16.0%	9.0%	13.0%	13.0%	11.0%	10.0%	10.0%	16.0%	15.0%	18.0%	17.0%	12.0%	12.0%	12.0%
Slightly increased 4	186	0	0	186	0	0	0	0	85	101	52	20	114	47	62	33	26	9	13	7	88	98
	28.0%	-	-	28.0%	-	-	-	-	33.0%	24.0%	29.0%	25.0%	27.0%	22.0%	39.0%	21.0%	27.0%	24.0%	24.0%	22.0%	28.0%	28.0%
									- 1						MO							
Neither increased or decreased 3	214	0	0	214	0	0	0	0	76	138	52	30	132	62	48	61	31	13	21	12	107	107
	32.0%	-	-	32.0%	-	-	-	-	29.0%	33.0%	29.0%	38.0%	32.0%	29.0%	30.0%	38.0%	33.0%	34.0%	39.0%	38.0%	34.0%	30.0%
Slightly decreased 2	24	0	0	24	0	0	0	0	7	17	8	4	12	7	4	8	2	2	2	1	17	7
Silgitity decircused 2	4.0%	-	-	4.0%	-	-	-	-	3.0%	4.0%	4.0%	5.0%	3.0%	3.0%	2.0%	5.0%	2.0%	5.0%	4.0%	3.0%	5.0%	2.0%
	11.070			11.070					3.070	1.070	1.070	3.070	3.070	5.070	2.070	3.070	2.070	3.070	1.070	5.070	U	2.070
Significantly decreased 1	9	0	0	9	0	0	0	0	2	7	5	2	2	2	3	2	1	3	0	1	4	5
	1.0%	-	-	1.0%	-	-	-	-	1.0%	2.0%	3.0%	3.0%	*	1.0%	2.0%	1.0%	1.0%	8.0%	-	3.0%	1.0%	1.0%
											L							MNOPR				
I don't know	161	0	0	161	0	0	0	0	48	113	39	13	109	75	27	30	21	4	9	7	66	95
	24.0%	-	-	24.0%	-	-	-	-	18.0%	27.0%	22.0%	16.0%	26.0%	35.0%	17.0%	19.0%	22.0%	11.0%	17.0%	22.0%	21.0%	27.0%
			_							Н				NOPQR								
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	267	0	0	267	0	0	0	0	128	139	76	30	161	68	78	58	40	16	22	11	125	142
	40.0%	-	-	40.0%	-	-	-	-	49.0%	34.0%	42.0%	38.0%	39.0%	32.0%	49.0%	36.0%	42.0%	42.0%	41.0%	34.0%	39.0%	40.0%
									_						MO							
BOTTOM 2 BOX	33	0	0	33	0	0	0	0	9	24	13	6	14	9	7	10	3	5	2	2	21	12
	5.0%	-	-	5.0%	-	-	-	-	3.0%	6.0%	7.0%	8.0%	3.0%	4.0%	4.0%	6.0%	3.0%	13.0%	4.0%	6.0%	7.0%	3.0%
Mann	3.6	_	_	3.6	_	_	_	_	3.8	3.5	3,6	3.5	3.6	3.6	3.6	3.6	3.7	MNP 3.4	3.6	3.5	3.5	3.6
Mean	3.0	1 -	-	3.0		-	-	-	3.6	3.3	3.0	3.3	3.0	3.0	5.0	3.0	3./	3.4	3.0	3.3	3.3	3.0
Std. Dev.	0.9	-	-	0.9	-	-	-	-	0.8	0.9	1	0.9	0.8	0.9	0.8	0.9	0.9	1.2	0.9	1	0.9	0.9
Std. Err.	*	_	_		_	-	_	_	0.1	0.1	0.1	0.1	*	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1
5.0. 2		+	1	1	+	+		+	0.1	0.1	0.1	0.1		0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	- 0.1

Statistics:

Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q35. Change as a result from organization's patient-focused efforts (trust) - Willingness of stakeholders to engage with us

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Daniel Dhanna Camanaian	675		0	675	0		0		261	44.4	180	79	44.6	24.4	100	450	05	38		32	319	356
Base: Pharma Companies	133	0	0	675	0	0	_	0		414			416	214	160	159	95 22		54	-	70	
Significantly increased 5		0	0	133	0	0	0	0	65	68	45	14	74	39	26	38		9	12	6		63
	20.0%	-	-	20.0%	-	-	-	-	25.0%	16.0%	25.0%	18.0%	18.0%	18.0%	16.0%	24.0%	23.0%	24.0%	22.0%	19.0%	22.0%	18.0%
Slightly increased 4	253	0	0	253	0	0	0	0	110	143	56	34	163	77	64	56	33	10	21	10	132	121
	37.0%	-	-	37.0%	-	=	-	-	42.0%	35.0%	31.0%	43.0%	39.0%	36.0%	40.0%	35.0%	35.0%	26.0%	39.0%	31.0%	41.0%	34.0%
									1												U	
Neither increased or decreased 3	156	0	0	156	0	0	0	0	52	104	46	15	95	46	38	41	24	11	15	7	73	83
	23.0%	-	-	23.0%	-	-	-	-	20.0%	25.0%	26.0%	19.0%	23.0%	21.0%	24.0%	26.0%	25.0%	29.0%	28.0%	22.0%	23.0%	23.0%
Slightly decreased 2	21	0	0	21	0	0	0	0	4	17	5	5	11	6	4	4	2	2	2	4	9	12
Signay decreased 2	3.0%	-	-	3.0%	-	-	-	-	2.0%	4.0%	3.0%	6.0%	3.0%	3.0%	2.0%	3.0%	2.0%	5.0%	4.0%	12.0%	3.0%	3.0%
																				MNOP		
Significantly decreased 1	3	0	0	3	0	0	0	0	1	2	3	0	0	0	2	1	0	1	0	0	2	1
	*	-	-	*	-	-	-	-	*	*	2.0%	-	-	-	1.0%	1.0%	-	3.0%	-	-	1.0%	*
I don't know	109	0	0	109	0	0	0	0	29	80	25	11	73	46	26	19	14	M 5	4	5	33	76
T don't know	16.0%	-	-	16.0%	-	-	-	-	11.0%	19.0%	14.0%	14.0%	18.0%	21.0%	16.0%	12.0%	15.0%	13.0%	7.0%	16.0%	10.0%	21.0%
	10.070			10.070					11.070	H	11.070	21.070	10.070	OR	10.070	12.070	15.070	15.070	7.070	10.070	10.070	T
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary	386	0	0	386	0	0	0	0	175	211	101	48	237	116	90	94	55	19	33	16	202	184
TOP 2 BOX	57.0%	-	-	57.0%	-	-	-	-	67.0%	51.0%	56.0%	61.0%	57.0%	54.0%	56.0%	59.0%	58.0%	50.0%	61.0%	50.0%	63.0%	52.0%
	37.0%	-	-	37.0%	-	-	-	-	67.0% I	51.0%	30.0%	61.0%	37.0%	34.0%	30.0%	39.0%	36.0%	30.0%	01.0%	30.0%	U	32.0%
BOTTOM 2 BOX	24	0	0	24	0	0	0	0	5	19	8	5	11	6	6	5	2	3	2	4	11	13
	4.0%	-	-	4.0%	-	-	-	,	2.0%	5.0%	4.0%	6.0%	3.0%	3.0%	4.0%	3.0%	2.0%	8.0%	4.0%	12.0%	3.0%	4.0%
Mean	3.9	_	-	3.9	-	-	-	-	4	3.8	3.9	3.8	3.9	3.9	3.8	3.9	3.9	3.7	3.9	MNOP 3.7	3.9	3.8
	5.5			5.5					i	5.0	5.5	5.0	5.5	3.3	3.0	2.2	5.5	3.7	3.3	3.7	3.3	
Std. Dev.	0.8	-	-	0.8	-	-	-	-	0.8	0.9	0.9	0.8	0.8	0.8	0.8	0.9	0.8	1	0.8	1	0.8	0.8
Std. Err.	*	_	_	*	_	-	_		0.1	*	0.1	0.1	*	0.1	0.1	0.1	0.1	0.2	0.1	0.2	*	*
Sta. Ell.		ļ <u> </u>	<u> </u>		<u> </u>	-			0.1		0.1	0.1		0.1	0.1	0.1	0.1	0.2	0.1	0.2	-	+

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q35. Change as a result from organization's patient-focused efforts (trust) - Company revenues

					Туре				Confi	dence	Pha	ırma: Company	size			Geo	ographical loca	tion			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
						group)		Patients														
		Α	В	С	D	E	F	G	Н	- 1	_	К	L	M	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
Significantly increased 5	96	0	0	96	0	0	0	0	55	41	31	18	47	15	20	34	17	5	10	5	42	54
	14.0%	-	-	14.0%	-	-	-	-	21.0%	10.0%	17.0%	23.0%	11.0%	7.0%	12.0%	21.0%	18.0%	13.0%	19.0%	16.0%	13.0%	15.0%
									- 1		L	L				MN	M		M			
Slightly increased 4	181	0	0	181	0	0	0	0	80	101	46	21	114	59	44	36	28	14	19	6	96	85
	27.0%	-	-	27.0%	-	-	-	-	31.0%	24.0%	26.0%	27.0%	27.0%	28.0%	28.0%	23.0%	29.0%	37.0%	35.0%	19.0%	30.0%	24.0%
																			0			
Neither increased or decreased 3	213	0	0	213	0	0	0	0	67	146	56	27	130	69	52	48	31	10	18	13	106	107
	32.0%	-	-	32.0%	-	-	-	-	26.0%	35.0%	31.0%	34.0%	31.0%	32.0%	32.0%	30.0%	33.0%	26.0%	33.0%	41.0%	33.0%	30.0%
										Н												
Slightly decreased 2	28	0	0	28	0	0	0	0	8	20	7	4	17	6	9	8	4	1	2	1	13	15
	4.0%	-	-	4.0%	-	-	-	-	3.0%	5.0%	4.0%	5.0%	4.0%	3.0%	6.0%	5.0%	4.0%	3.0%	4.0%	3.0%	4.0%	4.0%
Significantly decreased 1	5	0	0	5	0	0	0	0	2	3	4	0	1	1	2	2	0	1	1	0	4	1
	1.0%	-	-	1.0%	-	-	-	-	1.0%	1.0%	2.0%	-	*	*	1.0%	1.0%	-	3.0%	2.0%	-	1.0%	*
											L											
I don't know	152	0	0	152	0	0	0	0	49	103	36	9	107	64	33	31	15	7	4	7	58	94
	23.0%	-	-	23.0%	-	-	-	-	19.0%	25.0%	20.0%	11.0%	26.0%	30.0%	21.0%	19.0%	16.0%	18.0%	7.0%	22.0%	18.0%	26.0%
													K	NOPR	R	R						T
Sigma	675	0	0	675	0	0	0	0	261	414	180	79	416	214	160	159	95	38	54	32	319	356
	100.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary																						
TOP 2 BOX	277	0	0	277	0	0	0	0	135	142	77	39	161	74	64	70	45	19	29	11	138	139
	41.0%	-	-	41.0%	-	-	-	-	52.0%	34.0%	43.0%	49.0%	39.0%	35.0%	40.0%	44.0%	47.0%	50.0%	54.0%	34.0%	43.0%	39.0%
									l l								М		М			
BOTTOM 2 BOX	33	0	0	33	0	0	0	0	10	23	11	4	18	7	11	10	4	2	3	1	17	16
	5.0%	-	-	5.0%	-	-	-	-	4.0%	6.0%	6.0%	5.0%	4.0%	3.0%	7.0%	6.0%	4.0%	5.0%	6.0%	3.0%	5.0%	4.0%
	2.5			2.5						0.5	2.5	2.0	2.6	0.5						2.6	2.5	
Mean	3.6	+ -	-	3.6	-	-	-	-	3.8	3.5	3.6	3.8	3.6	3.5	3.6	3.7	3.7	3.7	3.7	3.6	3.6	3.7
Std. Dev.	0.9	_	_	0.9	_				0.9	0.8	1	0.9	0.8	0.8	0.9	1	0.9	0.9	0.9	0.9	0.9	0.9
Stu. Dev.	0.9	-	-	0.9	-	-	-	-	0.9	0.8	1	0.9	0.8	0.8	0.9	1	0.9	0.9	0.9	0.9	0.9	0.9
Ctd Fee	*	_	+			-			0.1	*	0.1	0.1	*	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1
Std. Err.	-	-	-	-	-	-	-	-	0.1	-	0.1	0.1	-	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1
												1										

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

Minimum Base: 5 (**), Small Base: 15 (*)

Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

tient Centricity Global Benchmarks

Table: 74

Q35. Change as a result from organization's patient-focused efforts (trust) - GRID SUMMARY

	Employee engagement	Employee attraction/re tention	Patient outcomes	Health care professionals trust in us	Patients and patient advocacy groups trust in us	Payors, health system bureaucrats and	Willingness of stakeholders to engage with us	Company revenues
						government bodies trust		
	A	В	С	D	E	F	G	Н
Base: Pharma Companies	675	675	675	675	675	675	675	675
Significantly increased 5	160	111	137	169	149	81	133	96
- 0	24.0%	16.0%	20.0%	25.0%	22.0%	12.0%	20.0%	14.0%
	BFGH	F	BFH	BCFGH	BFH		BFH	
Slightly increased 4	267	201	239	229	243	186	253	181
enginary menerates	40.0%	30.0%	35.0%	34.0%	36.0%	28.0%	37.0%	27.0%
	BDFH		BFH	FH	BFH		BFH	
Neither increased or decreased 3	142	204	137	148	142	214	156	213
	21.0%	30.0%	20.0%	22.0%	21.0%	32.0%	23.0%	32.0%
		ACDEG				ACDEG		ACDEG
Slightly decreased 2	28	37	14	22	18	24	21	28
- ·	4.0%	5.0%	2.0%	3.0%	3.0%	4.0%	3.0%	4.0%
	С	CDEG				С		С
Significantly decreased 1	14	18	5	8	11	9	3	5
	2.0%	3.0%	1.0%	1.0%	2.0%	1.0%	*	1.0%
	CGH	CDFGH			CG	G		
I don't know	64	104	143	99	112	161	109	152
	9.0%	15.0%	21.0%	15.0%	17.0%	24.0%	16.0%	23.0%
		Α	ABDEG	Α	Α	ABDEG	Α	ABDEG
Sigma	675	675	675	675	675	675	675	675
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
6								
Summary	40-	212	276	200	202	267	206	077
TOP 2 BOX	427	312	376	398	392	267	386	277
	63.0%	46.0%	56.0%	59.0%	58.0%	40.0%	57.0%	41.0%
	BCDEFGH	FH	BFH	BFH	BFH		BFH	

BOTTOM 2 BOX	42	55	19	30	29	33	24	33
	6.0%	8.0%	3.0%	4.0%	4.0%	5.0%	4.0%	5.0%
	CDEG	ACDEFGH		С		С		С
Mean	3.9	3.6	3.9	3.9	3.9	3.6	3.9	3.6
	BFH		BFH	BFH	BFH		BFH	
Std. Dev.	0.9	1	8.0	0.9	0.9	0.9	0.8	0.9
Std. Err.	*	*	*	*	*	*	*	*

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G/H Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G/H Minimum Base: 5 (**), Small Base: 15 (*)



Q35. Change as a result from organization's patient-focused efforts (trust) - Top 2 Box Summary

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ition			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower
		Α	В	С	D	E	F	G	Н	I	J	K	L	M	N	0	Р	Q	R	S	T	U
Base: Pharma Companies	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
Employee engagement	427	0	0	427	0	0	0	0	188	239	110	52	265	133	101	94	67	28	40	23	213	214
Employee engagement	63.0%	-	-	63.0%	-	-	-	-	72.0%	58.0%	61.0%	66.0%	64.0%	62.0%	63.0%	59.0%	71.0%	74.0%	74.0%	72.0%	67.0%	60.0%
	001075			00.075					1	00.075	02.07.				00.071	00.071			0	12.071		
Employee attraction/retention	312	0	0	312	0	0	0	0	146	166	93	31	188	89	76	68	54	21	29	19	169	143
	46.0%	-	-	46.0%	-	-	-	-	56.0%	40.0%	52.0%	39.0%	45.0%	42.0%	48.0%	43.0%	57.0%	55.0%	54.0%	59.0%	53.0%	40.0%
									1								MO				U	
Patient outcomes	376	0	0	376	0	0	0	0	175	201	90	44	242	113	89	91	53	19	33	18	175	201
	56.0%	-	-	56.0%	-	-	-	-	67.0%	49.0%	50.0%	56.0%	58.0%	53.0%	56.0%	57.0%	56.0%	50.0%	61.0%	56.0%	55.0%	56.0%
									- 1													
Health care professionals trust in us	398	0	0	398	0	0	0	0	175	223	111	54	233	112	101	90	60	23	35	18	191	207
	59.0%	-	-	59.0%	-	-	-	-	67.0%	54.0%	62.0%	68.0%	56.0%	52.0%	63.0%	57.0%	63.0%	61.0%	65.0%	56.0%	60.0%	58.0%
Patients and patient advocacy groups trust in	392	0	0	392	0	0	0	0	172	220	105	50	237	127	M 94	94	55	19	32	12	185	207
Patients and patient advocacy groups trust in	58.0%	-	-	58.0%	-	-	-	-	66.0%	53.0%	58.0%	63.0%	57.0%	59.0%	59.0%	59.0%	58.0%	50.0%	59.0%	38.0%	58.0%	58.0%
us	30.070			30.070					00.070	33.070	30.070	03.070	37.070	\$	\$	S	S	30.070	33.070	30.070	30.070	30.070
Payors, health system bureaucrats and	267	0	0	267	0	0	0	0	128	139	76	30	161	68	78	58	40	16	22	11	125	142
government bodies trust in us	40.0%	-	-	40.0%	-	-	-	-	49.0%	34.0%	42.0%	38.0%	39.0%	32.0%	49.0%	36.0%	42.0%	42.0%	41.0%	34.0%	39.0%	40.0%
6									1						MO							
Willingness of stakeholders to engage with us	386	0	0	386	0	0	0	0	175	211	101	48	237	116	90	94	55	19	33	16	202	184
-	57.0%	-	-	57.0%	-	-	-	-	67.0%	51.0%	56.0%	61.0%	57.0%	54.0%	56.0%	59.0%	58.0%	50.0%	61.0%	50.0%	63.0%	52.0%
									1												U	
Company revenues	277	0	0	277	0	0	0	0	135	142	77	39	161	74	64	70	45	19	29	11	138	139
	41.0%	-	-	41.0%	-	-	-	-	52.0%	34.0%	43.0%	49.0%	39.0%	35.0%	40.0%	44.0%	47.0%	50.0%	54.0%	34.0%	43.0%	39.0%
				1					1								M		M			1

Statistics: Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Column Fesce (2/n), And (2/n), An



Q35. Change as a result from organization's patient-focused efforts (trust) - Bottom 2 Box Summary


					Туре				Confi	dence	Pha	rma: Company	y size			Geo	graphical loca	ition			Job ti	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower
		Α	В	С	D	E	F	G	Н	I	J	K	L	М	N	0	Р	Q	R	S	T	U
Base: Pharma Companies	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
Employee engagement	42	0	0	42	0	0	0	0	10	32	11	7.5	28	16	6	13	5	5	1	32	23	19
Employee engagement	6.0%	-	-	6.0%	-	-	-	-	4.0%	8.0%	6.0%	4.0%	7.0%	7.0%	4.0%	8.0%	5.0%	13.0%	7.0%	9.0%	7.0%	5.0%
	0.07.1									Н	0.07.		11011			0.075		N		0.07.0		0.075
Employee attraction/retention	55	0	0	55	0	0	0	0	13	42	15	7	33	14	10	23	6	2	5	2	24	31
	8.0%	-	-	8.0%	-	-	-	-	5.0%	10.0%	8.0%	9.0%	8.0%	7.0%	6.0%	14.0%	6.0%	5.0%	9.0%	6.0%	8.0%	9.0%
										Н						MNP						
Patient outcomes	19	0	0	19	0	0	0	0	5	14	8	2	9	5	6	5	1	4	2	1	12	7
	3.0%	-	-	3.0%	-	-	-	-	2.0%	3.0%	4.0%	3.0%	2.0%	2.0%	4.0%	3.0%	1.0%	11.0%	4.0%	3.0%	4.0%	2.0%
																		MOP				
Health care professionals trust in us	30	0	0	30	0	0	0	0	9	21	9	4	17	8	6	8	5	5	3	3	15	15
	4.0%	-	-	4.0%	-	-	-	-	3.0%	5.0%	5.0%	5.0%	4.0%	4.0%	4.0%	5.0%	5.0%	13.0%	6.0%	9.0%	5.0%	4.0%
																		MN				
Patients and patient advocacy groups trust in	29	0	0	29	0	0	0	0	9	20	11	2	16	7	7	9	4	4	4	2	19	10
us	4.0%	-	-	4.0%	-	-	-	-	3.0%	5.0%	6.0%	3.0%	4.0%	3.0%	4.0%	6.0%	4.0%	11.0%	7.0%	6.0%	6.0%	3.0%
																		M			U	
Payors, health system bureaucrats and	33	0	0	33	0	0	0	0	9	24	13	6	14	9	7	10	3	5	2	2	21	12
government bodies trust in us	5.0%	-	-	5.0%	-	-	-	-	3.0%	6.0%	7.0%	8.0%	3.0%	4.0%	4.0%	6.0%	3.0%	13.0%	4.0%	6.0%	7.0%	3.0%
											L							MNP				
Willingness of stakeholders to engage with us	24	0	0	24	0	0	0	0	5	19	8	5	11	6	6	5	2	3	2	4	11	13
	4.0%	-	-	4.0%	-	-	-	-	2.0%	5.0%	4.0%	6.0%	3.0%	3.0%	4.0%	3.0%	2.0%	8.0%	4.0%	12.0%	3.0%	4.0%
_						1						1		 		1				MNOP		1
Company revenues	33	0	0	33	0	0	0	0	10	23	11	4	18	7	11	10	4	2	3	1	17	16
	5.0%	-	-	5.0%	-	=	-	-	4.0%	6.0%	6.0%	5.0%	4.0%	3.0%	7.0%	6.0%	4.0%	5.0%	6.0%	3.0%	5.0%	4.0%

Statistics: Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Columns Tesses (2/m), And (2/m),



Q35. Change as a result from organization's patient-focused efforts (trust) - Mean Summary

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ition			Job tit	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower
		A	В	С	D	E	F	G	Н	_	j	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Pharma Companies	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
Employee engagement	3.9	-	-	3.9	-	-	-	-	4.1	3.7	3.9	3.9	3.9	3.8	3.9	3.8	3.9	3.8	4	4	3.9	3.9
Employee attraction/retention	3.6	-	-	3.6	-	-	-	-	3.8	3.5	3.7	3.5	3.6	3.6	3.6	3.5	3.8	3.7	3.7	3.8	3.7	3.6
Patient outcomes	3.9	=	-	3.9	=	=	=	-	4.1	3.8	3.9	3.9	3.9	3.9	3.9	3.9	4	3.7	4	4	3.8	4
Health care professionals trust in us	3.9	÷	-	3.9	-	-	-	-	4.1	3.8	4	4.1	3.8	3.8	3.9	3.9	4	3.8	4	4	3.9	3.9
Patients and patient advocacy groups trust in	3.9	-	-	3.9	-	-	_	-	4	3.8	3.9	4	3.9	3.9	3.9	3.9	3.9	3.6	3.9	3.7	3.9	3.9
us Payors, health system bureaucrats and	3.6	-	-	3.6	-	-	-	-	3.8	3.5	3.6	3.5	3.6	Q 3.6	3.6	3.6	3.7	3.4	3.6	3.5	3.5	3.6
government bodies trust in us Willingness of stakeholders to engage with us	3.9		_	3.9	_		_	_	1	3.8	3.9	3.8	3.9	3.9	3.8	3.9	3.9	3.7	3.9	3.7	3.9	3.8
willingness or stakeholders to engage with us		-	-		-	-	-	-	1													
Company revenues	3.6	=	-	3.6	-	-	-	-	3.8	3.5	3.6	3.8	3.6	3.5	3.6	3.7	3.7	3.7	3.7	3.6	3.6	3.7

Statistics:

Overlap formulae used - Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)
Table of Contents



Q64. Overall trust in pharmaceutical industry

				Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
	А	В	С	D	Е	F	G	Н	1	J	K	L	М	N	0	Р	Q	R	S	Т	U
142	72	0	0	0	70	122	142	26	117	0	0	0	0	0	0	0	0	0	0	0	0
8	5	0	0	0	3	7	8	3	5	0	0	0	0	0	0	0	0	0	0	0	0
6.0%	7.0%	-	-	-	4.0%	6.0%	6.0%	12.0%	4.0%	-	-	-	-	-	-	-	-	-	-	-	-
40 28.0%	18 25.0%	0 -	0 -	0 -	22 31.0%	33 27.0%	40 28.0%	13 50.0%	27 23.0%	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
41	25	0	0	0	16	36	41	6	35	0	0	0	0	0	0	0	0	0	0	0	0
29.0%	34.0%	-	-	-	23.0%	29.0%	29.0%	23.0%	30.0%	-	-	-	-	-	-	-	-	-	-	-	-
39 27.0%	21 29.0%	0	0	0 -	18 26.0%	34 28.0%	39 27.0%	4 15.0%	35 30.0%	0	0	0	0	0	0	0	0	0 -	0	0 -	0
10	2	0	0	0	8	9	10	0	10	0	0	0	0	0	0	0	0	0	0	0	0
7.0%	3.0%	-	-	-	11.0% Δ	7.0% Δ	7.0% A	-	9.0%	-	-	-	-	-	-	-	-	-	-	-	-
5 3.0%	3.0%	0 -	0 -	0 -	3 4.0%	4 3.0%	5 3.0%	0 -	5 4.0%	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
143 100.0%	73 100.0%	0	0	0 0.0%	70 100.0%	123 100.0%	143 100.0%	26 100.0%	117 100.0%	0	0	0	0	0 0.0%	0 0.0%	0	0	0	0	0 0.0%	0 0.0%
48 34.0%	23 32.0%	0 -	0 -	0 -	25 36.0%	40 33.0%	48 34.0%	16 62.0%	32 27.0%	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
49	23	0	0	0	26	43	49	4	45	0	0	0	0	0	0	0	0	0	0	0	0
34.0%	32.0%	-	-	-		35.0%	34.0%		Н	-	-	-	-	-	-	-	-	-	-	-	=
3	3	-	-	-	2.9	3	3	3.6 I	2.8	-	-	-	-	-	-	=	-	-	-	-	-
1	1	-	-	-	1.1	1.1	1	0.9	1	-	-	-	-	-	-		-	-	-	-	-
0.1	0.1	-	-	-	0.1	0.1	0.1	0.2	0.1	-	-	-	-	-	-	-	-	-	-	-	-
	143 8 6.0% 40 28.0% 41 29.0% 39 27.0% 10 7.0% 5 3.0% 143 100.0% 48 34.0% 49 34.0% 3	Health Charity	Health Charity		Health Charity	Total Patient or Health Charity Suppliers Pharma HCP (not part of any other group)	Total Patient or Health Charity Patients only (not part of any other group)	Total Patient or Health Charity Patient Charity Patient Charity Patient Charity Patient Charity Patient Charity Patient Charity and Patients Charity an	Total Patient or Health Charity Patient or Health Charity Patient or Health Charity Patient or Health Charity and Patients Patients only (not part of any other group) Patients only (charity and Patients Patients only (charity and Patients only (charity and Patients only (charity and Patients) Patients only (charity and Pat	Total Patient or Health Charity Suppliers Pharma HCP Pure patient (not part of any other group) Patient Health Charity and Patients Confident Charity	Total Patient or Health Charity Patient Charity Patient Charity Patient Charity Patient Charity Patient Charity Patient Charity and Patients Patien	Total Patient or Health Charity Patients Pharma HCP Pure patient (not part of any other group) Patients only Patients only Patients only Patients Confident Charity Charit	Total Patient or Health Charity Patient or Health Charity and Health Charity and Patients only other group) Patients Patients only other group) Patients Patients	Total Polient or Health Chairty Polient Polient Polient Polient Confident Chairty Polient Confident Chairty Polient Confident Chairty Confiden	Total Polient or Health Charity Palma HCP Purpalent (not part of any other group) Palent Polients only Patient Polients only Patient Polients only Patient Polients Polien	Total Patient Suppliers Pharma HCP Pure patient Patients only the Health Charity and group) Patient Charity and group) Patients Pa	Total Patient Suppliers Suppliers Pharma HCP Pharma HCP any other group) Patient Charity and Patients Confident Charity and Patients Ch	Total Patient or Suppliers Pharma MCP Patient part of any other group) Pharma MCP Pharma Ph	Total Patient of the lath Charity Patient Patien	Total Patient or Suppliers Pharma McP Para patient Patient Charly any other group) Patients Charly any other group) Patients Charly any other Ghospital Charly any other Ghospital Charly any other Ghospital Charly and Charly any other Ghospital Charly and Ghospital Charly and Ghospital Charly and Ghospital Charly and Ghospital Ghospital Charly and Ghospital G	Total Patient or Suppliers Pharma MCP Pare patient Control of the part of th

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q67. Trust in relevant pharmaceutical industry

				Type				Confi	dence	Pha	arma: Company	size			Geo	graphical loca	ation			Job tit	le/level
Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
	А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
130	67	0	0	0	63	110	130	24	106	0	0	0	0	0	0	0	0	0	0	0	0
14 11.0%	8 12.0%	0 -	0 -	0 -	6 10.0%	12 11.0%	14 11.0%	4 17.0%	10 9.0%	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
42 32.0%	21 31.0%	0 -	0 -	0 -	21 33.0%	34 31.0%	42 32.0%	12 50.0%	30 28.0%	0	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
39 30.0%	21 31.0%	0 -	0 -	0 -	18 29.0%	33 30.0%	39 30.0%	6 25.0%	33 31.0%	0	0 -	0	0 -	0 -	0 -	0	0 -	0 -	0	0	0 -
28 22.0%	14 21.0%	0 -	0 -	0 -	14 22.0%	25 23.0%	28 22.0%	2 8.0%	26 25.0%	0	0 -	0	0 -	0 -	0 -	0	0 -	0 -	0 -	0	0 -
5 4.0%	1 1.0%	0 -	0 -	0 -	4 6.0%	5 5.0%	5 4.0%	0 -	5 5.0%	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
2 2.0%	2 3.0%	0 -	0 -	0 -	0 -	1 1.0%	2 2.0%	0	2 2.0%	0 -	0	0	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
130 100.0%	67 100.0%	0	0	0	63 100.0%	110 100.0%	130 100.0%	24 100.0%	106 100.0%	0	0	0	0	0	0	0	0	0	0	0	0
56 43.0%	29 43.0%	0 -	0 -	0	27 43.0%	46 42.0%	56 43.0%	16 67.0%	40 38.0%	0	0 -	0	0 -	0 -	0 -	0	0 -	0	0 -	0	0 -
33 25.0%	15 22.0%	0 -	0 -	0 -	18 29.0%	30 27.0%	33 25.0%	2 8.0%	31 29.0%	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
3.2	3.3	-	-	-	3.2	3.2	3.2	3.8	Н 3.1	-	-	÷	-	-	-	1	-	-	-	÷	-
1	1	-	-	-	1.1	1.1	1	0.8	1.1	-	-	-	-	-	-	-	-	-	-	-	-
																					1
	130 14 11.0% 42 32.0% 39 30.0% 5 4.0% 2 2.0% 130 100.0% 56 43.0% 33 25.0%	## Health Charity A 130 67 14 8 11.0% 12.0% 42 21 32.0% 31.0% 39 21 30.0% 31.0% 28 14 22.0% 21.0% 5 1 4.0% 1.0% 2 2 2.0% 3.0% 130 67 100.0% 100.0% 56 29 43.0% 43.0% 33 15 25.0% 22.0% 3.2 3.3	Health Charity		Health Charity	Patient or Health Charity	Patient or Health Charity	Patient or Health Charity	Total Patient or Health Charity Patient Charity Charity Patient Charity Patient Charity Patient Charity Patient Charity Charity Charity Charity Charity and Patients Patients only Patient Charity and Patients Patients only Patient Charity and Patients Patients only Charity and Patients Patients only Charity and Patients Patients only Charity and Patients only Patient Charity and Patients only Patient Charity and Patients only Patients only Patients only Charity and Patients only Pat	Patient or Health Charity	Total Patient or Health Charity Patient Charity Patients C	Total Patient or Health Charity Patient Charity Confident Charity Co	Total Patient of Health Charity Patient Charity Patient Charity Patient Charity Charity Confident Charity Char	Patient of Health Charity Patient Charity and Fall Patients only (not part of any other group) Patient Health Charity and Patients Patients Patients	Total Patient Health Charity Charity Patient Health Charity Patient Health Charity Patient Health Charity Patient Health Charity and Health Charity and Health Charity and Patient Health Charity and Health Chari	Total Patient or Suppliers Pharma HCP Pure patient or Charity Charity Charity Charity Charity Charity and Patient Patient Charity and Patient	Patient or Negaliers Patient or Negaliers Patients Patient Charity Patient Charity Patient Charity and patient Patients P	Total Patient or Suppliers Pharma MCP Pure patient Posterior of any other group) Patient Charity and group Patients only Patients only	Total Patient or Suppliers Pharms NCP Pare patient Patients only Patients only Patients Pa	Total Patient or Inches Patient Patien	Total Patient or Suppliers Plasma NCP Purp patient Autority and Patient Charity and

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

Minimum Base: 5 (**), Small Base: 15 (*)

Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company helps make sure that the people who need medicines have access to them

					Туре				Confi	dence	Pha	ırma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н		J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Patient charity groups Patient/Carers	88	51	0	0	0	37	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	10	4	0	0	0	6	71	10	2	8	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 3	11.0%	8.0%	-	-	-	16.0%	10.0%	11.0%	13.0%	11.0%	-	-	-	-	-	-	-	-	-	-	-	-
4	18	7	0	0	0	11	17	18	4	14	0	0	0	0	0	0	0	0	0	0	0	0
	20.0%	14.0%	-	-	-	30.0%	24.0% A	20.0%	27.0%	19.0%	-	-	-	-	-	-	-	-	-	-	-	-
3	20	12	0	0	0	8	16	20	1	19	0	0	0	0	0	0	0	0	0	0	0	0
	23.0%	24.0%	-	-	-	22.0%	23.0%	23.0%	7.0%	26.0%		-	-	-	-	-	-	-	-	-	-	-
2	18	11	0	0	0	7	15	18	4	14	0	0	0	0	0	0	0	0	0	0	0	0
	20.0%	22.0%	-	-	-	19.0%	21.0%	20.0%	27.0%	19.0%	-	-	-	-	-	-	-	-	-	-	-	-
Strongly disagree 1	15	13	0	0	0	2	11	15	2	13	0	0	0	0	0	0	0	0	0	0	0	0
	17.0%	25.0%	-	-	-	5.0%	15.0%	17.0%	13.0%	18.0%	-	-	-	-	-	-	÷	-	-	-	-	-
Don't know or NA	7	EFG 4	0	0	0	3	E 5	E 7	2	5	0	0	0	0	0	0	0	0	0	0	0	0
BOIL CKNOW OF INA	8.0%	8.0%	-	-	-	8.0%	7.0%	8.0%	13.0%	7.0%	-	-	-	-	-	-	-	-	-	-	-	-
Sigma	88	51	0	0	0	37	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
	100.0%	100.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Summary																						
TOP 2 BOX	28	11	0	0	0	17	24	28	6	22	0	0	0	0	0	0	0	0	0	0	0	0
	32.0%	22.0%	-	-	-	46.0% AFG	34.0% A	32.0% A	40.0%	30.0%	-	-	-	-	-	-	-	-	-	-	-	-
BOTTOM 2 BOX	33	24	0	0	0	9	26	33	6	27	0	0	0	0	0	0	0	0	0	0	0	0
	38.0%	47.0%	-	-	-	24.0%	37.0%	38.0%	40.0%	37.0%		-	-	-	-	-	-	-	-	-	-	-
Mean	2.9	EG 2.5	_	_	-	3.4	E 2.9	E 2.9	3	2.9	_	_	_	_	_	_		_	_	_	_	-
···cai	2.3	2.3				AFG	Α	Α Α	*	2.3												
Std. Dev.	1.3	1.3	-	-	-	1.2	1.3	1.3	1.4	1.3	-	-	-	-	-	-	-	-	-	-	-	-
Std. Err.	0.1	0.2	-	-	-	0.2	0.2	0.1	0.4	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Statistics																						

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company communicates with care and compassion, transparent and unbiased information on diseases, treatment options, and available resources

					Туре				Confi	dence	Pha	rma: Company	size			Gen	graphical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		A	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	P	Q	R	S	Т	U
Base: Patient charity groups Patient/Carers	88	51	0	0	0	37	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	7	1	0	0	0	6	6	7	2	5	0	0	0	0	0	0	0	0	0	0	0	0
	8.0%	2.0%	-	-	-	16.0%	8.0%	8.0%	13.0%	7.0%	-	-	-	-	-	-	-	-	-	-	-	-
						AFG		Α														
4	21	11	0	0	0	10	18	21	6	15	0	0	0	0	0	0	0	0	0	0	0	0
	24.0%	22.0%	-	-	-	27.0%	25.0%	24.0%	40.0%	21.0%	-	-	-	-	-	-	-	-	-	-	-	-
3	21	9	0	0	0	12	19	21	1	20	0	0	0	0	0	0	0	0	0	0	0	0
	24.0%	18.0%	-	-	-	32.0%	27.0%	24.0%	7.0%	27.0%	-	-	-	-	-	-	-	-	-	-	-	-
2	21	17	0	0	0	4	14	21	3	18	0	0	0	0	0	0	0	0	0	0	0	0
	24.0%	33.0%	-	-	-	11.0%	20.0%	24.0%	20.0%	25.0%	-	-	-	-	-	-	-	-	-	-	-	-
		EFG					E	E														
Strongly disagree 1	15	12	0	0	0	3	12	15	3	12	0	0	0	0	0	0	0	0	0	0	0	0
	17.0%	24.0%	-	-	-	8.0%	17.0%	17.0%	20.0%	16.0%	-	-	=	-	-	-	-	-	-	-	-	-
	_						E	E		_		_	_	_	_	_		_	_		_	
Don't know or NA	3	1	0	0	0	2	2	3	0	3	0	0	0	0	0	0	0	0	0	0	0	0
	3.0%	2.0%	-	-	-	5.0%	3.0%	3.0%	-	4.0%	-	-	-	-	-	-	-	-	-	-	-	-
Sigma	88	51	0	0	0	37	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
	100.0%	100.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
S																						
TOP 2 BOX	28	12	0	0	0	16	24	28	8	20	0	0	0	0	0	0	0	0	0	0	0	0
TOP 2 BOX	32.0%	24.0%	-	-	-	43.0%	34.0%	32.0%	53.0%	27.0%	-	-	-	-	-	-	-	-	-	-	-	-
	32.0%	24.0%	-	-	-	43.0%	34.0%	32.0% A	33.0%	27.0%	-	-	-	-	-	-	-	-	-	-	-	-
BOTTOM 2 BOX	36	29	0	0	0	7	26	36	6	30	0	0	0	0	0	0	0	0	0	0	0	0
	41.0%	57.0%	-	-	-	19.0%	37.0%	41.0%	40.0%	41.0%		-	-	-	-	-	-	-	-	-	-	-
		EFG					E	E														
Mean	2.8	2.4	-	-	-	3.3	2.9	2.8	3.1	2.8	-	-	-	-	-	-	-	-	-	-	-	-
						AFG	Α	Α														<u> </u>
Std. Dev.	1.2	1.1	-	-	-	1.2	1.2	1.2	1.4	1.2	-	-	-	-	-	-	-	-	-	-	-	-
Std. Err.	0.1	0.2	_	-	_	0.2	0.1	0.1	0.4	0.1	-	-	-	_	_	_	-	_	-	_	-	-
Sto. Ell.	0.1	0.2				0.2	0.1	0.1	0.4	0.1		ļ			1						1	+

Statistics:

Overlap formulae used

- Column Means:


Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company provides easy-to-understand and convenient information in plain language because they understand that "words matter"

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			loh tit	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		Α	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Patient charity groups Patient/Carers	88	F4	0	0		37	74	88	15	73	0	^	0			0			0	0	0	
Strongly agree 5	15	51 6	0	0	0	9	71 13	15	5	10	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	17.0%	12.0%	-	-	-	24.0%	18.0%	17.0%	33.0%	14.0%	-	-	-	-	-	-	-	-	-	-	-	-
4	20 23.0%	11 22.0%	0 -	0 -	-	9 24.0%	17 24.0%	20 23.0%	4 27.0%	16 22.0%	-	-	0 -	-	-	-	- 0	-	0 -	0 -	0 -	-
							40			40	•											
3	22 25.0%	14 27.0%	-	-	-	8 22.0%	18 25.0%	22 25.0%	4 27.0%	18 25.0%	0	- 0	0 -	-	0	-	0	0	-	0 -	-	-
2	14	9	0	0	0	5	11	14	0	14	0	0	0	0	0	0	0	0	0	0	0	0
	16.0%	18.0%	-	-	-	14.0%	15.0%	16.0%	-	19.0%	-	-	-	-	-	-	-	-	-	-	-	-
Strongly disagree 1	12	9	0	0	0	3	8	12	1	11	0	0	0	0	0	0	0	0	0	0	0	0
	14.0%	18.0%	-	-	-	8.0%	11.0%	14.0%	7.0%	15.0%	-	-	-	-	-	-	-	-	-	-	-	-
Don't know or NA	5	2	0	0	0	3	4	5	1	4	0	0	0	0	0	0	0	0	0	0	0	0
	6.0%	4.0%	-	-	-	8.0%	6.0%	6.0%	7.0%	5.0%	-	-	-	-	-	-	-	-	-	-	-	-
Sigma	88	51	0	0	0	37	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
	100.0%	100.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Summary																						
TOP 2 BOX	35	17	0	0	0	18	30	35	9	26	0	0	0	0	0	0	0	0	0	0	0	0
	40.0%	33.0%	-	-	-	49.0%	42.0%	40.0%	60.0%	36.0%	-	-	-	-	-	-	-	-	-	-	-	-
воттом 2 вох	26	18	0	0	0	8	19	26	1	25	0	0	0	0	0	0	0	0	0	0	0	0
	30.0%	35.0%	-	-	-	22.0%	27.0%	30.0%	7.0%	34.0% H	-	-	-	-	-	-	-	-	-	-	-	-
Mean	3.1	2.9	-	-	-	3.5	3.2	3.1	3.9	3	-	-	-	-	-	-	-	-	-	-	-	-
Std. Dev.	1.3	1.3	_	-	-	1.3	A 1.3	1.3	I* 1.2	1.3	_	-	-	_	_	_		_	-	-	_	-
		1.5				1.5	1.5	1.5		1.5												
Std. Err.	0.1	0.2	-	-	-	0.2	0.2	0.1	0.3	0.2		-	-	-	-	-	-	-	-	-	-	-
Chatistics																		1				<u> </u>

Statistics:

Overlap formulae used


- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company helps you gain affordable access to their medications

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or	Suppliers	Pharma	HCP	Pure patient	Patients only	Patient	Very	Less	Small	Medium	Large	Global	Europe	North and	Asia	Africa	South	Australasia	Department	
	1000	Health Charity	Supplied			(not part of any other group)	,	Health Charity and Patients	confident	confident			23.50	5.520	Zarope	Central America			America	, , , , , , , , , , , , , , , , , , , ,	Head or higher	managers o lower
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
												_						_				
Base: Patient charity groups Patient/Carers	88 13	51 6	0	0	0	37 7	71	88	15 3	73	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	15.0%	12.0%	-	-	-	19.0%	13.0%	13 15.0%	20.0%	10 14.0%	-		-		-		0	-	0	-	0	
	15.0%	12.0%	-	-	-	19.0%	13.0%	15.0%	20.0%	14.0%	-	-	-	-	-	-	-	-	-	-	-	-
4	18	8	0	0	0	10	16	18	2	16	0	0	0	0	0	0	0	0	0	0	0	0
	20.0%	16.0%	-	-	-	27.0%	23.0%	20.0%	13.0%	22.0%	-	-	-	-	-	-	-	-	-	-	-	-
2	15	10	0	0	0	5	13	15	3	12	0	0	0	0	0	0	0	0	0	0	0	0
	17.0%	20.0%	-	-	-	14.0%	18.0%	17.0%	20.0%	16.0%	-	-	-	-	-	-	-	-	-	-	-	-
	17.070	20.070				14.070	10.070	17.070	20.070	10.070												+
2	15	10	0	0	0	5	11	15	2	13	0	0	0	0	0	0	0	0	0	0	0	0
	17.0%	20.0%	-	-	-	14.0%	15.0%	17.0%	13.0%	18.0%	-	-	-	-	-	-	-	-	-	-	-	-
Strongly disagree 1	22	16	0	0	0	6	17	22	2	20	0	0	0	0	0	0	0	0	0	0	0	0
Strongly disagree 1	25.0%	31.0%	-	-	-	16.0%	24.0%	25.0%	13.0%	27.0%	-	-	-	-	-	-	-	-	-	-	-	-
Daniel Income and Ma	5	1	0	0	0	4	5	5	3	2	0	0	0	0	0	0	0	0	0	0	0	0
Don't know or NA	6.0%	2.0%	-	-	-	11.0%	7.0%	6.0%	20.0%	3.0%	-	-	-	-	-	-	-	-	-	-	-	-
	0.076	2.076	-	-	-	11.0%	7.076	A	20.076	3.0%	-	_	-	-	-		-		-	-	-	1
Sigma	88	51	0	0	0	37	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
	100.0%	100.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Summary																						
TOP 2 BOX	31	14	0	0	0	17	25	31	5	26	0	0	0	0	0	0	0	0	0	0	0	0
	35.0%	27.0%	-	-	-	46.0%	35.0%	35.0%	33.0%	36.0%	-	-	-	-	-	-	-	-	-	-	-	-
BOTTOM 2 BOX	37	26	0	0	0	11	28	37	4	33	0	0	0	0	0	0	0	0	0	0	0	0
	42.0%	51.0%	-	-	-	30.0%	39.0%	42.0% F	27.0%	45.0%		-	-	-	-	-	-	-	-	-	-	-
Mean	2.8	2.6	-	-	-	3.2	2.8	2.8	3.2	2.8	-	-	-	-	-	-	-	-	-	-	-	-
						AFG		Α	*													
Std. Dev.	1.4	1.4	-	-	-	1.4	1.4	1.4	1.5	1.4	-	-	-	-	-	-	-	-	-	-	-	-
Std. Err.	0.2	0.2	-	-	-	0.2	0.2	0.2	0.4	0.2	-	-	-	_	-	-	_	-	-	-	-	-
July 211.	3.2	J.2				3.2	3.2	U.2	0.4	U.Z		 		+	+			+		+	 	+

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company equips you to make informed choices about healthcare and treatment options

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		Α	В	С	D	E	F	G	Н	_	J	K	L	М	N	0	Р	Q	R	S	T	U
									4.5	70												
Base: Patient charity groups Patient/Carers	88	51	0	0	0	37 9	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	12	3	0	0	0	-	11 15.0%	12	5	7	0	0	0	0	0	0	0	0	0	0	0	0
	14.0%	6.0%	-	-	-	24.0% AG		14.0%	33.0%	10.0%	-	-	-	-	-	-	-	-	-	-	-	-
4	14	8	0	0	0	6 AG	A 12	A 14	2	12	0	0	0	0	0	0	0	0	0	0	0	0
4	16.0%	16.0%	-	-	-	16.0%	17.0%	16.0%	13.0%	16.0%	-	-	-	-	-	-	-	-	-	-		
l .	16.0%	16.0%	-	-	-	16.0%	17.0%	16.0%	13.0%	16.0%	-	-	-	-	-	-	-	-	-	-	-	-
2	23	13	0	0	0	10	18	23	3	20	0	0	0	0	0	0	0	0	0	0	0	0
	26.0%	25.0%	-	-	-	27.0%	25.0%	26.0%	20.0%	27.0%	-	-	-	-	-	-	-	-	-	-	-	-
	20.076	23.076	-	_	-	27.076	23.076	20.076	20.076	27.076		_	-	_		-		-	_		-	
2	20	16	0	0	0	4	16	20	1	19	0	0	0	0	0	0	0	0	0	0	0	0
_	23.0%	31.0%	-	-	-	11.0%	23.0%	23.0%	7.0%	26.0%	-	-	-	-	-	-	-	-	-	-	-	-
	23.070	EG				11.070	F F	E	7.070	20.070												+
Strongly disagree 1	14	10	0	0	0	4	10	14	2	12	0	0	0	0	0	0	0	0	0	0	0	0
	16.0%	20.0%		-	-	11.0%	14.0%	16.0%	13.0%	16.0%	-	-	-	-	-	-	-	-	-	-	-	-
Don't know or NA	5	1	0	0	0	4	4	5	2	3	0	0	0	0	0	0	0	0	0	0	0	0
	6.0%	2.0%	-	-	-	11.0%	6.0%	6.0%	13.0%	4.0%	,	-	-	-	-	-	-	-	-	-	-	-
								Α														
Sigma	88	51	0	0	0	37	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
	100.0%	100.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Summary																						
TOP 2 BOX	26	11	0	0	0	15	23	26	7	19	0	0	0	0	0	0	0	0	0	0	0	0
	30.0%	22.0%	-	-	-	41.0%	32.0%	30.0%	47.0%	26.0%	-	-	-	-	-	-	-	-	-	-	-	-
BOTTOM 2 BOX	34	26	0	0	0	8	26	34	3	31	0	0	0	0	0	0	0	0	0	0	0	0
	39.0%	51.0%	-	-	-	22.0%	37.0%	39.0%	20.0%	42.0%	-	-	-	-	-	-	-	-	-	-	-	-
		EFG					E	E														
Mean	2.9	2.6	-	-	-	3.4	3	2.9	3.5	2.8	-	-	-	-	-	-	-	-	-	-	-	-
						AFG	Α	A	1*													
Std. Dev.	1.3	1.2	-	-	-	1.3	1.3	1.3	1.5	1.2	-	-	-	-	-	-	-	-	-	-	-	-
Std. Err.	0.1	0.2	-	-	-	0.2	0.2	0.1	0.4	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Ctatistics					1	1								1	1							1

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company listens and responds to your feedback with respect and humility

					Туре				Confi	dence	Pha	arma: Company	size			Gen	graphical loca	tion			loh titl	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		Α	В	С	D	E	F	G	Н	ı	J	K	L	M	N	0	Р	Q	R	S	Т	U
Base: Patient charity groups Patient/Carers	88	51	0	0	0	37	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	14	6	0	0	0	8	12	14	3	11	0	0	0	0	0	0	0	0	0	0	0	0
	16.0%	12.0%	-	-	-	22.0%	17.0%	16.0%	20.0%	15.0%	-	-	-	-	-	-	-	-	-	-	-	-
4	13	7	0	0	0	6	10	13	3	10	0	0	0	0	0	0	0	0	0	0	0	0
	15.0%	14.0%	-	-	-	16.0%	14.0%	15.0%	20.0%	14.0%	-	-	-	-	-	-	-	-	-	-	-	-
3	24	14	0	0	0	10	19	24	3	21	0	0	0	0	0	0	0	0	0	0	0	0
	27.0%	27.0%	-	-	-	27.0%	27.0%	27.0%	20.0%	29.0%		-	-	-	-	-	-	-	-	-	-	-
2	15	13	0	0	0	2	11	15	2	13	0	0	0	0	0	0	0	0	0	0	0	0
	17.0%	25.0%	-	-	-	5.0%	15.0%	17.0%	13.0%	18.0%	-	-	-	-	-	-	-	-	-	-	-	-
	17.070	EFG				3.070	E	E	13.070	10.070												
Strongly disagree 1	15	11	0	0	0	4	12	15	2	13	0	0	0	0	0	0	0	0	0	0	0	0
	17.0%	22.0%	-	-	-	11.0%	17.0%	17.0%	13.0%	18.0%	-	-	-	-	-	-	-	-	-	-	-	-
Don't know or NA	7	0	0	0	0	7	7	7	2	5	0	0	0	0	0	0	0	0	0	0	0	0
	8.0%	-	-	-	-	19.0%	10.0%	8.0%	13.0%	7.0%	-	-	-	-	-	-	-	-	-	-	-	-
						AFG	Α	Α														
Sigma	88	51	0	0	0	37	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
	100.0%	100.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Summary																						
TOP 2 BOX	27	13	0	0	0	14	22	27	6	21	0	0	0	0	0	0	0	0	0	0	0	0
	31.0%	25.0%	-	-	-	38.0%	31.0%	31.0%	40.0%	29.0%	-	-	-	-	-	-	-	-	-	-	-	-
BOTTOM 2 BOX	30	24	0	0	0	6	23	30	4	26	0	0	0	0	0	0	0	0	0	0	0	0
	34.0%	47.0%	-	-	-	16.0%	32.0%	34.0%	27.0%	36.0%	-	-	-	-	-	-	-	-	-	-	-	-
		EFG					E	E														İ
Mean	3	2.7	-	-	-	3.4	3	3	3.2	2.9	-	-	-	-	-	-	-	-	-	-	-	-
Std. Dev.	1.3	1.3	-	-	_	AFG 1.3	1.4	A 1.3	* 1.4	1.3	-	-	-	_	-	-	-	-	-	-	-	-
	1.0	2.0				1.5		2.0														
Std. Err.	0.1	0.2	-	-	-	0.2	0.2	0.1	0.4	0.2		-	-	-	-	-	-	-	-	-	-	-
Statistics																						

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company partners with you to innovate and measure impact and outcomes that are important to you

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job tit	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	E	F	G	Н	1	J	K	L	М	N	0	Р	Q	R	S	Т	U
Base: Patient charity groups Patient/Carers	88	51	0	0	0	37	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	15 17.0%	8 16.0%	-	-	-	7 19.0%	10 14.0%	15 17.0%	4 27.0%	11 15.0%	-	-	-	-	-	-	-	-	-	-	-	-
4	16	9	0	0	0	7	10	16	3	13	0	0	0	0	0	0	0	0	0	0	0	0
	18.0%	18.0%	-	-	-	19.0%	14.0%	18.0%	20.0%	18.0%	-	-	-	-	-	-	-	-	-	-	-	-
_						_		F				_	_								_	
3	17	10 20.0%	0	0	0	7 19.0%	15 21.0%	17 19.0%	13.0%	15 21.0%	0	0	0	0	0	0	0	0	0	0	0	0
	19.0%	20.0%	-	-	-	19.0%	21.0%	19.0%	13.0%	21.0%	-	-	-	-	-	-	-	-	-	-	-	-
2	22	16	0	0	0	6	20	22	3	19	0	0	0	0	0	0	0	0	0	0	0	0
	25.0%	31.0%	-	-	-	16.0%	28.0% F	25.0%	20.0%	26.0%	-	-	-	-	-	-	-	-	-	-	-	-
Strongly disagree 1	13	8	0	0	0	5	11	13	2	11	0	0	0	0	0	0	0	0	0	0	0	0
	15.0%	16.0%	-	-	-	14.0%	15.0%	15.0%	13.0%	15.0%	-	-	-	-	-	-	-	-	-	-	-	-
Don't know or NA	5	0	0	0	0	5	5	5	1	4	0	0	0	0	0	0	0	0	0	0	0	0
	6.0%	-	-	-	-	14.0%	7.0%	6.0%	7.0%	5.0%	-	-	-	-	-	-	-	-	-	-	-	-
						AG																
Sigma	100.0%	51 100.0%	0.0%	0.0%	0.0%	37 100.0%	71 100.0%	88 100.0%	15 100.0%	73 100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	100.076	100.076	0.076	0.076	0.076	100.0%	100.076	100.076	100.076	100.076	0.076	0.076	0.078	0.076	0.076	0.0%	0.076	0.076	0.076	0.076	0.076	0.076
Summary																						
TOP 2 BOX	31	17	0	0	0	14	20	31	7	24	0	0	0	0	0	0	0	0	0	0	0	0
	35.0%	33.0%	-	-	-	38.0%	28.0%	35.0%	47.0%	33.0%	-	-	-	-	-	-	-	-	-	-	-	-
BOTTOM 2 BOX	35	24	0	0	0	11	31	F 35	5	30	0	0	0	0	0	0	0	0	0	0	0	0
BOTTOW 2 BOX	40.0%	47.0%	-	-	-	30.0%	44.0%	40.0%	33.0%	41.0%	-	-	-	-	-	-	-	-	-	-	-	-
							E															
Mean	3	2.9	-	-	-	3.2	2.8	3 F	3.3	2.9	,	-	-	-	-	-	-	-	-	-	-	-
Std. Dev.	1.4	1.3	-	-	-	1.4	1.3	1.4	1.5	1.3	-	-	-	-	-	-	-	-	-	-	-	-
Std. Err.	0.1	0.2	-	-	-	0.2	0.2	0.1	0.4	0.2	-	-	-	-	-	-	-	-	-	-	-	-
							· ·															

Statistics:

Overlap formulae used


- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company provides access to support programmes and resources to help you improve quality of life

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job tit	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		Α	В	С	D	E	F	G	Н	_	J	K	L	М	N	0	Р	Q	R	S	T	U
									4.5	70												
Base: Patient charity groups Patient/Carers	88 10	51	0	0	0	37 8	71	88 10	15 4	73 6	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	11.0%	4.0%	-	0	0	22.0%	8 11.0%	11.0%	27.0%	8.0%	0	0	0	-	0	0		0	0	0	-	0
	11.0%	4.0%	-	-	-	AFG	11.0%	11.0% A	27.0%	8.0%	-	-	-	-	-	-	-	-	-	-	-	-
4	21	14	0	0	0	7 AFG	16	21	3	18	0	0	0	0	0	0	0	0	0	0	0	0
[*	24.0%	27.0%	-	-	-	19.0%	23.0%	24.0%	20.0%	25.0%	-	-	-	-	-	-	-	-	-	-	-	-
3	18	10	0	0	0	8	14	18	3	15	0	0	0	0	0	0	0	0	0	0	0	0
	20.0%	20.0%	-	-	-	22.0%	20.0%	20.0%	20.0%	21.0%	-	-	-	=	-	-	-	-	-	-	-	=
			_										_			_		_	_	_	_	
2	16	12	0	0	0	4	14	16	2	14	0	0	0	0	0	0	0	0	0	0	0	0
	18.0%	24.0%	-	-	-	11.0%	20.0%	18.0%	13.0%	19.0%	-	-	-	-	-	-	-	-	-	-	-	-
Strongly disagree 1	17	12	0	0	0	5	13	17	1	16	0	0	0	0	0	0	0	0	0	0	0	0
	19.0%	24.0%	-	-	9	14.0%	18.0%	19.0%	7.0%	22.0%	9	-	=	-	-	-	÷	9	-	-	=	-
Don't know or NA	6	1	0	0	0	5	6	6	2	4	0	0	0	0	0	0	0	0	0	0	0	0
	7.0%	2.0%	-	-	-	14.0%	8.0%	7.0%	13.0%	5.0%	-	-	-	-	-	-	-	-	-	-	-	-
						Α	Α	Α														
Sigma	88	51	0	0	0	37	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
	100.0%	100.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Commence																						
TOP 2 BOX	31	16	0	0	0	15	24	31	7	24	0	0	0	0	0	0	0	0	0	0	0	0
TOP 2 BOX	35.0%	31.0%	-	-	-	41.0%	34.0%	35.0%	47.0%	33.0%	-	-	-	-	-	-	-	-	-	-	-	-
	33.070	31.0%	-	-	-	41.0%	34.076	33.076	47.070	33.070			-		-		-		-	-	-	
BOTTOM 2 BOX	33	24	0	0	0	9	27	33	3	30	0	0	0	0	0	0	0	0	0	0	0	0
	38.0%	47.0%	-	-	-	24.0%	38.0%	38.0%	20.0%	41.0%	-	-	-	-	-	-	-	-	-	-	-	-
		EG					E	E						1								
Mean	2.9	2.6	-	-	-	3.3	2.9	2.9	3.5	2.8	-	-	-	-	-	-	-	-	-	-	-	-
Std. Dev.	1.3	1.2	-	-	-	AFG 1.4	1.3	A 1.3	1.3	1.3	-	_	-	-	-	-	-	_	-	_	-	-
Stu. Dev.	1.3	1.2	-	-	-	1.4	1.3	1.5	1.3	1.3	-	<u> </u>	-	 	-	-	-	<u> </u>	-	-	-	
Std. Err.	0.1	0.2	-	-	-	0.2	0.2	0.1	0.4	0.2	-	-	-	-	-	-	-	-	-	-	-	-
		1																				

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - Everything the company does begin with an understanding of your needs and experiences

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		Α	В	С	D	E	F	G	Н	I	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Patient charity groups Patient/Carers	88	51	0	0	0	37	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	11	3	0	0	0	8	10	11	3	8	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	12.0%	6.0%	-	-	-	22.0%	14.0%	12.0%	20.0%	11.0%	-	-	-	-	-	-	-	-	-	-	-	-
	12.076	0.076				AG	A	12.0% A	20.076	11.0%					_	-		_				+
4	13	5	0	0	0	8	11	13	3	10	0	0	0	0	0	0	0	0	0	0	0	0
,	15.0%	10.0%	-	-	-	22.0%	15.0%	15.0%	20.0%	14.0%	-	-	-	-	-	-	-	-	-	-	-	-
2	18	10	0		0		13	10	5	13		0	0			0			0	0	0	
3	20.0%	20.0%	0	0	0	8 22.0%	18.0%	18 20.0%	33.0%	18.0%	0		0	0	0	0	0	0	0	-	0	0
	20.0%	20.0%	-	-	-	22.0%	18.0%	20.0%	33.0%	18.0%	-	-	-	-	-	-	-	-	-	-	-	-
2	20	17	0	0	0	3	17	20	3	17	0	0	0	0	0	0	0	0	0	0	0	0
	23.0%	33.0%	-	-	-	8.0%	24.0%	23.0%	20.0%	23.0%	-	-	-	-	-	-	-	-	-	-	-	-
		EG					E	E														
Strongly disagree 1	24	16	0	0	0	8	18	24	0	24	0	0	0	0	0	0	0	0	0	0	0	0
	27.0%	31.0%	-	-	-	22.0%	25.0%	27.0%	-	33.0%	-	-	-	-	-	-	-	-	-	-	-	-
										Н												
Don't know or NA	2	0	0	0	0	2	2	2	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	2.0%	-	-	-	-	5.0%	3.0%	2.0%	7.0%	1.0%	-	-	-	-	-	-	-	-	-	-	-	-
Sigma	88	51	0	0	0	37	71	88	15	73	0	0	0	0	0	0	0	0	0	0	0	0
	100.0%	100.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Summary TOP 2 BOX	24	8	0	0	0	16	21	24	6	18	0	0	0	0	0	0	0	0	0	0	0	0
TOP 2 BOX	27.0%	16.0%	-	-	-	43.0%	30.0%	27.0%	40.0%	25.0%	-	-	-	-	-	-	-	-	-	-	-	- 0
	27.0%	10.0%	-	-	-	43.0% AFG	30.0% A	27.0% A	40.0%	25.0%	-	-	-	-	-	-	-	-	-	-	-	+
BOTTOM 2 BOX	44	33	0	0	0	11	35	44	3	41	0	0	0	0	0	0	0	0	0	0	0	0
	50.0%	65.0%	-	-	-	30.0%	49.0%	50.0%	20.0%	56.0%	-	-	-	-	-	-	-	-	-	-	-	-
		EFG					E	E		Н												
Mean	2.6	2.3	-	-	-	3.1	2.7	2.6	3.4	2.5	-	-		-	-	-	-	-	-	-	-	-
						AFG	Α	Α	1*													I
Std. Dev.	1.4	1.2	-	-	-	1.5	1.4	1.4	1.1	1.4	-	-	-	-	-	-	-	-	-	-	-	-
Std. Err.	0.1	0.2	_	-	-	0.2	0.2	0.1	0.3	0.2	_	_	_	_	-		-	_	_	_	-	-
July Ell.	0.1	0.2				0.2	0.2	0.1	0.5	0.2		1	-			1					_	

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - The company helps empower you to help other patients and their families

Total Patient or Suppliers Pharma HCP Pure patient Patients only Patient Very Less Small Medium Large Global Europe North and Asia Africa South Australasia Department						Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			Job tit	tle/level
See Patient charity groups Patient/Career See Si		Total	Health	Suppliers	Pharma		(not part of any other	Patients only	Health Charity and	Very	Less				Global	Europe	North and Central				Australasia	Department Head or	
13 5 0 0 0 8 12 13 5 8 0 0 0 0 0 0 0 0 0			А	В	С	D	Е	F	G	Н	I	J	К	L	М	N	0	Р	Q	R	S	Т	U
13 5 0 0 0 8 12 13 5 8 0 0 0 0 0 0 0 0 0	Passa Patient sharity groups Patient/Carors	00	F1	0	0	0	27	71	00	15	72	0	0	0	0	0	0	0	0	0	0	0	0
15 0/8 10 0/8 - - - 22 0/8 17 0/8 15 0/8 33 0/8 11 0/8 - - - - - - - - -				-									-				-					-	0
4	Strongly agree 5																						-
180% 120% 120% 120% 120% 120% 120% 120% 130% 130% 130% 130% 120%		13.076	10.076			_	22.0%	17.0/6	13.076	33.076	11.076	-	-	-		-		-		_	_	-	
Second Parison	4	16	11	0	0	0	5	8	16	2	14	0	0	0	0	0	0	0	0	0	0	0	0
3		18.0%	22.0%	-	-	-	14.0%	11.0%	18.0%	13.0%	19.0%	-	-	-	-	-	-	-	-	-	-	-	-
200% 22.0%			F						F														
2	3			0	0	0				,		0	0	0	0	0	0	0	0	0	0	0	0
Strongly disagred 14		20.0%	22.0%	-	-	-	19.0%	23.0%	20.0%	20.0%	21.0%	-	-	-	-	-	-	-	-	-	-	-	-
Strongly disagree 1 14 10 0 0 0 0 4 9 14 1 13 0 0 0 0 0 0 0 0 0		20																_				_	-
Strongly disagree 1	2			-								-		-	-	-	_		-		-	-	0
Strongly disagree 1 14 10 0 0 0 4 9 14 1 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		23.0%	27.0%	-	-	-	16.0%		23.0%	13.0%	25.0%	-	-	-	-	-	-	-	-	-	-	-	-
Strick 16.0% 20.0% - - - 11.0% 13.0% 16.0% 7.0% 18.0% - - - - - - - - -	Strongly disagree 1	14	10	0	0	0	4	_	14	1	13	0	0	0	0	0	0	0	0	0	0	0	0
8.0% - - - 19.0% 10.0% 8.0% 13.0% 7.0% - - - - - - - - -		16.0%	20.0%	-	-	-	11.0%	13.0%	16.0%	7.0%	18.0%	-	-	-	-	-	-	=	-	-	-	-	-
Sigma Sigm	Don't know or NA	7	0	0	0	0	7	7	7	2	5	0	0	0	0	0	0	0	0	0	0	0	0
Sigma 88 51 0 0 0 37 71 88 15 73 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		8.0%	-	-	-	-	19.0%	10.0%	8.0%	13.0%	7.0%	-	-	-	-	-	-	-	-	-	-	-	-
10.0% 10.0% 0.0% 0.0% 0.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 0.0%							AFG	Α	Α														
Sumary TOP 2 BOX 33.0% 34	Sigma			0									0	0	0	0					0		0
TOP 2 BOX 29 16 0 0 0 13 20 29 7 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		100.0%	100.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
TOP 2 BOX 29	Summany																						
Std. Dev. Std.		29	16	0	0	0	13	20	29	7	22	0	0	0	0	0	0	0	0	0	0	0	0
BOTTOM 2 BOX 34	101 2 80%																			-			-
39.0% 47.0% 27.0% 39.0% 39.0% 20.0% 42.0%		33.070	31.070				33.070	20.070	33.070	17.070	30.070												+
Mean 2.9 2.7 3.2 2.9 2.9 3.6 2.8	BOTTOM 2 BOX	34	24	0	0	0	10	28			31	0	0	0	0	0	0	0	0	0	0	0	0
Mean 2.9 2.7 3.2 2.9 2.9 3.6 2.8		39.0%	47.0%	-	-	-	27.0%	39.0%	39.0%	20.0%	42.0%	-	-	-	-	-	-	-	-	-	-	-	-
Std. Dev. 13 1.3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2																							
Std. Dev. 1.3 1.3 - 1.4 1.3 1.3 1.4 1.3 - 1.5 1.5 1.4 1.3 1.3 1.4 1.3 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	Mean	2.9	2.7	-	-	-	3.2	2.9	2.9		2.8	-	-	-	-	-	-	-	-	-	-	-	-
	Std. Dev.	1.3	1.3	-	-	-	1.4	1.3	1.3		1.3	-	-	-	-	-	-	-	-	-	-	-	-
Std. Err. 0.1 0.2 - - - 0.3 0.2 0.1 0.4 0.2 - - - - - - - - -																							
	Std. Err.	0.1	0.2	-	-	-	0.3	0.2	0.1	0.4	0.2	-	-	-	-	-	-	-	-	-	-	-	-

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

tient Centricity Global Benchmarks

Table: 90

Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - GRID SUMMARY

	helps make sure that the people who need medicines have access to them	communicat es with care and compassion, transparent and unbiased information on diseases, treatment options, and available resources	provides easy-to- understand and convenient information in plain language because they understand that "words matter"	helps you gain affordable access to their medications	The company equips you to make informed choices about healthcare and treatment options	listens and responds to your feedback with respect and humility	partners with you to innovate and measure impact and outcomes that are important to you	provides access to support programmes and resources to help you improve quality of life	the company does begin with an understandin g of your needs and experiences	empower you to help other patients and their families
	Α	В	С	D	E	F	G	Н	l	J
Base: Patient charity groups Patient/Carers	88	88	88	88	88	88	88	88	88	88
Strongly agree 5	10	7	15	13	12	14	15	10	11	13
	11.0%	8.0%	17.0%	15.0%	14.0%	16.0%	17.0%	11.0%	12.0%	15.0%
			В	В		В	В			В
4	18	21	20	18	14	13	16	21	13	16
	20.0%	24.0%	23.0%	20.0%	16.0%	15.0%	18.0%	24.0%	15.0%	18.0%
2	20	I	22	45	22	2.4	47	F	40	40
3	20	21	22	15	23	24	17	18	18	18
	23.0%	24.0%	25.0%	17.0%	26.0%	27.0%	19.0%	20.0%	20.0%	20.0%
2	18	21	14	15	20	15	22	16	20	20
	20.0%	24.0%	16.0%	17.0%	23.0%	17.0%	25.0%	18.0%	23.0%	23.0%
Strongly disagree 1	15	15	12	22	14	15	13	17	24	14
	17.0%	17.0%	14.0%	25.0%	16.0%	17.0%	15.0%	19.0%	27.0%	16.0%
				ACG					BCEFGJ	
Don't know or NA	7	3	5	5	5	7	5	6	2	7
	8.0%	3.0%	6.0%	6.0%	6.0%	8.0%	6.0%	7.0%	2.0%	8.0%
								1		
Sigma	88	88	88	88	88	88	88	88	88	88

	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary										
TOP 2 BOX	28	28	35	31	26	27	31	31	24	29
	32.0%	32.0%	40.0%	35.0%	30.0%	31.0%	35.0%	35.0%	27.0%	33.0%
			EI							
BOTTOM 2 BOX	33	36	26	37	34	30	35	33	44	34
	38.0%	41.0%	30.0%	42.0%	39.0%	34.0%	40.0%	38.0%	50.0%	39.0%
				С					ACEFHJ	
Mean	2.9	2.8	3.1	2.8	2.9	3	3	2.9	2.6	2.9
			BEI		I	I	1			I
Std. Dev.	1.3	1.2	1.3	1.4	1.3	1.3	1.4	1.3	1.4	1.3
Std. Err.	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G/H/I/J Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G/H/I/J Minimum Base: 5 (**), Small Base: 15 (*)



Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - Top 2 Box Summary

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job ti	itle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other	Patients only	Patient Health Charity and	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		Charity				group)		Patients								America					iligilei	lower
		Α	В	С	D	E	F	G	Н	- 1	J	К	L	М	N	0	Р	Q	R	S	T	U
Base: Patient charity groups Patient/Carers	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
The company helps make sure that the people	28	11	0	0	0	17	24	28	6	22	0	0	0	0	0	0	0	0	0	0	0	0
who need medicines have access to them	32.0%	22.0%	-	-	-	46.0%	34.0%	32.0%	40.0%	30.0%	-	-	-	-	-	-	-	-	-	-	-	-
						AFG	Α	Α														
The company communicates with care and	28	12	0	0	0	16	24	28	8	20	0	0	0	0	0	0	0	0	0	0	0	0
compassion, transparent and unbiased	32.0%	24.0%	-	-	-	43.0%	34.0%	32.0%	53.0%	27.0%	-	-	-	-	-	-	-	-	-	-	-	-
information on diseases, treatment options.								Α														
The company provides easy-to-understand and	35	17	0	0	0	18	30	35	9	26	0	0	0	0	0	0	0	0	0	0	0	0
convenient information in plain language	40.0%	33.0%	-	-	-	49.0%	42.0%	40.0%	60.0%	36.0%	-	-	-	-	-	-	-	-	-	-	-	-
because they understand that 'words matter'																						
The company helps you gain affordable access	31	14	0	0	0	17	25	31	5	26	0	0	0	0	0	0	0	0	0	0	0	0
to their medications	35.0%	27.0%	-	-	-	46.0%	35.0%	35.0%	33.0%	36.0%	-	-	-	-	-	-	3	-	-	-	=	-
The company equips you to make informed	26	11	0	0	0	15	23	26	7	19	0	0	0	0	0	0	0	0	0	0	0	0
choices about healthcare and treatment	30.0%	22.0%	-	-	-	41.0%	32.0%	30.0%	47.0%	26.0%	-	-	-	-	-	-	-	-	-	-	-	-
options The company listens and responds to your	27	13	0	0	0	14	22	27	6	21	0	0	0	0	0	0	0	0	0	0	0	0
	31.0%	25.0%	-	-	-	38.0%	31.0%	31.0%	40.0%	29.0%	-	-	-	-	-	-	-	-	-	-	-	-
feedback with respect and humility	31.0%	25.0%	-	-	-	38.0%	31.0%	31.0%	40.0%	29.0%	-	-	-	-	-	-	-	-	-	-	-	+
The company partners with you to innovate	31	17	0	0	0	14	20	31	7	24	0	0	0	0	0	0	0	0	0	0	0	0
and measure impact and outcomes that are	35.0%	33.0%	-	-	-	38.0%	28.0%	35.0%	47.0%	33.0%	-	-	-	-	-	-	-	-	-	-	-	-
important to you								F														
The company provides access to support	31	16	0	0	0	15	24	31	7	24	0	0	0	0	0	0	0	0	0	0	0	0
programmes and resources to help you	35.0%	31.0%	-	-	-	41.0%	34.0%	35.0%	47.0%	33.0%	-	-	-	-	-	-	-	-	-	-	-	-
improve quality of life																						
Everything the company does begin with an	24	8	0	0	0	16	21	24	6	18	0	0	0	0	0	0	0	0	0	0	0	0
understanding of your needs and experiences	27.0%	16.0%	-	-	-	43.0%	30.0%	27.0%	40.0%	25.0%	-	-	-	-	-	-	-	-	-	-	-	-
	***					AFG	A	A														1
The company helps empower you to help other	29	16	0	0	0	13	20	29	7	22	0	0	0	0	0	0	0	0	0	0	0	0
patients and their families	33.0%	31.0%	-	-	-	35.0%	28.0%	33.0%	47.0%	30.0%	-	-	-	-	-	-	-	-	-	-	-	-
patients and their rannings	22.070	22.070				23.070		22.070		22.070												+

Statistics:

Overlap formulae used

- Column Means:


- column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: S (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)

Table of Contents



Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - Bottom 2 Box Summary

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job ti	itle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	st Senior managers o lower
		Α	В	С	D	E	F	G	Н	I	J	K	L	М	N	0	Р	Q	R	S	Т	U
Base: Patient charity groups Patient/Carers	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
The company helps make sure that the people	33	24	0	0/3	0	9	26	33	6	27	0	0	0	0	0	0	0	0	0	0	0	0
	38.0%	47.0%	-	-	-	24.0%	37.0%	38.0%	40.0%	37.0%	-	0	-	-	-	-	-	-	-	-	-	-
who need medicines have access to them	36.0%	47.0% EG	-	-	-	24.0%	57.0%	36.0%	40.0%	37.0%	-	-	-	-	-	-	-	-	-	-	-	+
The company communicates with care and	36	29	0	0	0	7	26	36	6	30	0	0	0	0	0	0	0	0	0	0	0	0
	41.0%	57.0%	-	-	-	19.0%	37.0%	41.0%	40.0%	41.0%	-	0	-	-	-	-	-	-	-	U	- 0	-
compassion, transparent and unbiased	41.0%	57.0% EFG	-	-	-	19.0%	57.0% F	41.0%	40.0%	41.0%	-	-	-	-	-	-	-	-	-	-	-	+
information on diseases, treatment options. The company provides easy-to-understand and	26	18	0	0	0	8	19	26		25	0	0	0	0	0	0	0	0	0	0	0	0
			-	-		22.0%	27.0%	30.0%	7.0%	34.0%	_	U	-		-	-		-	-	U	U	
convenient information in plain language	30.0%	35.0%	-	-	-	22.0%	27.0%	30.0%	7.0%		9	-	-	-	-	-	-	-	-	-	-	-
because they understand that 'words matter'		2.5					20			Н						-						
The company helps you gain affordable access	37	26	0	0	0	11	28	37	4	33	0	0	0	0	0	0	0	0	0	0	0	0
to their medications	42.0%	51.0%	-	-	-	30.0%	39.0%	42.0%	27.0%	45.0%	-	-	-	-	-	-	-	-	-	-	-	-
								E														
The company equips you to make informed	34	26	0	0	0	8	26	34	3	31	0	0	0	0	0	0	0	0	0	0	0	0
choices about healthcare and treatment	39.0%	51.0%	-	-	-	22.0%	37.0%	39.0%	20.0%	42.0%	-	-	-	-	-	-	-	-	-	-	-	-
options		EFG					E	E														
The company listens and responds to your	30	24	0	0	0	6	23	30	4	26	0	0	0	0	0	0	0	0	0	0	0	0
feedback with respect and humility	34.0%	47.0%	-	-	-	16.0%	32.0%	34.0%	27.0%	36.0%	-	-	-	-	-	-	-	-	-	-	-	-
		EFG					E	E														
The company partners with you to innovate	35	24	0	0	0	11	31	35	5	30	0	0	0	0	0	0	0	0	0	0	0	0
and measure impact and outcomes that are	40.0%	47.0%	-	-	-	30.0%	44.0%	40.0%	33.0%	41.0%	-	-	-	-	-	-	-	-	-	-	-	-
important to you							E															
The company provides access to support	33	24	0	0	0	9	27	33	3	30	0	0	0	0	0	0	0	0	0	0	0	0
programmes and resources to help you	38.0%	47.0%	-	-	-	24.0%	38.0%	38.0%	20.0%	41.0%	-	-	-	-	-	-	-	-	-	-	-	-
improve quality of life		EG					E	E														
everything the company does begin with an	44	33	0	0	0	11	35	44	3	41	0	0	0	0	0	0	0	0	0	0	0	0
understanding of your needs and experiences	50.0%	65.0%	-	-	-	30.0%	49.0%	50.0%	20.0%	56.0%	-	-	-	-	-	-	-	-	-	-	-	-
		EFG					E	E		Н												
The company helps empower you to help other	34	24	0	0	0	10	28	34	3	31	0	0	0	0	0	0	0	0	0	0	0	0
patients and their families	39.0%	47.0%	-	-	-	27.0%	39.0%	39.0%	20.0%	42.0%	-	-	-	-	-	-	-	-	-	-	-	-
parameter and their remines							F							1	1							1

Statistics:

Overlap formulae used

- Column Means:

- column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: S (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)

Table of Contents



Q71. Company related statements agreement 1-5 scale - Pateint centricity within relevant pharma industry - Mean Summary

					Туре				Conf	dence	Pha	rma: Company	/ size			Geo	graphical loca	ation			Job ti	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	t Senior managers or lower
		А	В	С	D	Е	F	G	Н	1	J	K	L	M	N	0	P	Q	R	S	Т	U
Base: Patient charity groups Patient/Carers	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
The company helps make sure that the people	2.9	2.5	-	-	-	3.4	2.9	2.9	3	2.9	-	-	-	-	-	-	-	-	-	-	-	- 350
who need medicines have access to them						AFG	A	A	*													+
The company communicates with care and	2.8	2.4	-	-	-	3.3	2.9	2.8	3.1	2.8	-	-	-	-	-	-	-	-	-	-	-	-
compassion, transparent and unbiased						AFG	Α	Α														
The company provides easy-to-understand and	3.1	2.9	-	-	-	3.5	3.2	3.1	3.9	3		-	-	-	-	-	-	-	-	-		-
convenient information in plain language							Α		1*													
The company helps you gain affordable access	2.8	2.6	-	-	-	3.2	2.8	2.8	3.2	2.8	-	-	-	-	-	-	-	-	-	-	-	-
to their medications						AFG		Α	*													
The company equips you to make informed	2.9	2.6	-	-	-	3.4	3	2.9	3.5	2.8	-	-	-	-	-	-	-	-	-	-	-	-
choices about healthcare and treatment						AFG	Α	Α	1*													
The company listens and responds to your	3	2.7	-	-	-	3.4	3	3	3.2	2.9	-	-	-	-	-	-	-	-	-	-	-	-
feedback with respect and humility						AFG		Α	*													
The company partners with you to innovate	3	2.9	-	-	-	3.2	2.8	3	3.3	2.9	-	-	-	-	-	-	-	-	-	-	-	-
and measure impact and outcomes that are								F	*													
The company provides access to support	2.9	2.6	-	-	-	3.3	2.9	2.9	3.5	2.8	-	-	-	-	-	-	-	-	-	-	-	-
programmes and resources to help you						AFG		Α	*													
Everything the company does begin with an	2.6	2.3	-	-	-	3.1	2.7	2.6	3.4	2.5	-	-	-	-	-	-		-	-	-		-
understanding of your needs and experiences						AFG	Α	Α	1*													
The company helps empower you to help other	2.9	2.7	-	-	-	3.2	2.9	2.9	3.6	2.8	-	-	-	-	-	-	-	-	-	-	-	-
patients and their families									1*													


Statistics: Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/k/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)
Table of Contents



Q80. Delivering patient centricity status statements agreement 1-5 scale - When companies focus on delivering the best patient outcomes, we will create the best results for patients, healthcare professionals and our companies

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		Α	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	T	U
Base: Patient groups	143	73	0	0	0	70	123	143	26	117	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	96 67.0%	51 70.0%	0 -	0 -	0 -	45 64.0%	83 67.0%	96 67.0%	17 65.0%	79 68.0%	0	0	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
4	20 14.0%	12 16.0%	0 -	0 -	0 -	8 11.0%	16 13.0%	20 14.0%	3 12.0%	17 15.0%	0 -	0 -	0 -	0 -	0 -	0 -	-	0 -	0 -	0 -	0 -	0 -
3	10 7.0%	5 7.0%	0 -	0 -	0 -	5 7.0%	9 7.0%	10 7.0%	0 -	10 9.0%	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
2	1.0%	0 -	0 -	0 -	0 -	1.0%	1 1.0%	1 1.0%	0 -	1 1.0%	0	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
Strongly disagree 1	3.0%	1 1.0%	0 -	0 -	0 -	3 4.0%	3 2.0%	4 3.0%	1 4.0%	3 3.0%	0	0	0 -	0	0	0 -	0	0 -	0	0	0 -	0 -
Don't know or NA	12 8.0%	4 5.0%	0 -	0 -	0 -	8 11.0%	9.0%	12 8.0%	5 19.0%	7 6.0%	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
Sigma	143 100.0%	73 100.0%	0	0 0.0%	0	70 100.0%	123 100.0%	143 100.0%	26 100.0%	117 100.0%	0	0	0 0.0%	0	0	0.0%	0	0.0%	0	0	0	0 0.0%
Summary																						
TOP 2 BOX	116 81.0%	63 86.0%	0 -	0 -	-	53 76.0%	99 80.0%	116 81.0%	20 77.0%	96 82.0%	-	0 -	-	0 -	-	-	-	0 -	0 -	0 -	0 -	0 -
BOTTOM 2 BOX	5 3.0%	1 1.0%	0 -	0 -	0 -	4 6.0%	4 3.0%	5 3.0%	1 4.0%	4 3.0%	0	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
Mean	4.5	4.6	-	-	-	4.5	4.6	4.5	4.7	4.5	-	-	-	-	-	-	-	-	-	-	-	-
Std. Dev.	0.9	0.7	-	-	-	1.1	0.9	0.9	0.9	0.9	-	-	-	-	-	-	-	-	-	-	-	-
Std. Err.	0.1	0.1	-	-	-	0.1	0.1	0.1	0.2	0.1	-	-	-	_	_	_	-	-	-	_	-	-

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q80. Delivering patient centricity status statements agreement 1-5 scale - Finding the intersection where optimal outcomes for patients, healthcare professionals and pharma companies all coincide is the crucial skill in the pharma, biotech and medical device industry

					Туре				Confi	dence	Pha	rma: Company	size			Gen	graphical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		Α	В	С	D	E	F	G	Н	ı	J	K	L	М	N	0	Р	Q	R	S	T	U
Base: Patient groups	143	73	0	0	0	70	123	143	26	117	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	83 58.0%	38 52.0%	0 -	0 -	0 -	45 64.0%	72 59.0%	83 58.0%	16 62.0%	67 57.0%	0	0	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
4	27 19.0%	15 21.0%	0 -	0 -	-	12 17.0%	24 20.0%	27 19.0%	6 23.0%	21 18.0%	0	0	0 -	-	0 -	0 -	-	0 -	-	0 -	0 -	0 -
3	14 10.0%	8 11.0%	0 -	0 -	0 -	6 9.0%	13 11.0%	14 10.0%	1 4.0%	13 11.0%	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
2	5 3.0%	4 5.0%	0 -	0 -	0 -	1 1.0%	3 2.0%	5 3.0%	1 4.0%	4 3.0%	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
Strongly disagree 1	5 3.0%	3.0%	0 -	0 -	0 -	3 4.0%	5 4.0%	5 3.0%	0	5 4.0%	0	0	0 -	0	0	0	0	0	0	0	0 -	0
Don't know or NA	9 6.0%	6 8.0%	0 -	0 -	0 -	3 4.0%	6 5.0%	9 6.0%	2 8.0%	7 6.0%	0	0 -	0 -	0 -	0 -	0 -	0	0 -	0	0 -	0 -	0 -
Sigma	143 100.0%	73 100.0%	0	0	0	70 100.0%	123 100.0%	143 100.0%	26 100.0%	117 100.0%	0	0 0.0%	0 0.0%	0	0	0.0%	0	0	0	0	0 0.0%	0.0%
Summary																						
TOP 2 BOX	110 77.0%	53 73.0%	0 -	0 -	-	57 81.0%	96 78.0%	110 77.0%	22 85.0%	88 75.0%	-	0 -	0 -	-	0 -	-	0 -	0 -	-	0 -	0 -	0 -
ВОТТОМ 2 ВОХ	10 7.0%	6 8.0%	0 -	0 -	0 -	4 6.0%	8 7.0%	10 7.0%	1 4.0%	9 8.0%	0	0	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
Mean	4.3	4.2	-	-	=	4.4	4.3	4.3	4.5	4.3	-	-	-	=	-	-	-	-	=	-	-	-
Std. Dev.	1.1	1.1	-	-	-	1	1.1	1.1	0.8	1.1	-	-	-	-	-	-	-	-	-	-	-	-
Std. Err.	0.1	0.1	-	-	-	0.1	0.1	0.1	0.2	0.1	-	-	-	_	-	_		-	_	_	-	-

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q80. Delivering patient centricity status statements agreement 1-5 scale - Focusing on patients" needs leads to better business outcomes

					Туре				Confi	dence	Pha	ırma: Company	size			Geo	graphical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		Α	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Patient groups	143	73	0	0	0	70	123	143	26	117	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	96	52	0	0	0	44	85	96	18	78	0	0	0	0	0	0	0	0	0	0	0	0
strongly agree s	67.0%	71.0%	-	-	-	63.0%	69.0%	67.0%	69.0%	67.0%	-	-	-	-	-	-	-	-	-	-	-	-
4	16	9	0	0	0	7	14	16	1	15	0	0	0	0	0	0	0	0	0	0	0	0
	11.0%	12.0%	-	-	-	10.0%	11.0%	11.0%	4.0%	13.0%		-	-	-	-	-	=	-	-	-	-	-
3	9	3	0	0	0	6	7	9	2	7	0	0	0	0	0	0	0	0	0	0	0	0
	6.0%	4.0%	-	-	-	9.0%	6.0%	6.0%	8.0%	6.0%	-	-	-	-	-	-	÷	-	-	-		-
2	1	1	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0
	1.0%	1.0%	-	-	-	-	1.0%	1.0%	9	1.0%	-	-	-	-	-	-	÷	-	-	-		-
Strongly disagree 1	7	4	0	0	0	3	4	7	1	6	0	0	0	0	0	0	0	0	0	0	0	0
	5.0%	5.0%	-	-	-	4.0%	3.0%	5.0% F	4.0%	5.0%	-	-	-	-	-	-	-	-	-	-	-	-
Don't know or NA	14	4	0	0	0	10	12	14	4	10	0	0	0	0	0	0	0	0	0	0	0	0
	10.0%	5.0%	-	-	-	14.0%	10.0%	10.0%	15.0%	9.0%	-	-	-	-	-	-	÷	-	-	-		-
Sigma	143	73	0	0	0	70	123	143	26	117	0	0	0	0	0	0	0	0	0	0	0	0
	100.0%	100.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Summary																						
TOP 2 BOX	112	61	0	0	0	51	99	112	19	93	0	0	0	0	0	0	0	0	0	0	0	0
	78.0%	84.0%	-	-	-	73.0%	80.0% E	78.0%	73.0%	79.0%	-	-	-	-	-	-	-	-	-	-	-	-
BOTTOM 2 BOX	8	5	0	0	0	3	5	8	1	7	0	0	0	0	0	0	0	0	0	0	0	0
	6.0%	7.0%	-	-	-	4.0%	4.0%	6.0% F	4.0%	6.0%	-	-	-	-	-	-	-	-	-	-	-	-
Mean	4.5	4.5	-	-	-	4.5	4.6	4.5	4.6	4.5	-	-	-	-	-	-	-	-	-	-	-	-
Std. Dev.	1	1.1	-	-	-	1	G 0.9	1	1	1.1	i	-	-	-	-	-	-	-	-	-	-	-
																						↓
Std. Err.	0.1	0.1	-	-	-	0.1	0.1	0.1	0.2	0.1	-	-	-	-	-	-	-	-	-	-	-	-

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q80. Delivering patient centricity status statements agreement 1-5 scale - A long-term focus is key to success with patient-centric efforts

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	tion			Job ti	itle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	
		А	В	С	D	E	F	G	Н	ı	J	К	L	M	N	0	Р	Q	R	S	Т	U
Base: Patient groups	143	73	0	0	0	70	123	143	26	117	0	0	0	0	0	0	0	0	0	0	0	0
	86	42	0	0	0	44	78	86	17	69	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	60.0%	58.0%	-	-	-	63.0%	63.0% G	60.0%	65.0%	59.0%	-	-	-	-	-	-	-	-	-	-	-	-
4	38	19	0	0	0	19	31	38	7	31	0	0	0	0	0	0	0	0	0	0	0	0
	27.0%	26.0%	-	-	-	27.0%	25.0%	27.0%	27.0%	26.0%	-	-	-	-	-	-	-	-	-	-	-	-
3	6	4	0	0	0	2	6	6	0	6	0	0	0	0	0	0	0	0	0	0	0	0
	4.0%	5.0%	9	-	-	3.0%	5.0%	4.0%	=	5.0%	-	-	÷	-	-	-	÷	-	-	-	п	-
2	3	2	0	0	0	1	2	3	0	3	0	0	0	0	0	0	0	0	0	0	0	0
	2.0%	3.0%	-	-	-	1.0%	2.0%	2.0%	-	3.0%	-	-	-	-	-	-	-	-	-	-	-	-
Strongly disagree 1	2	1	0	0	0	1	1	2	0	2	0	0	0	0	0	0	0	0	0	0	0	0
	1.0%	1.0%	-	-	-	1.0%	1.0%	1.0%	-	2.0%	-	-	-	-	-	-		-	-	-	-	-
Don't know or NA	8	5	0	0	0	3	5	8	2	6	0	0	0	0	0	0	0	0	0	0	0	0
	6.0%	7.0%	-	-	=	4.0%	4.0%	6.0% F	8.0%	5.0%	-	-	=	-	-	-	=	-	-	-	=	-
Sigma	143	73	0	0	0	70	123	143	26	117	0	0	0	0	0	0	0	0	0	0	0	0
	100.0%	100.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Summary																						
TOP 2 BOX	124	61	0	0	0	63	109	124	24	100	0	0	0	0	0	0	0	0	0	0	0	0
	87.0%	84.0%	-	-	-	90.0%	89.0%	87.0%	92.0%	85.0%	-	-	1	-	-	-	-	-	-	-	-	-
BOTTOM 2 BOX	5	3	0	0	0	2	3	5	0	5	0	0	0	0	0	0	0	0	0	0	0	0
	3.0%	4.0%	-	-	-	3.0%	2.0%	3.0%	-	4.0%	-	-	-	-	-	-	-	-	-	-	-	-
Mean	4.5	4.5	-	-	-	4.6	4.6	4.5	4.7	4.5	-	-	-	-	-	-	-	-	-	-	-	-
Std. Dev.	0.8	0.9	-	-	-	0.8	0.7	0.8	0.5	0.9	-	-	-	-	-	-	-	-	-	-	=	-
Std. Err.	0.1	0.1	-	-	-	0.1	0.1	0.1	0.1	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Statistics:																						

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q80. Delivering patient centricity status statements agreement 1-5 scale - Pharma companies can act in the best interest of patients but I don"t believe we can achieve long-term business success by doing so

					Туре				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Patient groups	143	73	0	0	0	70	123	143	26	117	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	12 8.0%	7 10.0%	0 -	0 -	0 -	5 7.0%	8 7.0%	12 8.0%	3 12.0%	9 8.0%	0	0	0 -	0 -	0	0 -	0	0	0	0	0	0 -
4	13 9.0%	5 7.0%	0 -	0 -	0 -	8 11.0%	12 10.0%	13 9.0%	2 8.0%	11 9.0%	0	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
3	21 15.0%	9 12.0%	0 -	0 -	0 -	12 17.0%	17 14.0%	21 15.0%	5 19.0%	16 14.0%	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
2	24 17.0%	15 21.0%	0 -	0 -	0 -	9 13.0%	21 17.0%	24 17.0%	7 27.0%	17 15.0%	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
Strongly disagree 1	62 43.0%	35 48.0%	0 -	0 -	0 -	27 39.0%	55 45.0%	62 43.0%	7 27.0%	55 47.0%	0	0	0 -	0	0	0 -	0	0	0	0	0	0 -
Don't know or NA	11 8.0%	3.0%	0 -	0 -	0 -	9 13.0% AFG	10 8.0% A	11 8.0% A	2 8.0%	9 8.0%	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
Sigma	143 100.0%	73 100.0%	0.0%	0.0%	0.0%	70	123 100.0%	143 100.0%	26 100.0%	117 100.0%	0.0%	0.0%	0.0%	0.0%	0	0 0.0%	0.0%	0	0	0	0	0 0.0%
Summary																						
TOP 2 BOX	25 17.0%	12 16.0%	-	0 -	-	13 19.0%	20 16.0%	25 17.0%	5 19.0%	20 17.0%	-	-	-	-	0 -	-	-	-	0 -	0 -	-	-
BOTTOM 2 BOX	86 60.0%	50 68.0% EG	0 -	0 -	0 -	36 51.0%	76 62.0% F	86 60.0%	14 54.0%	72 62.0%	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
Mean	2.2	2.1	-	-	-	2.3	2.1	2.2	2.5	2.1	-	-	-	-	-	-	-	-	-	-	-	-
Std. Dev.	1.4	1.3	-	-	-	1.4	1.3	1.4	1.4	1.4	-	-	-	-	-	-	-	-	-	-	-	-
Std. Err.	0.1	0.2	-	-	-	0.2	0.1	0.1	0.3	0.1	1	-	-	-	-	-	-	-	-	-	-	-

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q80. Delivering patient centricity status statements agreement 1-5 scale - Pharma companies must serve shareholders first

					Туре				Confi	dence	Pha	ırma: Company	, size			Geo	graphical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	нср	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	M	N	0	Р	Q	R	S	Т	U
Base: Patient groups	143	73	0	0	0	70	123	143	26	117	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	21 15.0%	12 16.0%	0 -	0 -	0 -	9 13.0%	17 14.0%	21 15.0%	4 15.0%	17 15.0%	0	0 -	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -
4	13 9.0%	8 11.0%	0 -	0 -	0 -	5 7.0%	10 8.0%	13 9.0%	3 12.0%	10 9.0%	-	0 -	0 -	0 -	0 -	0 -	-	0 -	0 -	0 -	0 -	0 -
3	24 17.0%	16 22.0%	0 -	0 -	0 -	8 11.0%	19 15.0%	24 17.0%	4 15.0%	20 17.0%	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
2	19 13.0%	8 11.0%	0 -	0 -	0 -	11 16.0%	17 14.0%	19 13.0%	4 15.0%	15 13.0%	0	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
Strongly disagree 1	62 43.0%	27 37.0%	0 -	0 -	0 -	35 50.0%	57 46.0%	62 43.0%	11 42.0%	51 44.0%	0	0 -	0 -	0	0	0 -	0	0	0 -	0 -	0 -	0 -
Don't know or NA	4 3.0%	3.0%	0 -	0 -	0 -	3.0%	3 2.0%	4 3.0%	0	4 3.0%	0	0 -	0 -	0 -	0 -	0 -	0	0 -	0 -	0 -	0 -	0 -
Sigma	143 100.0%	73 100.0%	0	0	0	70 100.0%	123 100.0%	143 100.0%	26 100.0%	117 100.0%	0	0	0 0.0%	0	0	0 0.0%	0	0	0 0.0%	0 0.0%	0 0.0%	0 0.0%
Summary																						
TOP 2 BOX	34 24.0%	20 27.0%	0 -	0 -	0 -	14 20.0%	27 22.0%	34 24.0%	7 27.0%	27 23.0%	0	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
ВОТТОМ 2 ВОХ	81 57.0%	35 48.0%	0 -	0 -	0 -	46 66.0% AG	74 60.0% AG	81 57.0% A	15 58.0%	66 56.0%	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -	0 -
Mean	2.4	2.6 F	-	-	-	2.1	2.3	2.4	2.4	2.4	-	-	-	-	-	-	-	-	-	-	-	-
Std. Dev.	1.5	1.5	-	-	-	1.5	1.5	1.5	1.5	1.5	-	-	-	-	-	-	-	-	-	-	-	-
Std. Err.	0.1	0.2	-	-	-	0.2	0.1	0.1	0.3	0.1	-	-	8	3	-	-	-	-		-	-	-

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)



Q80. Delivering patient centricity status statements agreement 1-5 scale - Pharma''s goals are misaligned with serving patients optimally

					Туре				Confi	dence	Pha	rma: Company	size			Gen	graphical loca	ation			loh tit	tle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia		
		А	В	С	D	E	F	G	Н	ı	J	К	L	М	N	0	Р	Q	R	S	Т	U
Base: Patient groups	143	73	0	0	0	70	123	143	26	117	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	53	30	0	0	0	23	45	53	5	48	0	0	0	0	0	0	0	0	0	0	0	0
Strongly agree 5	37.0%	41.0%	-	-	-	33.0%	37.0%	37.0%	19.0%	41.0%	-	-	-	-	-	-	-	-	-	-	-	-
	37.070	112.070				33.070	37.070	37.070	13.070	Н												1
4	32	13	0	0	0	19	27	32	8	24	0	0	0	0	0	0	0	0	0	0	0	0
	22.0%	18.0%	-	-	-	27.0%	22.0%	22.0%	31.0%	21.0%		-	-	-	-	-	-	-	-	-	-	-
3	29	18	0	0	0	11	24	29	8	21	0	0	0	0	0	0	0	0	0	0	0	0
ľ	20.0%	25.0%	-	-	-	16.0%	20.0%	20.0%	31.0%	18.0%	-	-	-	-	-	-	-	-	-	-	-	-
2	11	5	0	0	0	6	11	11	3	8	0	0	0	0	0	0	0	0	0	0	0	0
	8.0%	7.0%	-	-	-	9.0%	9.0%	8.0%	12.0%	7.0%	-	-	-	-	-	-	=	-	-	-	-	-
Strongly disagree 1	8	5	0	0	0	3	8	8	0	8	0	0	0	0	0	0	0	0	0	0	0	0
0,11011	6.0%	7.0%	-	-	-	4.0%	7.0%	6.0%		7.0%	-	-	-	-	-	-	-	-	-	-	-	-
Don't know or NA	10	2	0	0	0	8	8	10	2	8	0	0	0	0	0	0	0	0	0	0	0	0
	7.0%	3.0%	-	-	-	11.0%	7.0%	7.0%	8.0%	7.0%	-	-	-	-	-	-	-	-	-	-	-	-
						AF		A														
Sigma	143	73	0	0	0	70	123	143	26	117	0	0	0	0	0	0	0	0	0	0	0	0
	100.0%	100.0%	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Summary																						
TOP 2 BOX	85	43	0	0	0	42	72	85	13	72	0	0	0	0	0	0	0	0	0	0	0	0
	59.0%	59.0%	-	-	-	60.0%	59.0%	59.0%	50.0%	62.0%	-	-	-	-	-	-	-	-	-	-	-	-
BOTTOM 2 BOX	19	10	0	0	0	9	19	19	3	16	0	0	0	0	0	0	0	0	0	0	0	0
BOTTOW 2 BOX	13.0%	14.0%	-	-	-	13.0%	15.0%	13.0%	12.0%	14.0%	-	-	-	-	-	-	-	-	-	-	-	-
Mean	3.8	3.8	-	-	-	3.9	3.8	3.8	3.6	3.9	-	_	_	_	_	_		_	_	_	-	_
ivican	3.8	3.0	-	-	-	3.3	3.0	3.0	3.0	3.3	-	-	-	<u> </u>	-			<u> </u>	-		-	
Std. Dev.	1.2	1.3	-	-	=	1.2	1.3	1.2	1	1.3	-	-	-	-	-	-	-	-	-	-	-	-
Std. Err.	0.1	0.1	-	-	-	0.1	0.1	0.1	0.2	0.1	-	-	-	-	-	-	-	-	-	-	-	-
		1			†																	1

Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U

Minimum Base: 5 (**), Small Base: 15 (*)

tient Centricity Global Benchmarks

Table: 101

Q80. Delivering patient centricity status statements agreement 1-5 scale - GRID SUMMARY

	When companies focus on delivering the best patient outcomes, we will create the best results for patients, healthcare professionals and our companies	pharma, biotech and medical device industry	Focusing on patients" needs leads to better business outcomes	A long-term focus is key to success with patient-centric efforts	of patients but I don"t believe we can achieve long-term business success by doing so	shareholders first	Pharma''s goals are misaligned with serving patients optimally
	A	В	С	D	E	F	G
Base: Patient groups	143	143	143	143	143	143	143
Strongly agree 5	96	83	96	86	12	21	53
	67.0%	58.0%	67.0%	60.0%	8.0%	15.0%	37.0%
	EFG	EFG	EFG	EFG			EF
4	20	27	16	38	13	13	32
	14.0%	19.0%	11.0%	27.0%	9.0%	9.0%	22.0%
		CEF		ACEF			ACEF
3	10	14	9	6	21	24	29
	7.0%	10.0%	6.0%	4.0%	15.0%	17.0%	20.0%
					ACD	ACD	ABCD
2	1	5	1	3	24	19	11
	1.0%	3.0%	1.0%	2.0%	17.0%	13.0%	8.0%
					ABCDG	ABCD	ACD
Strongly disagree 1	4	5	7	2	62	62	8
	3.0%	3.0%	5.0%	1.0%	43.0%	43.0%	6.0%

			D		ABCDG	ABCDG	
Don't know or NA	12	9	14	8	11	4	10
	8.0%	6.0%	10.0%	6.0%	8.0%	3.0%	7.0%
	F		F				
Sigma	143	143	143	143	143	143	143
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Summary							
TOP 2 BOX	116	110	112	124	25	34	85
	81.0%	77.0%	78.0%	87.0%	17.0%	24.0%	59.0%
	EFG	EFG	EFG	BCEFG			EF
BOTTOM 2 BOX	5	10	8	5	86	81	19
	3.0%	7.0%	6.0%	3.0%	60.0%	57.0%	13.0%
					ABCDG	ABCDG	ACD
Mean	4.5	4.3	4.5	4.5	2.2	2.4	3.8
	EFG	EFG	EFG	EFG			EF
Std. Dev.	0.9	1.1	1	0.8	1.4	1.5	1.2
Std. Err.	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Jiu. Lii.	0.1	0.1	0.1	0.1	0.1	0.1	0.1

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G Minimum Base: 5 (**), Small Base: 15 (*)

- Column Proportions:

Columns Tested (5%): A/B/C/D/E/F/G Minimum Base: 5 (**), Small Base: 15 (*)



Q80. Delivering patient centricity status statements agreement 1-5 scale - Top 2 Box Summary

					Туре				Confi	dence	Pha	rma: Company	/ size			Geo	graphical loca	ition			Job ti	itle/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	t Senior managers or lower
		Α	В	С	D	E	F	G	Н	1	J	K	L	M	N	0	Р	Q	R	S	Т	U
Base: Patient groups	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
When companies focus on delivering the best	116	63	336	0	100	53	99	116	20	96	100	79	0	0	0	159	95	0	0	32	0	330
	81.0%	86.0%	-	-	-	76.0%	80.0%	81.0%	77.0%	82.0%	-	U	-	-	-	-	-	-	-	U	-	-
patient outcomes, we will create the best	81.0%	80.0%	-	-	-	70.0%	80.0%	81.0%	77.0%	82.0%	-	-	-	-	-	-		-	-	-	-	+
results for patients, healthcare professionals Finding the intersection where optimal	110	53	0	0	0	57	96	110	22	88	0	0	0	0	0	0	0	0	0	0	0	0
	77.0%	73.0%	-	-	-	81.0%	78.0%	77.0%	85.0%	75.0%	U	U	-	U	-	-	-	-	-	U	U	-
outcomes for patients, healthcare professionals	77.0%	73.0%	-	-	-	81.0%	76.0%	77.0%	85.0%	75.0%	-	-	-	-	-	-		-	-	-	-	+
and pharma companies all coincide is the Focusing on patients' needs leads to better	112	61	0	0	0	51	99	112	19	93	0	0	0	0	0	0	0	0	0	0	n	0
= -	78.0%	84.0%	-	-	-	73.0%	80.0%	78.0%	73.0%	79.0%	-	U	-	-	-	-	-	-	-	U	-	-
business outcomes	76.0%	84.0%	-	-	-	73.0%	80.0% F	78.0%	73.0%	79.0%	-	-	-	-	-	-	-	-	-	-	-	+
A long-term focus is key to success with patient-	124	61	0	0	0	63	109	124	24	100	0	0	0	0	0	0	0	0	0	0	0	0
centric efforts	87.0%	84.0%	-	-	-	90.0%	89.0%	87.0%	92.0%	85.0%	1	-	-	-	-	-	-	-	-	-	1	-
Pharma companies can act in the best interest	25	12	0	0	0	13	20	25	-	20	0	0	0	0	0	0	0	0	0	0	0	0
· ·	17.0%	16.0%				19.0%	16.0%	17.0%	19.0%	17.0%		U	-	U	-			·	U	U	U	
of patients but I don't believe we can achieve	17.0%	16.0%	-	-	-	19.0%	16.0%	17.0%	19.0%	17.0%	-	-	-	-	-	-	-	-	-	-	-	-
long-term business success by doing so	34	20	0	0	0	14	27	34	-	27	0		0	0	0	0	0	0			0	0
Pharma companies must serve shareholders					-				27.00/			U	•	U				-	U	U		
first	24.0%	27.0%	-	-	-	20.0%	22.0%	24.0%	27.0%	23.0%	,	-	-	-	-	-	-	-	-	-	-	-
Pharma's goals are misaligned with serving	85	43	0	0	0	42	72	85	13	72	0	0	0	0	0	0	0	0	0	0	0	0
patients optimally	59.0%	59.0%	-	-	-	60.0%	59.0%	59.0%	50.0%	62.0%	-	-	-	-	-	-	-	-	-	-	-	-

Statistics:


Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

Column Proportions:

Column Stested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)



Q80. Delivering patient centricity status statements agreement 1-5 scale - Bottom 2 Box Summary

					Type				Confi	dence	Pha	rma: Company	size			Geo	graphical loca	ition			Job tit	le/level
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower
		Α	В	С	D	E	F	G	Н	1	J	K	L	М	N	0	Р	Q	R	S	T	U
Base: Patient groups	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356
When companies focus on delivering the best	5	1	0	0	0	4	4	5	1	4	0	0	0	0	0	0	0	0	0	0	0	0
patient outcomes, we will create the best	3.0%	1.0%	-	-	-	6.0%	3.0%	3.0%	4.0%	3.0%	-	-	-	-	-	-	-	-	-	-	-	-
results for patients, healthcare professionals																						
Finding the intersection where optimal	10	6	0	0	0	4	8	10	1	9	0	0	0	0	0	0	0	0	0	0	0	0
outcomes for patients, healthcare professionals	7.0%	8.0%	-	-	-	6.0%	7.0%	7.0%	4.0%	8.0%	-	-	-	-	-	-	-	-	-	-	-	-
and pharma companies all coincide is the																						
Focusing on patients' needs leads to better	8	5	0	0	0	3	5	8	1	7	0	0	0	0	0	0	0	0	0	0	0	0
business outcomes	6.0%	7.0%	-	-	-	4.0%	4.0%	6.0% F	4.0%	6.0%	-	-	-	-	-	-	-	-	-	-	=	-
A long-term focus is key to success with patient-	5	3	0	0	0	2	3	5	0	5	0	0	0	0	0	0	0	0	0	0	0	0
centric efforts	3.0%	4.0%	-	-	-	3.0%	2.0%	3.0%	÷	4.0%	-	-	-	-	-	-	÷	-	-	-	-	-
Pharma companies can act in the best interest	86	50	0	0	0	36	76	86	14	72	0	0	0	0	0	0	0	0	0	0	0	0
of patients but I don't believe we can achieve	60.0%	68.0%	-	-	-	51.0%	62.0%	60.0%	54.0%	62.0%	-	-	-	-	-	-	-	-	-	-	-	-
long-term business success by doing so		EG					E	E														
Pharma companies must serve shareholders	81	35	0	0	0	46	74	81	15	66	0	0	0	0	0	0	0	0	0	0	0	0
first	57.0%	48.0%	-	=	-	66.0%	60.0%	57.0%	58.0%	56.0%	-	-	-	-	-	-	-	-	-	-	=	-
						AG	AG	A														
Pharma's goals are misaligned with serving	19	10	0	0	0	9	19	19	3	16	0	0	0	0	0	0	0	0	0	0	0	0
patients optimally	13.0%	14.0%	-	-	-	13.0%	15.0%	13.0%	12.0%	14.0%	-	-	-	-	-	-	-	-	-	-	-	-
																			1			


Statistics:

Overlap formulae used

- Column Means:

Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U Minimum Base: 5 (**), Small Base: 15 (*)

wininum base: 3 (), Jinan base: 12 ()
Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)
Table of Contents



Q80. Delivering patient centricity status statements agreement 1-5 scale - Mean Summary

					Туре				Confi	dence	Pha	rma: Compan	y size			Geo	graphical loca	ation			Job title/level		
	Total	Patient or Health Charity	Suppliers	Pharma	НСР	Pure patient (not part of any other group)	Patients only	Patient Health Charity and Patients	Very confident	Less confident	Small	Medium	Large	Global	Europe	North and Central America	Asia	Africa	South America	Australasia	Department Head or higher	Senior managers or lower	
		Α	В	С	D	E	F	G	Н	ı	J	K	L	M	N	0	P	Q	R	S	Т	U	
Base: Patient groups	1282	73	358	675	106	70	123	143	387	895	180	79	416	214	160	159	95	38	54	32	319	356	
When companies focus on delivering the best	4.5	4.6	-	-	-	4.5	4.6	4.5	4.7	4.5	-	-	-	-	-	-	-	-	-	-	-	-	
patient outcomes, we will create the best																							
Finding the intersection where optimal	4.3	4.2	-	-	-	4.4	4.3	4.3	4.5	4.3	-	-	-	-	-	-	-	-	-	-	-	-	
outcomes for patients, healthcare professionals																							
Focusing on patients' needs leads to better	4.5	4.5	-	-	-	4.5	4.6	4.5	4.6	4.5	-	-	-	-	-	-	-	-	-	-	-	-	
business outcomes							G																
A long-term focus is key to success with patient-	4.5	4.5	-	-	-	4.6	4.6	4.5	4.7	4.5	-	-	-	-	-	-	-	-	-	-	-	-	
centric efforts																							
Pharma companies can act in the best interest	2.2	2.1	-	-	-	2.3	2.1	2.2	2.5	2.1	-	-	-	-	-	-	-	-	-	-	-	-	
of patients but I don't believe we can achieve																							
Pharma companies must serve shareholders	2.4	2.6	-	-	-	2.1	2.3	2.4	2.4	2.4	-	-	-	-	-	-	-	-	-	-	-	-	
first		F																					
Pharma's goals are misaligned with serving	3.8	3.8	-	-	-	3.9	3.8	3.8	3.6	3.9	-	-	-	-	-		-	-	-	-	-	-	
patients optimally																							

Statistics: Overlap formulae used - Column Means:

Column Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)

valunium base, 3 (*), sinal base, 13 (*)
Column Proportions:
Columns Tested (5%): A/B/C/D/E/F/G, H/I, J/K/L, M/N/O/P/Q/R/S, T/U
Minimum Base: 5 (**), Small Base: 15 (*)
Table of Contents